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INTRODUCTION

Back&round
It is hypothesized

that B-carboline-N-methyltransferases (BC-NMT) and

the neurotoxic products of their catalytic activities, N-methylated
B-carbolinium cations. (MeBCs+),

may play a role in the pathogenesis of

idiopathic Parkinson's disease (Collins 1994; Collins et al. 1985).

This

hypothesis was originally based on the structural similarity between MeBCs+
and

neurotoxic

1-methyl-4-phenylpyridinium

ion

(MPP+ ).

In the central

nervous system of human and nonhuman primates, MPP+ selectively
the dopaminergic nigrostriatal system of the basal ganglia,

destroys

resulting in a

parkinsonian condition (Burns et al. 1983; Burns et al. 1984; Chiueh et al. 1984;
Langston 1995; Langston et al. 1983).

In support of this hypothesis, previous

work indicates that MeBCs+ share several toxic properties with MPP+ (Albores
et al. 1990; Cobuzzi et al. 1994; Collins 1994; Collins et al. 1996; Collins et al. 1992;
Collins et al. 1995; Drucker et al. 1990; Fields et al. 1992; Neafsey et al. 1995;
Neafsey et al. 1989).

In addition, MeBCs+ have been detected in postmortem

human brain tissue from normal subjects (Matsubara et al. 1993), but such
studies have not been done in Parkinson's cases.

Notably, MeBCs+ are elevated

in the lumbar cerebrospinal fluid of Parkinson's patients relative to control
values (Matsubara et al. 1995).
Relevant to this dissertation was the finding that mammalian brain
possesses enzymatic activities capable of generating neurotoxic MeBCs+ from
simple B-carbolines (BCs) (Collins et al. 1992).

In tissue homogenates from

2

guinea pig and rat brain, various BCs are N-methylated at both their pyridyl
(2N-) and indole (9N-) nitrogens by S-adenosyl-L-methionine-dependent
N-methyltransferases (Collins et al. 1992; Matsubara et al. 1992b).

These

activities have been designated as 6C-2N-methyltransfe'rase (BC-2-NMT) and
BC-9N-methyltransferase (BC-9-NMT), for N-methylation occurring at the
pyridyl and indole nitrogens of BCs, respectively.

Matsubara et al. (1993)

detected BC-2-NMT activity, but not BC-9-NMT activity, in postmortem normal
human brain tissue.
The primary focus of this dissertation is a more detailed investigation of
the

properties

particularly

the

of these

neurotoxin-producing

2N-methylation

BC-N-methyltransferases,

activity.

Specific Aims

Aim 1

Characterization of optimal assay conditions used in the assessment of brain
B-carboline-2N-methyltransferase

(BC-2-NMT)

activity.

Enzyme

characterization is a prerequisite to the partial purification of bovine brain
BC-2-NMT (Aim 2), and to comparison of its activity in human postmortem
brains from control and Parkinson's disease subjects (Aim 3 ).

3
Aim 2

Partial

purification

of

bovine

brain

B-carboline-2N-methyltransferase

(BC-2-NMT) using conventional protein purification techniques.

Results from

this aim should lay the foundation for subsequent studies on BC-2-NMT,
including

determination of its protein sequence, cloning of the gene, and

perhaps speculation regarding its physiological function.

Related to the

physiological function of BC-2-NMT is the finding that BC-2-NMT activity may
be due to

phenylethanolamine-N~methyltransferase

(PNMT).

Evidence in

support of the equivalency of BC-2-NMT and PNMT or a PNMT-like activity is
presented in this dissertation.

Aim 3

Measurement of B-carboline-2N-methyltransferase
B-carboline-9N-methyltransferase

(BC-9-NMT)

(BC-2-NMT)

activities

in

and

postmortem

human brains from Parkinson's disease (PD) and control individuals.
regions evaluated include frontal cortex, substantia nigra, and putamen.

Brain
This

study expands upon Matsubara' s original work by including PD brain and two
additional brain regions in the assessment of both BC-NMT activities.

CHAPTER 1
REVIEW OF RELEVANT LITERATURE

Parkinson's

Disease

Clinical Symptoms and
Pathogenesis
Parkinson's disease (PD) is a chronic disorder of the extrapyramidal
motor system.

The disease onset is insidious and progresses slowly, with the

time from the beginning of the pathological process to manifestation of
clinical symptoms being several years (Berkow 1977; Koller et al. 1991).
Clinically, Parkinson's disease is primarily characterized by the following
motor symptoms: bradykinesia, akinesia, pill-rolling tremor, muscular
rigidity, postural instability, shuffling gait, lack of facial expression, and
infrequent blinking.

However, nonmotor symptoms occur variably in PD,

including loss of the sense of smell, depression, dementia, and sensory
disturbances.

In addition, numerous autonomic nervous system disturbances

have been noted, such as orthostatic hypotension, excessive sweating,
dermatitis, gastrointestinal symptoms, sexual dysfunction,

and urological

problems (Koller et al. 1995).
Neuropathologically, PD affects the basal ganglia system, where there is
specific loss of the dopaminergic, pigmented substantia nigra (pars compacta)
(Berkow 1977; Koller and Pahwa 1995).

Cell bodies in the substantia nigra pars
4
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compacta project to the striatum (caudate and putamen), and degeneration of
the nigrostriatal pathway results in a profound decrease in the
neurotransmitter dopamine in the striatum.

The nigral projections to the

putamen are apparently more affected in PD than projections to the caudate
(Kish et al. 1988).

Motor symptoms of PD do not present clinically until striatal

dopamine decreases to about 20% of control levels (Kollerand Pahwa 1995).

In

addition to nigrostriatal degeneration, neuronal loss frequently occurs in the
locus ceruleus, nucleus basalis of Meynert, peripeduncular nucleus, and in the
dorsal motor nucleus of the vagus (Forno 1995, 1996).
Small intraneuronal inclusions, known as Lewy bodies, are the
pathological hallmark of PD.

Lewy bodies may contain lipofuscin,

neuromelanin, mitochondria, and other organelles.

Common to all Lewy

bodies are biochemically-altered neurofilament proteins -- Lewy body
neurofilaments

are

abnormally

and cross-linked (Forno 1996).

phosphorylated,

ubiquitinated,

proteolyzed,

Definitive pathologic diagnosis of PD must

include the presence of Lewy bodies in the substantia nigra; however, several
other dopaminergic, as well as nondopaminergic, brain nuclei often exhibit
these cytoplasmic inclusions (Forno 1995, 1996).

The dopaminergic ventral

tegmentum may also demonstrate Lewy bodies, both in the presence and
absence of nerve cell loss.

Lewy bodies are frequently present in

noradrenergic neurons of the locus ceruleus and sympathetic ganglion.
Several cholinergic nuclei may also exhibit Lewy bodies, including the
nucleus basalis of Meynert, the peripeduncular nucleus, the Edinger-Westphal
nucleus,

the intermediosacral nucleus,

(Forno 1995).

and intestinal

autonomic ganglion

The serotonergic dorsal raphe and superior central sulcus often

display these inclusions.

The posterior and lateral cell groups of the
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hypothalamus, the dorsal motor nucleus of the vagus, the cerebral cortex, as
well as the olfactory tubercle may demonstrate Lewy bodies in PD.

Forno

(1995) states that "the widespread affection of these selected nuclei is such an
integral part of the disease process that it [presence of Lewy bodies] deserves
to be considered in relation to the etiology of the disorder."

Epidemiology
Epidemiology examines the interrelationships between host, agent, and
environment in disease.

Epidemiologic data related to Parkinson's disease are

often difficult to interpret due to the long latency period preceding the
clinical presentation PD (Koller et al. 1991).

Roman's recent review of the

neuroepidemiology of PD addresses the numerous problems associated with
interpretation of epidemiologic data:

specifically, adaptation of universal

diagnostic criteria in PD, and improved design of epidemiological studies would
reduce the problems associated with data interpretation (Roman et al. 1995).
Parkinson's disease is a disease of aging in that clinical manifestations
usually are not observed until after age fifty, and it affects 1.5% of the
population between 70 and 79 years of age (Martilla 1987).

Both the

prevalence and incidence of PD increases with advancing age.

The

prevalence of PD varies geographically -- from 18 cases per 100,000 population
in China, to 182 per 100,000 in Iceland.

Incidence rates worldwide vary

between 2 to 24 cases per 100,000 population.

There is apparently a slightly

higher preponderance of PD in males than females (Roman et al. 1995).
In epidemiologic terms, "agent" has application primarily in the study
of infectious diseases and may have some significance with a subset of
Parkinson's cases.

Fazzini et al. (Fazzini et al. 1992) reported the presence of
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elevated levels of antibodies to coronovirus in the cerebrospinal fluid of PD
patients.

Kohbata et al. (Kohbata et al. 1993) demonstrated the presence of

antibodies to the soil-pathogen, Nocardia

asteroides, in the serum of PD

patients; moreover, this organism causes a parkinson-like syndrome in mice
(Kohbata et al. 1991 ).

Zack and Tanner (1995) recently reviewed infectious

diseases and their relevance to PD.

The authors conclude that, although there

is not strong evidence to support a primary role for a single pathogen in PD,
hypotheses that an infectious process may increase the susceptibility of
predisposed individuals to the disease merit further investigation.
Preliminary data regarding the factors and lifestyles associated with the
risk for developing PD include living in an industrialized nation, rural living
and drinking of well-water, a tendency toward less use of alcohol and tobacco,
less physical activity, and a more rigid preclinical personality (Koller et al.
1990; Kondo et al. 1993; Tanner 1989).

Tanner and Zack (1995) have reviewed

comorbid conditions proposed to have a relationship with PD; the comorbid
conditions were endocrine disorders (thyroid disease, diabetes mellitus);
metabolic abnormalities (cytochrome P450 enzymes, mitochondrial
dysfunction); mood disorders (depression, anxiety); stroke; atherosclerosis;
cancer; physiologic stress; head trauma; and drug use.

They conclude that

"none [of these associations] likely contribute to more than a few of all cases
of Parkinson's disease ..... but [these associations] may provide pieces to the
etiologic puzzle."
As mentioned above, metabolic biomarkers that have been studied in
Parkinson's disease include those enzymes involved in the metabolism of
xenobiotics.

In patients diagnosed with PD sulfur metabolizing enzymes were

underactive, and monoamine oxidase-B activity was variable.

Most pertinent
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to this dissertation is the demonstration of an impaired metabolism of pyridine
derivatives in Parkinson's disease, as evidenced by accumulation in the urine
of N-methylated derivatives of nicotinamide following oral administration of
the compound.

Notably, levels of N-methylated nicotinamide were 100-fold

greater in PD compared to control subjects -- suggesting either increased Nmethylation of nicotinamide, or decreased catabolism of N-methylated
nicotinamide in PD (Williams 1995; Williams et al. 1993).

Etiology

General

Hypotheses

Etiology refers to the cause of a disease.

Parkinsonian symptoms may

occur during treatment with dopamine antagonists, as a consequence of
carbon monoxide or manganese poisoning, with cerebral trauma or tumor, and
following encephalitis (Berkow 1977; Koller and Pahwa 1995).

However, the

cause which underlies idiopathic Parkinson's disease remains a mystery,
although roles for heredity, infection, metabolic dysfunction, and the
environment have been proposed (Barbeau 1984).

As reviewed by Jenner et

al. (1992), study of the substantia nigra after death in PD patients reveals the
following changes, which may provide clues regarding the mechanisms that
underlie the disease:

mitochondrial complex I deficiency, depleted levels of

reduced glutathione as well as high levels of lipid peroxidation products
(indicators of oxidative stress), high iron, and low f erritin levels.

These

authors summarize by stating that current views predict an interplay between
environmental or endogenous agents (toxins) and a genetic predisposition to
the disease -- an interplay that ultimately manifests in the neurochemical and
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clinical features of Parkinson's disease.
The environmental toxin theory of the etiology of PD is central to this
dissertation, and will therefore be addressed in more detail.

An Environmental Cause for PD?
The theory implicating a role for an environmental toxin in PD gained
impetus with discovery of the selective nigrostriatal toxin
1-methyl-4-phenyl-1,2,3 ,6-tetrahydropyridine (MPTP) (Langston et al.

1983 ).

MPTP is a contaminant in meperidine that was illicitly synthesized for "streetdrug" concoctions.

Drug-users that injected the meperidine mixtures

presented in hospital emergency rooms with classic parkinsonian symptoms
(Langston et al. 1983).

Further research showed that MPTP produces a

parkinsonian-like condition in nonhuman primates (Burns et al. 1983; Davis et
al. 1979; Langston et al. 1984a; Langston et al. 1983).

Furthermore, following

MPTP administration, postmortem pathological findings included the
characteristic degeneration of the nigrostriatal pathway was observed in
nonhuman primates (Burns et al. 1983; Burns et al. 1984; Langston et al. 1984a),
as well as one human case (Davis et al. 1979).

Positron emission tomography of

18F-labeled dihydroxyphenylalanine (DOPA) uptake appears to be useful in
assessment of striatal dopamine deficiency, since the rank order of 1sp - D 0 PA
uptake was:

<

MPTP-induced parkinsonian subjects < Parkinson's patients

asymptomatic MPTP-exposed subjects < normal control individuals (Calne et

al. 1985).
MPTP is a lipophilic molecule that crosses the blood brain barrier; it is
nontoxic prior to bioactivation to its active metabolite, neurotoxic 1-methyl-4phenylpyridinium ion (Langston et al. 1984b; Markey et al. 1984).

Monoamine
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oxidase (MAO) catalyzes the oxidation of MPTP to an intermediate, 1-methyl-4phenyl-2,3-dihydropyridinium ion

(MPDP+); MPDP+ is then further oxidized to

MPP+ (Chiba et al. 1985; Trevor et al. 1988).

Current literature indicates that

MPTP is a substrate for both MAO-A and MAO-B, but that in brain, glial MAO-B
preferentially forms MPP+ (Di Monte et al. 1992; Salach et al. 1984).

MPP+ is

actively taken up into dopaminergic neurons via the dopamine transporter
(Javitch et al. 1985); therein, MPP+ accumulates in mitochondria where it
inhibits Complex I (NADH dehydrogenase) of the respiratory chain (Nicklas et
al. 1985; Salach et al. 1984).

Inhibition of this complex ultimately results in an

inability of the mitochondria to carry out oxidative phosphorylation and
synthesize adenosine triphosphate (ATP) (Chan et al. 1991).

As a consequence

of decreased ATP production, cellular homeostasis is disrupted, and neuronal
cell death ensues (Mizuno et al. 1988; Nicklas et al. 1985; Salach et al. 1984).
Inhibition of mitochondrial respiration also places the cell in a state of
oxidative stress (Takeshige et al. 1979; Zeevalk et al. 1996; Zoccarato et al. 1988).
The cationic nature of MPP+ is believed to be an important structural feature
required for toxicity since it likely facilitates pyridinium ion transport into
dopaminergic cells, and accumulation of the cation down the electrochemical
gradient into mitochondria (Davey et al. 1992).
The discovery of MPTP advanced the hypothesis that an environmental
agent may play a causative, or at least a contributory role in the pathogenesis
of PD.

Although MPTP has not been detected in the environment, several

chemicals exist both endogenously and exogenously which are structurally
similar to MPTP or its neurotoxic metabolite MPP+.

One such group of

compounds are the N-methylated B-carbolines (MeBCs+) (Collins and Neafsey
1985).
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N- Methylated B-C arbolines:
Structure. Toxicity. and
Formation

Structure of N-Methylated BCs
N-methylated

B-carbolines

(MeBCs+), particularly the 2N-methylated

derivatives are structural analogues of MPP+ (Figure 1) (Collinsand Neafsey

1985).

ezp~rn3
ti

2-methylnorharmanium ion (2-MeNH+)

Gl3
2,9-dimethylnorharmanium ion (2,9-Me2NH+)
+

~;-CH3

N~Gl3
I

CH3
2-methylharmanium ion (2-MeH+)

2, 9-dimethylharmanium ion ( 2, 9-Me2 H+)

ID-

2-methylharmolium ion (2-MeHo+)

2-methylharminium ion (2-MeHI+)

IN
CH3

A
norharman (NH)

Figure 1.
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N-methylated BCs are structural analogues of neurotoxic MPP+.
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Toxicity of N-Methylated 6-Carbolines

N-methylated

6-carbolines

(Me6Cs+) are also functional analogues of

neurotoxic MPP+, because like MPP+, Me6Cs+ exert cytotoxic effects both in
vitro and in vivo.

Inhibition of Mitochondrial

Respiration

Like MPP+, Me6Cs+ inhibit respiration in isolated liver mitochondria
(Albores et al. 1990; Fields et al. 1992).

Several Me6Cs+ inhibit mitochondrial

respiration at Complex I (N ADH dehydrogenase) almost as effectively as MPP+,
and inhibition at Complex II (succinate dehydrogenase) is greater by Me6Cs+
than by MPP+ (Table 1).

In contrast to MPP+, Me6Cs+ also weakly inhibit

mitochondrial respiration at Complex III (coenzyme Q-cytochrome C reductase)
(Fields et al. 1992).
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Table

1.--Inhibition of Mitochondrial Respiration
by MPP+ and MeBCs+
Site of Inhibition
Complex I

Complex II

Compound

IC50 <µM)

IC50 CµM)

MPP+

171

>1200

2-MeNH+

1145

n.d.

2-MeH+

2850

n.d.

2-MeHi+

186

225

2-MeHo+

209

225

2,9-Me2NH+

90-100

n.d.

2,9-MezH+

100

250

Table modified from Albores et al. (Albores et al. 1990) and Fields et al. (Fields et
al. 1992). Key to abbreviations: n.d.=not done, MPP+=l-methyl-4phenylpyridinium ion, 2-MeNH+=2-methylnorharmanium ion, 2-MeH+= 2methylharmanium ion, 2-MeHi+=2-methylharminium ion, 2-MeHo+=2methylharmolium ion, 2,9-Me 2NH+=N,N-2,9-dimethylnorharmanium ion, 2,9Me2H+=N,N-2,9-dimethylharmanium ion, and ICso=concentration of compound
that inhibited respiration to 50% of control. See Figure 1 for structures.
Inhibition of Dopamine Uptake
Both BCs and MeBCs inhibit dopamine uptake into striatal synaptosomes
isolated from rat brain, albeit more weakly than MPP+ (Drucker et al. 1990).
Nonmethylated BCs (e.g, norharman, barman, harmine, and harmol) inhibited
dopamine uptake with ICsos in the range 12-33 µM.

Their 2N-methylated

derivatives demonstrated IC50s ranging from 15-88 µM.

These values are an

order of magnitude higher than the ICso for inhibition of dopamine uptake by
MPP+ (0.4 µM).

Inhibition of dopamine uptake by 2,9-Me2BCs+ has not been
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evaluated.

These data suggest that BCs and MeBCs are substrates for the

dopamine transporter.

A representative MeBC+, 2(14C H 3 )-harmine, has been

shown to be a substrate for the dopamine transporter as evidenced by its
partially

nomifensin-inhibitable,

Na+-dependent accumulation into striatal

synaptosomes (Drucker et al. 1990).

Toxicity to PC 12 Cells in Culture
Several N-methylated BCs are toxic to PC 12 cells in culture as indicated
by the release of lactate dehydrogenase into the culture media (Cobuzzi et al.
1994; Collins et al. 1992).

In low energy media (glucose=0.22 mM) the rank

order toxicity of these proposed neurotoxins was: MPP+ = 2,9-Me 2 NH + > 2-MeHi+
= 2,9-Me2H+ > 2-MeH+.

In high energy media (i.e., containing 25x more

glucose) toxicity due to these compounds was abolished.

It was suggested that

in the presence of high glucose the effects of mitochondrial inhibition
(decreased ATP synthesis) are compensated for by increased ATP synthesis
from anaerobic glycolysis (Cobuzzi et al. 1994).

In addition, evidence indicates

that these compounds are toxic to rat primary mesencephalic cultures,
although not as selectively as MPP+ (Collins et al. 1996; Collins et al. 1995).
mechanisms which underlie MeBC+ toxicity have not be clearly elucidated,
inhibition of mitochondrial respiration is likely

Nii:rostriatal

The
but

to contribute.

De~eneration

Like MPP+, several MeBCs+ cause nigrostriatal damage following
unilateral stereotaxic injection of the compounds into the substantia nigra of
rats (Neafsey et al. 1995; Neafsey et al. 1989).

Injected MeBCs+ produced nigral
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lesions that ranged in size from 25 - 94% of the lesion-size produced by MPP+.
In addition, several compounds reduced ipsilateral striatal dopamine content to
23 - 64% of control dopamine levels.

The most effective MeBCs+ were 2,9-

M e 2NH + and 2,9-Me2H+; both compounds produced nigral lesions that were
comparable to those produced by MPP+, and reduced striatal dopamine to 3742% of control values.

MeBCs+ in CSP From Control and Normal Cases
Matsubara et al. (1995) recently detected simple BCs and their
N-methylated derivatives in the lumbar cerebrospinal fluid (CSP) of control
subjects and parkinsonian patients.

Results show a significantly higher

quantity of total N-methylated BCs (2-MeBCs+ plus 2,9-Me 2BCs+) in the CSP of
persons with idiopathic PD versus controls;

measurements were 85 ± 18

fmol/ml and 20 ± 4 fmol/ml in PD and controls, respectively.

Moreover, 2,9-

M e2NH + was present in the CSP from 12 of 22 PD patients, but absent in control
CSP.

MeBCs+ in Normal Human Brain
Matsubara detected

MeBCs+ rn the substantia nigra and parietal cortex of

postmortem normal human brain tissue (Matsubara et al. 1993, 1996).

In the

substantia nigra 2-MeNH+ (3.14 ± 1.47 pmol/g tissue) and 2,9-Me2NH+ (0.77 ±
0.12 pmoles/g tissue) were present in all samples (N=4).

In the cortex 2-MeNH+

(0.17 ± 0.02 pmoles/g tissue) was present in each sample (N=13), and
2,9-Me 2NH+ (0.10 ± 0.02 pmoles/g tissue) was detected in 11 of 13 cases.

Neither

2-MeH+ or 2,9-Me 2 H+ was detected in the substantia nigra (N=4), but 2 of the 13
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cases demonstrated 2-MeH+ (0.02 ± 0.02 pmoles/g tissue) and 2,9-Me2H + (0.03 ±
0.02 pmoles/g tissue) in the parietal cortex.

Formation of N-Methylated BCs in Brain
Most pertinent to this dissertation is the discovery that MeBCs+ are
formed from simple BCs via an S-adenosyl-L-methionine (SAM)-dependent
enzymatic process in the presence of guinea pig and rat brain homogenates
(Collins et al. 1992; Matsubara et al. 1992b).

Moreover, it was later shown that

normal human brain exhibits J3C-2N-methyltransferase activity, but not J3C9N-methyltransferase activity (Matsubara et al. 1993).

These BC-N-

methyltransferase activities will be discussed in further detail below
(Figure 2).
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BC-N-Methyltransferases
and Their Substrates
Substrates
B-carboline 2N-methyltransferase (BC-2-NMT) forms 2-MeBCs+ from
simple BCs, such as norharman, harman, and harmine (Collins et al. 1992;
Matsubara et al. l 992b ).

Norharman and harman substrates are present in

mammalian tissues, including normal human brain (Airaksinen et al. 1981;
Bosin et al. 1989; Collins 1983; Fekkes et al. 1992; Matsubara 1996; Matsubara et
al. 1993; Schouten et al. 1986; Shoemaker et al. 1980).

Norharman and barman

levels are higher in the substantia nigra relative to the parietal cortex of
normal human brains (Matsubara 1996).

In the parietal cortex norharman

and harman were present at 0.58 ± 0.11 and 0.24 ± 0.04 pmoles/g tissue,
respectively (N=l3).

In the substantia nigra norharman and harman were

detected at 16.00 ± 8.00 and 1.04 ± 0.11 pmoles/g tissues, respectively.
Interestingly, Kuhn et al. (1995) reported significantly elevated (p=0.01)
plasma norharman in PD patients (30.0 ± 52.7, range 0-192 pg/ml) compared to
control subjects (4.9 ± 7.9, range 0-26.5 pg/ml).

Mean plasma values for

harman were elevated in PD but were not significantly different than control
values.
The presence in brain of simple BCs, which can serve as substrates of
the BC-2-NMT, is not surprising given their widespread availability from
exogenous as well as endogenous sources.

Blood-brain barrier penetration of

representative BCs and 2-MeBCs+ was recently demonstrated by Matsubara et
al. (1996).

He utilized striatal microdialysis to show that NH, 9-MeNH, and

2-Me NH+ are present in the brain following intraperitoneal (i.p). injection of
these compounds into C57 /black mice.

Blood-brain barrier penetration of
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nonmethylated simple BCs (NH and 9-MeNH) was expected, due to their
presumably hydrophobic structure; however, entry of the charged MeBCs+
<2-MeNH+) was quite surprising.

Simple BCs may be formed endogenously by

the condensation of indoleamines and aldehydes to form
tetrahydro-B-carbolines, which may be subsequently oxidized to the
corresponding BC (Melchior et al. 1982; Susilo et al. 1987).

Exogenous sources

of simple BCs include: plants, tobacco smoke, industrial waste, alcoholic
beverages, soy sauce, and pyrrolyzed tryptophan-rich foods such as meat
(Adachi et al. 1991; Bosin et al. 1988; Felton et al. 1990; Gross et al. 1993;
Holmstedt 1982; Rommelspacher et al. 1985a; Rommelspacher et al. 1985b).
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B-C arboli ne-N -Methyl tr an sf erase( s)
Two SAM-dependent N-methyltransferase (BC-NMT) activities have been
detected in guinea pig and rat brain homogenates (Collins et al. 1992;
Matsubara et al. 1992b).
The first activity, BC-2N-methyltransferase (BC-2-NMT), catalyzes the
2N-methylation of simple BCs to form 2-MeBCs+.

This activity has also been

measured in normal postmortem human brain (Matsubara et al. 1993), where
activity was 1.30 ± 0.42 pmol/h/mg protein in the substantia nigra, and 1.06 ±
0.26 pmol/h/mg protein in the parietal cortex.

Substrates that have been

identified for BC-2-NMT include: norharman, barman, harmine, 9methylnorharman, and 9-methylharmine (Matsubara et al.

1992b).

Curiously,

the soil-residing bacteria, Kitasatosporia setae, possesses an enzyme activity
that is also able to 2N-methylate norharman (Peczynska-Czoch et al. 1987).
Whether this N-methyltransferase and BC-2-NMT are the same enzyme
requires

further

investigation.

The second activity, BC-9N-methyltransferase (BC-9-NMT), catalyzes the
9N-methylation of 2-MeBCs+ to form 2,9-Me 2 BCs+.
appear to be substrates for BC-9-NMT.

Non-methylated BCs do not

It is yet to be determined if BC-2-NMT

activity and BC-9-NMT activity are due to a single enzyme, or represent distinct
enzymatic activities.

N-methylation of BCs appears to occur sequentially, with

N-methylation at the pyridyl (2N-) nitrogen preceding
methylation.

indole (9N-)

This sequence is predicted because no 9-MeNH was detected in an

incubation in which norharman was the substrate;
were the only detectable products.
2-methylnorharmanium,
(Matsubara et al. 1992b).

2-MeNH+ and 2,9-Me 2 N H +

Substrates identified for BC-9-NMT include:

2-methylharmanium,

and

2-methylharminium

ions
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The pH optimum for BC-9N-methyltransferase activity from guinea pig
whole-brain homogenate was in the range 8.2-8.3 using a phosphate buffer
system.

The pH optimum for BC-2N-methyltransferase activity was not

determined.

Kinetic parameters for methylation of norharman derivatives at

a fixed concentration of SAM (8 µM) in crude guinea pig brain homogenates
were as follows (Matsubara et al. 1992b):

Ymax
(pmol/h/m~

Activity

Substrate

BC-9-NMT

2-MeNH+

17.8

4.9

BC-2-NMT

9-MeNH

17.8

2.2

protein)

Previous studies from this laboratory indicate that guinea pig brain BC2-NMT activity resides primarily in the nuclear (236.1 pmol/h total activity)
and microsomal (14.3 pmol/h total activity) subcellular fractions.

BC-9-NMT

activity was found in the nuclear (233.8 pmol/h total activity), microsomal
(82.7 pmol/h total activity), and mitochondrial (58.6 pmol/h total activity)
fractions.

Neither BC-methyltransferase activity was detected in undialyzed

cytosol (Matsubara et al. 1992b).
The regional distribution of both BC-NMT activities was assessed in
guinea pig brain (Matsubara et al. 1992b).

BC-2-NMT specific activity was

highest in the pons/medulla (6 pmol/h/mg protein) and lowest in the frontal
cortex (0.5 pmol/h/mg protein).

Intermediate BC-2-NMT activity was found in

the hippocampus, hypothalamus, striatum, and midbrain.

Similarly, BC-9-NMT

specific activity was also highest in the pons/medulla (9 pmol/h/mg protein)
and lowest in the frontal cortex (2 pmol/h/mg protein).

Intermediate BC-9-

NMT activity was detected in the hypothalamus, hippocampus, midbrain, and

22
striatum.

Overall, the specific activity of BC-9-NMT was higher than that of

BC-2-NMT activity in every brain region tested, particularly in the

hypothalamus.
Matsubara et al. (1996) recently reported the presence of cerebral
2-MeNH+ following i.p injection of norharman or 9-MeNH in C57/black mice.
The author speculated that injected 9-MeNH is demethylated in the liver to
norharman, and that the norharman is then available for methylation by
BC-2-NMT to 2-MeNH+. In the same study 2,9-Me 2 NH + was detected in mouse
brains following i.p injection of norharman, 9-methylnorharman, or
2-MeNH+.

A most interesting finding is that subchronic treatment with

norharman or 2-MeNH+ not only selectively reduced nigrostriatal dopamine,
but also produced bradykinesia in these mice.

These experiments are

consistent with the hypothesis that in vivo formation of MeBCs+ by BC-2-NMT
and BC-9-NMT reduces striatal dopamine, which produces a parkinsonian
condition.

S-Adenosyl-L-Methioni ne-Dependen t
Me th yl trans f erases
General
Enzymes

that catalyze S-adenosyl-L-methionine (SAM)-dependent

methylation of a substrate belong to the E.C. 2.2.1 class as defined by the
International Enzyme Commission (Barman 1969).

A generic SAM-dependent

methyltransferase reaction is diagrammed in Figure 3.
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All SAM-dependent methyltransferases studied to date are inhibited by
S-adenosyl-L-homocysteine (SAH) in a competitive manner.

Inhibition by

SAH is not surprising since products often inhibit the enzymes responsible for
their formation, and SAH is a co-product of SAM-dependent methylation
reactions.

Inhibition by SAH varies, depending upon the enzyme affected,

with Ki's falling into the 100 nM - 12 µM range (Deguchi et al. 1971; Lawrence
et al. 1990).

Therefore, if an enzyme under study is truly a SAM-dependent

methyltransferase, inhibition by SAH should be a property of that enzyme.
BC-NMT inhibition by SAH was not investigated by Matsubara.
In addition, a peptide inhibitor of methyltransferase reactions has also
been reported;

this peptide is proposed to inhibit many methyltransferases

via a noncompetitive mechanism (Park et al. 1993).

This inhibitor was

purified from rat liver cytosol, and exhibited the following characteristics:
29 amino acids, 52% glycine with no basic amino acid residues, and a molecular
weight of 2584.

The authors noted that extensive dialysis is required for

removal of the inhibitor from tissue homogenates.

Enzymatic N-Methylation
of Azaheterocycles
The presence of a SAM-dependent N-methyltransferase activities have
been detected in dialyzed cytosolic fractions from rabbit and guinea pig lung,
kidney, spleen, and brain. These rather nonspecific activities have been
assigned a number of names including amine-N-methyltransferases A and B,
indolethylamine-N-methyltransferase,

and

(Ansher et al. 1986a; Ansher et al. 1986b).

arylamine-N-methy l transferase
The nonspecificity of these enzymes

is typified by their ability to N-methylate a variety of azaheterocycles at the
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pyridyl nitrogen.
pyridinium ion;

N-methylation results in the formation of a quaternary
recall that this cationic feature is essential for the

neurotoxicity due to MPP+.
Interestingly,

pyrido-N-methyltransferase

activities

(e.g.,

amine

N-methyltransferases A and B) -- present in human, monkey, mouse, and
rabbit brain -- are capable of forming MPTP from precursor
4-phenyl-1,2,3,6-tetrahydropyridine. These enzymes also act on
4-phenylpyridine to generate MPP+.

As summarized in Table 2, the specific

activities of these N-methyltransferase activities in mammalian brain
homogenates (Ansher et al. 1986a) are comparable to the N-methylation
activities reported toward BCs (Matsubara et al. 1993) and
tetrahydro-B-carbolines by Matsubara et al. (Matsubara et al. l 992a) .

Table 2.--N-Methylation of Various Azaheterocycles
N-Methyltransferase

Ac ti vi ty

(pmole/h/mi: protein)
Substrate
4-phenylpyridine

Human
(a)

4-phenyltetrahydropyridine
9-methylnorharman

(b)

(a)

Brain

Rat Brain

3.7

2.7

0.17

6.8

1.30 (cortex)

0.4

1.06 (nigra)
tetrahydro-B-carboline

(c)

2.6

Table 2 summarizes data from three investigators: (a) Ansher et al. (1986a) , (b)
Matsubara et al. (1993), and (c) Matsubara et al. (1992a) . Note that assays were
not run under identical conditions.

26
Studies indicate that these

amine-N-methyltransferases have

the

following properties: (a) reside in the cytosolic fraction of tissue homogenates,
(b) usually unmeasurable prior to dialysis, and (c) higher in fresh vs. frozen
tissue (Ansher et al. 1986a; Ansherand Jakoby 1986b).
purified these

Ansher and Jakoby

amine-N-methyltransferases A and B from rabbit liver;

the

enzymes have very broad and overlapping specificity for a number of
primary, secondary and tertiary amines (Ansher et al. 1986a; Ansherand
Jakoby 1986b).

The azaheterocycles tested included the above-mentioned

pyridine derivatives, as well as
evaluated as substrates.

isoquinoline, but BCs were apparently not

Rabbit Ii ver cytosolic activities exhibited pH optima of

6.2 and 7.8 for transferase A and B, respectively.
Saavedra et al. (1973) described the distribution of a

cytosolic

nonspecific N-methyltransferase present in the brain of several species,
including human postmortem brain tissue.

That SAM-dependent enzyme

utilizes tryptamine as well as several other amines as substrates.

Similar to

BC-2-NMT, the enzyme exhibited a KM with respect to SAM of 52 µM and a
tissue-dependent

Vmax

in the range 2 - 15 pmol/h/mg protein.

Naoi et al. (Naoi et al. 1989a) reported the presence of
methyltransferase
potentially

activity in human brain homogenates

neurotoxic

a cytosolic N-

that forms

N-methyl-1,2,3 ,4-tetrahydroisoquinoline

tetrahydroisoquinoline (TIQ).

from

Likewise, Matsubara identified a cytosolic

N-methyltransferase activity present in rodent brain that catalyzes
methylation at the 2N-nitrogen of tetrahydro-B-carbolines (Matsubara et al.
1992a).

It is conceivable that BC-NMT activity is due to any of the above-

mentioned

enzymatic

activities.
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General Enzyme Properties
and Terminolo~y
This portion of the literature review contains information directly
related to the content of this dissertation, and therefore is not intended to
cover enzyme properties and kinetics in detail (Barman 1969; Lehninger
1975).

General Characteristics of Enzymes
The International Enzyme Commission has numerically classified
enzymes according to the type of reactions that they catalyze (Barman 1969).
Each characterized enzyme is assigned a number comprised of four figures:
the first figure places the enzyme in a main group (e.g., group 2 =
transferases), the second figure identifies the subclass (e.g., subclass
methyltransferases),

=

the third figure represents the sub-subclass, and finally

the fourth figure is the serial number of the specific enzyme within its subsubclass.

As noted previously, SAM-dependent methyltransferases belong to

E.C.2.2.1.
Nearly all enzymes are proteins with a primary structure composed of
amino acids linked covalently by peptide bonds; interactions between amino
acid side-chains give rise to secondary structure which then participates in
higher order structure.

Amino acid side-chains, as well as the a-amino

and

a-carboxyl termini, impart acid-base, polar, and nonpolar properties to
regions of the protein.

These properties are exploited in the purification

techniques that are described in a subsequent section of this chapter.
Enzymes catalyze biological reactions, and as catalysts are not consumed
during the reactions in which they participate.

Analogous to other chemical
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catalysts, enzymes affect reaction rate but not the equilibrium of the reactions
that they catalyze.
Properties unique to enzyme catalysts are detailed below and include:
sensitivity to extremes of temperature, pH, ionic strength, other solvent
conditions,

and specificity toward its substrate(s).

Sensitivity to Temperature. pH. Ionic Streni;th. Solvents
Changes in these parameters affect amino acid side-chains of the
enzyme, leading to alterations in ionization state which affects hydrogen
bonding and hydrophobic interactions.

These changes are often detrimental

to the physical, chemical, and catalytic stability of the enzyme.

Substrate

Specificity

Substrate specificity of an enzyme is divided into four categories.
(1) Absolute specificity.

This type of specificity implies that an enzyme will

act on a single substrate.
(2) Group specificity.

Group specificity applies to enzymes that act on more

than one substrate, but require certain atomic groupings within those
substrates.
(3) Reaction specificity.

This type of enzyme requires the least amount of

specificity, and describes enzymes that do not require strict atomic groupings
in the vicinity of the reactions that they catalyze.
(4) Stereochemical specificity.

This kind of specificity implies that an enzyme

will only effect a reaction on one stereoisomer of a given substrate.
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Other

Characteristics
Enzyme catalyzed reactions should exhibit linear formation of product

as a function of time and protein concentration, assuming that the enzyme
remains active and substrates are not limiting during the assay.

Effect of Additives
Miscellaneous additives may stabilize or destabilize enzymes during
their assay and purification, as discussed by Scopes (1994a) and Deutscher
(1990).

Antioxidants.

When enzymes are removed from their intracellular

environment (reducing conditions) an antioxidant such as dithiothreitol or
mercaptoethanol is often needed to maintain enzyme stability and activity.

Protease Inhibitors.

Tissue disruption may result in the release of cellular

proteases; therefore protease inhibitors are often utilized, especially during
the early steps of enzyme isolation.
shown in Table 3.

Commonly used protease inhibitors are
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Table 3.--Commonly Used Protease Inhibitors
[adapted from Scopes (1994a) and Deutscher (1990)]

Protease Inhibitor

Protease Class Inhibited

phenyl methyls u l fo n y l
fluoride (PMSF)

serine

proteases

0.1-1 mM

benzamidine

serine

proteases

1 mM

aprotinin

serine

proteases

5 µg/ml

leupeptin

thiol

proteases

1 µg/ml

antipain

thiol

proteases

1 µg/ml

pepstatin A

acid proteases

1 µg/ml

EDTNEGTA

metalloproteases

0.1-1 mM

Metals.

Useful

Concentration

Many enzymes require metals for activity, while others are inhibited

in presence of metals.

Transition elements that may affect enzyme activity

include:

Mn2+, Fe2+/3+, Co2+, Ni2+, Cul+/2+, Zn2+, Ca2+, and Mg2+ (Gray 1971).

Enzyme

Terminoloi:y

Miscellaneous terms associated with enzymes, particularly enzyme
kinetics, are listed in the GLOSSARY of this dissertation (Barman 1969; Dixon et
al. 1979b; Lehninger 1975).

Other concepts are presented below.
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The Michaelis-Menten equation

Michaelis-Menten equation and kinetics.

mathematically describes -- for a single-substrate enzyme or often a
two-substrate enzyme (when one of the substrates is fixed at a saturating
concentration) --

the relationship between

the following parameters: initial

rate of the reaction (v), substrate concentration [S], and kinetic constants (KM
and Vmax).

[E] + [S]

[ES]

[E] + [P]

Reaction:

= Vmax

[SJ I ([S] +KM)

Equation:

v

Assumptions:

[P] and [E] interaction is negligible,
therefore k_2 is negligible, kcat is first-order,
[SJ, [E], and [ES] in equilibrium (steady-state)

Graphically:

- - - - - - - - · Ymax

v

[S]
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Lineweaver-Burk equation.
transformation of the
Equation:

This equation is a commonly used linear

Michaelis-Menten equation.
1/v

= (KM/V max)(l/[S])

+ 1/Vmax

Graphically:

1/[S]

Hanes equation.
Menten

This is another linear transformation of the Michaelis-

equation.

Equation:

[S]/v = (KM/V max) + ([S]/V max)

Graphically:

slope= l!Ymax

[S]/v

[S]
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Dixon Equations and Plots for Inhibition
Dixon Equation and Plot for
Competitive Inhibition
Substrate:

l/v

[S 00 ] >[S2] >[S1]

Inhibitor: [I]
l/v = {KM/(Ymax[SJKi)}[I] + (l!YmaxHl + (KM/[S])}

[S2]

[Soo]
[I]

Dixon Equation and Plot for
Noncompetitive Inhibition
Substrate:

l/v

[S 00] > [S 2] > [SI]

[S2]

Inhibitor: [I]
l/v = {1 + (KM/[S])/(YmaxKi)}[I] + (lNmaxHl + (KM/[S])}

[I]

Ilxon Equation and Plot for
Uncompetitive Inhibition
Substrate:

l/v

[Sool > [S2] >[Si]

Inhibitor: [I]
l/v = {l/(YmaxKi)}[I] + (1/YmaxHl + (KM/[S])}
slope = l/(V maxKi)
Ki= ll(Vmaxslope)
[I]
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Literature Related to
Protein Purification
General
This section of the literature review is intended to be a simple overview
of applicable protein purification techniques.

Enzyme purification may

include the following general sequence of steps: preparation of tissue extract,
subcellular fractionation, ammonium sulfate or other bulk precipitation
techniques,

miscellaneous chromatographic methods,

polyacrylamide gel electrophoresis (Deutscher

and usually

1990).

Total Protein Assays
UV Absorption at 280 nm and 260 nm
This is a nondestructive method that is frequently used to monitor
protein in crude extracts or column effluents.
this method is its lack of sensitivity.

The primary disadvantage of

Absorbance at 280 nm is due to the

presence of tryptophan and tyrosine residues in proteins, as well as nucleic
acids. Proteins absorb little at 260 nm, a wavelength at which absorbance is
due primarily to the pyrimidine and purine residues of nucleic acids.
Therefore, a reasonable estimate of the quantity of protein present in a
relatively clear sample may be obtained by measuring the absorbance of the
sample at 280 nm and 260 nm for use in the following equation:

protein concentration (mg/mL) = 1.55A2so - 0.76A260
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Lowry Protein Assay
This method is based upon the interaction of Cu2+ with peptide bonds to
form a complex; under basic conditions the complex is reduced to Cu 1 +.

Folin

Reagent then interacts with both the complexed Cul+ and the side-chains of
tyrosine, tryptophan, and cysteine.

This interaction slowly imparts a blue

color to the mixture, which is detected at 500 nm to 750 nm using UV
spectroscopy.

Absorbance at a set wavelength in this range correlates with

protein concentration in the original sample.

Solutions required in this assay

are described in Scopes (Scopes 1994c) and in Appendix A of this dissertation.

Coomassie Blue Dye Bindin2 Assay
This method is based on an observed shift in absorbance from 465 nm to

595 nm under acidic conditions when protein interacts with the negatively
charged dye.

Side chain groups in proteins that facilitate this interaction

include those of arginine, histidine, lysine, tyrosine, tryptophan, and
phenylalanine.

Solutions required in this assay

are described in Scopes

(1994c) and in Appendix A of this dissertation.

Subcellular

Fractionation

This technique could be considered a gross means of protein
fractionation in that it allows for the separation of many undesirable proteins
and nonproteinaceous materials from the enzyme of interest based on their
location in distinct subcellular compartments.

Subcellular fractionation

methodology has been recently reviewed by Storrie and Madde (Deutscher
1990).

Subcellular fractionation is routinely done using modifications of the

differential centrifugation protocol (Table 4) (Alberts et al. 1989).
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Table 4. -- Subcellular Fractionation Protocol
[adapted from Alberts (1989)]
Centrifu~ation

Steps

Parameters

Pellet Contains

low speed

IOOOg, 10 min.

whole cells, nuclei, cytoskeletons

medium speed

20,000g, 20 min.

mitochondria,

high

speed

80,000g' 1 hr.

microsomes, small vesicles

very

high

150,000g, 3 hrs.

ribosomes, viruses, large

lysosomes,

peroxisomes

macromolecules

Bulk Precipitation Techniques
This technique exploits the effects of salts or organic solvents on
protein conformation and consequently protein solubility.

Proteins with

variable amino acid compositions can be separated based on their behavior at
different electrolyte or solvent concentrations. Commonly used precipitants
are the neutral salt, ammonium sulfate, or organic solvents such as
polyethylene glycol, ethanol, or acetone.

Bulk precipitation techniques are

discussed in detail by Scopes (1994a), as well as Englard and Seifer in the
Methods in Enzymology series (Deutscher 1990).

In practice, the precipitant is

added in small aliquots while the protein extract is stirred at low temperature.
The mixture is stirred for a defined period and then centrifuged to pellet and
isolate precipitated proteins.

Additional precipitant may then be added to the

resulting supernatant, the mixture again centrifuged, and so on.

Proteins are

therefore fractionated (precipitated) based on their individual solubilities in
progressively more concentrated salt solution or organic solvent.
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Chromatographic

Methods

General
A series of laboratory guides published by Pharmacia are suitable
primary references for chromatographic isolation of proteins (Pharmacia
1991; Pharmacia 1993a; Pharmacia 1993b; Pharmacia 1994).

These guides

describe in detail the practical aspects of preparing, using, and maintaining
various chromatographic resins.

The books "Protein Purification: Principles

and Practice" by Scopes (1994a) and "Guide to Protein Purification" by
Deutscher (1990) are also invaluable resources during the development of a
protein purification protocol.

Each of these references was utilized in the

preparation of the remainder of this literature review.
In general, all chromatographic methods exploit the properties of the
protein in solution by differentially promoting or preventing binding of
proteins to chromatographic resins.

Chromatographic resins are

commercially available that have been chemically modified to possess the
numerous functional groups and characteristics described below.
Both ion exchange and hydrophobic interaction chromatographic
methods are considered high capacity methods because they allow for
fractionation of samples composed of larger quantities of proteins, as
compared to lower capacity methods such as gel filtration and affinity
chromatography.

High capacity methods are typically utilized early in

purification procedures, while lower capacity methods follow later,

in order

of decreasing capacity and/or specificity for the protein to be isolated.
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Ion

Exchange

Chromatography

Ion exchange chromatography (IEC) allows for separation of sample
molecules as a function of the charge of the exchanger and proteins.

Anion

exchangers contain positively charged groups such as quaternary amines or
diethylaminoethyl
protein molecules.

(DEAE);

these

exchangers interact with

negatively-charged

Cation exchangers, possess negatively charged groups

such as a sulfonic acid or carboxymethyl (CM) side-chains; these resins
interact with positively-charged protein molecules.

Both pH and ionic

strength are manipulated in order to affect the interaction of protein with the
exchanger.

For example, proteins are typically applied to an anion exchange

column under conditions of low salt in buffer at pH 7-9; under these conditions
many proteins have a net negative charge, and therefore bind to the
positively-charged exchanger.

Proteins are routinely eluted from ion-

exchange matrices using an increasing salt gradient, or less commonly a pH
gradient.

Fractions from the column are collected and assayed for total protein

content and protein of interest.

Hydrophobic

Interaction

Chromatography

Hydrophobic interaction chromatography (HIC) enables
of proteins based on their hydrophobicity.

the

separation

HIC matrices contain hydrophobic

moieties such as simple ethyl to dodecyl alkyl chains or phenyl groups.
Hydrophobic interactions between proteins and the HIC matrix are favored
under conditions of high salt and low pH.

Temperature and additives may also

affect HIC interactions, albeit in a less straightforward manner.

Therefore,

samples are usually applied to HIC columns in a high salt buffer, with the same
buffer being utilized to pre-equilibrate the column.

Successive elution of
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bound protein is often achieved using a gradient of decreasing salt
concentration.

Occasionally organic solvents or other additives are utilized in

elution buffers for HIC.
subsequently

Affinity

Column effluent is collected in fractions that are

assayed for total protein and proteins of interest.

Chromatography

In general, affinity chromatographic methods take advantage of the
specificity of an interaction between an enzyme and its substrates or
inhibitors.

A substrate or inhibitor that is specific for the enzyme of interest

is covalently attached to a suitable chromatographic matrix by conventional
methods.

Dye chromatography is a subset of affinity chromatography, in

which dye molecules are covalently attached to the matrix.

The affinity

column is equilibrated with sample buffer and then the sample is applied to
the column.
gradients.

Elution of bound protein may be accomplished using salt or pH
Tightly bound proteins are often eluted by a solution containing

either the substrate/inhibitor or a substrate/inhibitor analogue.

Column

fractions are assayed for total protein and proteins of interest.

Gel

Filtration Chromatography
Gel filtration chromatography (GFC) is synonymous with size-exclusion

chromatography (SEC).
size;

In this method molecules are separated on the basis of

GFC matrices are available with a range of pore sizes which either

exclude or allow passage of sample molecules.

Excluded molecules elute from

the column first, while molecules that are able to enter matrix pores are eluted
from the column as a function of decreasing molecular weight.

This method

not only serves to fractionate proteins based on their size, but also has utility
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in the determination of the approximate molecular weight of proteins and
peptides.

These gels are also used to desalt protein and peptide solutions, as

well as to carry-out buffer exchange on sample solutions.

Sequence of Chromato2raphic Steps
Ion exchange chromatography is routinely used early in a purification
procedure depending upon the method used to bulk precipitate proteins
following subcellular fractionation.

If ammonium sulfate is used as the

precipitant, hydrophobic interaction chromatography (HIC)

should follow,

since application to HIC columns is typically achieved under conditions of
high salt concentration, such as the solutions generated following ammonium
sulfate precipitation.

If polyethylene glycol is used as the precipitant, ion

exchange chromatography should follow the PEG step,

since solutions are

usually applied to IEC columns under low salt conditions and PEG may interfere
with HIC.

Additional Comments
Reference to other relevant literature, not cited in this chapter
("Review of Relevant Literature"), is more appropriately included in the
"Discussion" sections of the individual chapters.

CHAPTER2
B-CARBOLINE-9N-METHYL TRANSFERASE

Back~round

This chapter is included for completeness and historical purposes.

It is

not presented in as much detail as subsequent chapters, and therefore only
key studies are considered.

Due to BC-9-NMT's novel activity -- methylation of

an indole nitrogen -- this enzyme was originally the proposed focus of this
dissertation project.

Unfortunately, BC-9-NMT activity could not be

consistently measured in animal brain, but this activity was consistently
detected in postmortem human brain (Chapter 5).

The BC-9-NMT project was

eventually abandoned in favor of investigations pertaining to brain BC-2Nmethyltransferase activity; however certain several BC-9-NMT studies are
described in this chapter.
Studies presented in this chapter include: (a) determination of kinetic
constants for BC-9-NMT with respect to S-adenosyl-L-methionine; (b) detection
of BC-9-NMT activity in guinea pig brain and various rat organs;
(c) comparison of BC-9-NMT activity in phosphate and TRIS buffer; (d) BC-9NMT activity as a function of time; (e) the effect of homogenate dialysis on
detectable activity; (f) evaluation of BC-9-NMT activity in bovine brain and
yeast -- these sources were evaluated as possible starting materials for
purification purposes; and (g) subcellular localization of BC-9-NMT activity
from bovine brain.
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Materials and Methods

Reagents
B-Carboline substrate,

2-methylnorharmanium iodide

(2-MeNH+ ), was

synthesized in our laboratory according to Matsubara (l 992b). Unlabeled
S-adenosyl-L-methionine (chloride, iodide, or toluenesulfonate salt) was
purchased from Sigma Chemical Company.

Tritiated S-[methyl-3 H] -

adenosyl-L-methionine (60-85 Ci/mmol) was bought from American
Radiolabeled Chemicals or Dupont NEN.

All other reagents were appropriately

pure for their intended use and were utilized as purchased.

Preparation of BC-9-NMT Source
Guinea

Pi~

Brain

Frozen guinea pig brain was purchased from either Rockland or Harlan.
Extract preparation was done at 0-5 °C.

Brain was thawed slightly, cut into

small pieces, and homogenized in a glass homogenizer by a motor-driven
teflon pestle (5-10 up-and-down strokes

@

100 rpm).

In indicated experiments,

homogenation was accomplished using a Tissuemizer® set at its lowest setting.
Brain (1 g) was homogenized in 2-10 ml of homogenation buffer, consisting of
10 mM Na2HP04 (pH 7.4) or 100 mM TRIS (pH 8.3).

Yeast Extract
Red Star active dry yeast (5 g) was added to a polypropylene or glass

centrifuge tube containing 15 ml of 100 mM TRIS buffer (pH 8.3).

The mixture

was vortexed until the powder was completely wetted to form a slurry.

Small

glass beads (0.5-1 mm in diameter, 15 ml in all) were added to the slurry, and
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the mixture was vortexed vigorously in order to disrupt yeast cell walls.
vortexing cycles (30 seconds per cycle) were carried-out.

Six

Between each cycle

the tube was placed on ice for 2-3 minutes to dissipate heat generated during
the disruption process.

Cell debris was removed from the extract by passage

through glass wool or centrifugation.

Bovine Brain
Bovine brain was utilized in some experiments.

Tissue procurement and

preparation are described in detail in subsequent sections.

Protein

Determination

A Coomassie blue dye-binding method was utilized as described in Scopes
(Scopes 1994c).

Details are in Appendix A.
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The BC-9-NMT Assay
This activity catalyzes the transfer of the tritiated methyl moiety from
S-adenosyl-L-methionine (SAM)
form

to 2-methylnorharmanium ion (2-MeNH+) to

2-methyl-9(3H-methyl)-norharmanium

adenosyl-L-homocysteine

(Figure

ion

(2,9-Me2NH+) and S-

4).
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Figure 4. BC-9-NMT assay. Site of tritium label *.
Abbreviations:
2-methylnorharmanium ion (2-MeNH+), 2,9-dimethylnorharmanium ion (2,9Me2NH+), S-adenosyl-L-methionine (SAM), S-adenosyl-L-homocysteine (SAH).
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The BC, 2-MeNH+, was chosen over other substrates (e.g. norharman) since its
pyridyl position (2N-) is already methylated, allowing for measurement of
9N-methylation exclusively.

This substrate is most like a physiological

substrate for BC-9-NMT. The assay was performed as previously reported by
Matsubara et al. (1993) with modifications.

Concentrated stock solutions of

2-MeNH+ and SAM were combined with organ fraction or yeast extract in 1.5
ml polypropylene microcentrifuge tubes.

The SAM was usually dissolved in 10

mM Na2HP04 buffer (pH 7.4), 2-MeNH+ was prepared in 100 mM Na2HP04 buffer
(pH 9.5),

and tissue homogenate or yeast extract was present in 10 mM Na2HP04

buffer (pH 7.4 ).

However, in indicated studies, substrates and enzyme extract

were made in 100 mM TRIS buffer (pH 8.3).

Stock solution volumes usually

remained constant across studies, while stock solution concentrations and
final pH varied depending upon the experiment.

Assay volume was typically

370 µI, comprised of the following stock solutions: 50 µl 3H-SAM,

20 µl non-

radioactive SAM,

In assays that

200 µl 2-MeNH+, and 100 µl enzyme solution.

excluded radioactive SAM, total volume was routinely 200 µl: 50 µ1 each of 2MeNH+ and SAM stocks, plus 100 µl enzyme extract.
substrates are indicated in individual experiments.

Final concentrations of
The assay was gently

vortexed and subsequently maintained at 37 °C in a shaking water bath for 1560 minutes.
The reaction was then treated in one of two ways:
use of solid-phase extraction (SPE) cartridges.

with or without the

When SPE was excluded from

the reaction work-up, the assay was terminated by placing the tubes on ice
and adding 8.6 µI of concentrated perchloric acid (HCI04).
was pelleted by centrifugation at 3000g for 5 minutes.

Precipitated protein

If noted, the pellet was
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resuspended in 0.5-1.0 ml of 0.1 N HC10 4, centrifuged, and the resulting
supernatant combined with the first.

Combined supernatant was transferred

to a weighed 1.1 ml conical glass HPLC vial, and the vial plus contents was reweighed.

After injection of this solution onto the HPLC column, vial plus

contents were weighed again so that injection weight could be calculated.
Solid-phase extraction (SPE) cartridges are prefabricated devices that
contain chromatographic resins
polypropylene housings.

(packing

material) packaged in

These housings have luer fittings at each end to

facilitate connection to either a syringe or a vacuum manifold with
appropriate connectors, which allows for passage of solution through the
cartridge.
material.

Cartridges may contain various quantities (100 mg-1 g) of packing
Packing material is typically silica-based and may be derivatized

with ion-exchange or reverse-phase (e.g., C 18) functional groups.

In general,

samples are applied to pretreated cartridges; pretreatment often includes the
same solutions in the subsequent elution of sample components.

Use of SPE

cartridges allows for the separation or enrichment of sample components
based on the affinity of these components for the packing material under
various solvent conditions.

In the studies reported in this dissertation the

rationale for the use of ammonium hydroxide, methanol (acetonitrile), and
acidified methanol (acetonitrile) is discussed in detail in the "Discussion"
section of this chapter.
When the SPE procedure was included in the work-up,

the BC-9-NMT

reaction was terminated by placement on ice and addition of 200 µ1 0.5 N HCl04.
The mixture was centrifuged to pellet precipitated protein (3000xg for 5
minutes), and supernatant was transferred to a glass culture tube containing
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100 µl concentrated ammonium hydroxide (NH40H) and 1.0 ml Milli-Q water.
The protein pellet was vigorously resuspended in 500 µl 0.01 N HCl0-1- and
centrifuged

(3000g for 5 minutes); the resulting supernatant was mixed with

100 µl 1 N potassium hydroxide and then combined in the glass tube with the
initial

supernatant.
Contents of the glass tube were slowly applied to a Sep-Pak® C18 Plus

solid-phase extraction cartridge (Millipore-Waters part no. 20515, 360 mg). The
SPE cartridge was previously pretreated with 5 ml each of methanol (or
acetonitrile):5 N acetic acid (3: 1, v/v), methanol or acetonitrile, and 1% NH 40 H
(w/v) in that sequence.

Slow application of all solutions to the cartridge (2 to 5

drops per second) was achieved using a syringe or a vacuum manifold.
Following sample application, the extraction cartridge was washed with 5 ml of
1% (w/v) NH40H followed by 5 ml methanol or acetonitrile.

These two SPE

fractions and the sample application fraction were analyzed for 2,9-Me2NH+.
The final eluent (2x2 ml) -- containing 3:1 (v/v) methanol (or acetonitrile):
5 N acetic acid -- promoted elution of 2,9-Me 2 NH+ from the cartridge into a
clean glass culture tube.

This eluate was evaporated to dryness at 30-40 °C

using a Speed Vac concentrator (Savant Instruments Inc., Hicksville NY).

Reverse-Phase High Performance
Liquid Chromatography
(RP-HPLC)
BC-9-NMT activity was quantitated by measuring 2-9(3H-methyl)Me 2 NH+ present in the reaction work-up using RP-HPLC.
method are described in Appendix B.

Details of the HPLC

Acidified supernatant -- the solution
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resulting from the work-up that excluded SPE -- was assayed "as-is".

When the

SPE protocol was used the resulting Speed Vac residue was dissolved in 200 µ1
HPLC mobile phase or 0.01 N HCl04 by sonication and vortcxing and then
filtered.

Samples were filtered through a 0.45 µm nylon membrane filter

(Micro-Spin, Chrom-Tech Inc.) prior to injection (10-150 µ1) onto the HPLC
system.

Isocratic HPLC analysis was carried out under ambient conditions on a

Bondclone 10 µm C18 column (Phenomenex™, 300 mm x 3.9 mm).

Mobile phase

consisted of 17% (v/v) HPLC grade acetonitrile mixed with 83% (v/v) aqueous
buffer.

Buffer contained 1 M sodium phosphate monobasic adjusted to pH 3.5

with phosphoric acid (final mobile phase pH 4.0 ± 1).

The HPLC system was a

Shimadzu SIL-9A programmable autosampler, a Beckman 1 lOA pump or BAS
PM40 (0.8 ml/minute), and an in-line radioactive flow detector (Radiomatic
Instruments

Flo-One\B ).

Ultima-Flo™ AP (Packard Instruments) liquid

scintillation cocktail was used at a flow rate of 2.8 ml per minute, resulting in a
scintillation fluid to mobile phase mixing ratio of 7:2.

The radioactive flow

detector was equipped with a 2.5 ml flow cell and an automatic stream splitter.
It was necessary to bypass the radioactive flow detector by splitting the HPLC

column effluent to waste until about 17-18 minutes into the run to reduce
interference due to tritiated materials (e.g., 3H-SAM) present in the sample.
Radioactive peak area corresponding to 2,9-Me2N H + (retention time 19-20
minutes) was integrated using Radiomatic Flo-One\B system software.

Peak

area was reported as total counts per minute (cpm) under the 2,9-Me2NH+
curve.

Flo-One\B counting efficiency and reaction specific activity were

determined routinely; this allowed for calculation of pmoles tritiated 2,9Me2NH+.
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Strong-Cation Exchange High Performance
Liquid Chromatography
(SCX-HPLC)
An alternate HPLC method was SCX-HPLC with fluorescence detection
(see details in Appendix B).
RP-HPLC.

Sample preparation was the same as described for

Isocratic SCX-HPLC analysis was carried out under ambient

conditions on a strong cation exchange column (Vydac catalog #401 TP104, 250
m mx 4.6 mm).

Mobile phase consisted of 50% (v/v) HPLC grade acetonitrile

mixed with 50% (v/v) aqueous buffer.

Buffer contained 300 mM ammonium

chloride and 200 mM ammonium acetate, adjusted to pH 3.4 with glacial acetic
acid (final mobile phase pH 4.5 ± 1).

The HPLC system included a Shimadzu

SIL-9A programmable autosampler, a Beckman l IOA or BAS PM40 pump (0.8
ml/minute), and a Perkin-Elmer LC240 fluorescence detector.

Excitation and

emission wavelengths for detection of 2,9-Me 2NH + were 310 nm and 450 nm,
respectively.

Data reporting and integration were achieved with a Shimadzu

C-R lB Chromatopac reporting integrator.
were: NH

@

6.5-7.5 minutes, 2-MeNH+

minutes, and 2,9-Me2NH+

@

@

Retention times for relevant BCs
9.5-10.5 minutes, 9-MeNH

14-15 minutes (Figure 6).

@

10.5-11.5

Peak areas for 2,9-

Me2NH+ standard solutions of known concentration were analyzed in order to
plot a standard curve.

The resulting linear equation was used to calculate the

concentration of 2,9-Me2NH + present in BC-9-NMT reactions (Figure 7).
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Figure 6. Rendition of representative SCX chromatogram. Compounds:
NH=norharman, 2-Me2NH+=2-methylnorharmanium ion, 2,9-Me2NH+=2,9dimethylnorharmanium ion. Column (SCX): Vydac 401TP104, 250 mm x 4.6 mm.
Mobile phase (0.8 ml/min): 50% acetonitrile + 50% pH 3.4 buffer, buffer=300
mM ammonium chloride + 200 mM ammonium acetate. Fluorescence detection:
excitation at 310 nm, emission at 450 nm.
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Figure 7. SCX chromatography standard curve. Refer to Figure 6 for details.
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First Experiment Replicating the
BC-9-NMT Activity Reported
by Matsubara
Assays (370 µI) contained guinea pig brain homogenate (0.636 mg
protein), 1.08 mM 2-MeNH+, and SAM (8.1 µM, 4.28 µCi) in sodium phosphate
buffer at a final pH of 8.55.

Assays were maintained at 37 °C for one hour.

The

SPE procedure was not utilized in the work-up.
Determination of Apparent Kinetic Constants
With Respect to the Methyl Donor
(SAM)
Assays included guinea pig brain homogenate (0.716 mg protein), 2MeNH+ (1.08 mM), 3H-SAM (7.1 or 14.2 µCi), and SAM at a final concentration
ranging from 10 - 400 µM.
in sodium phosphate buffer.

Total assay volume was 370 µI and final pH was 8-8.1
No SPE work-up was done following assay

incubation at 37 °C for one hour.

BC-9-NMT activity -- expressed as pmoles of

2,9-Me2NH+ formed per hour per mg protein (pmol/h/mg protein) -- was
determined at each SAM concentration.
SAM" sample was not evaluated.

Due to a technical problem the "10 µM

Plotting and curve-fitting were accomplished

using Kaleidagraph™ data analysis/graphics application software (Abelbeck
Software).

The Lineweaver-Burk analysis was used to plot data and determine

the kinetic constants, KM and Vmax (Lehninger 1975).

TRIS Buffer Compared to Phosphate Buffer and
BC-9-NMT Activity in Yeast Extract
All substrates were dissolved in 100 mM TRIS buffer (pH 8.3) instead of
sodium phosphate buffer; concentrations were 1.08 mM 2-MeNH+ and 500 µM
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SAM (16.8 µCi).

Guinea pig brain was homogenized in the same TRIS buffer

using a Tissuemizer®; 100 µl of the resulting homogenate (1.132 mg protein)
was added to each BC-9-NMT assay.
1.338 mg protein.

Yeast extract, 100 µ1 per assay, contained

Reactions were prepared in duplicate and maintained at

37 °C for one hour.

One set of incubations was subjected to the SPE procedure

and the other was not.
Measurement of BC-9-NMT Activity
in Various Rat Organs
Organs were quickly dissected from an ether-anesthetized, adult-female
Sprague-Dawley rat.
stored at -80 °C.

Tissues were placed on foil on dry-ice, wrapped, and then

Rat tissues analyzed for BC-9-NMT activity included:

lung,

liver, kidney, spleen, and thymus.

Guinea pig brain was also evaluated and

served as a comparative control.

Tissue homogenates (5 ml buffer per gram

tissue) were prepared in 100 mM TRIS buffer (pH 8.3) using a Tissuemizer®.
BC-9-NMT assays contained 1.08 mM 2-MeNH+ and SAM (8.1 µM, 7 .5 µCi) in TRIS
buffer at a final pH 8.3.
SAM.

Assay volume was 185 µl due to a limited supply of 3H-

Samples were maintained at 37 °C for one hour.

The SPE procedure was

included in this experiment, and tritiated 2,9-Me2N H + was measured in each
SPE fraction.

Syringes were used to apply sample and eluents to the SPE

cartridges.

Fluorescence Detection of 2,9-Me2NH+ Product
(Rather Than Radioactive Detection)
Reactions consisted of guinea pig brain homogenate

(100 µl, 1.28 mg

protein), 100 µM 2-MeNH+, and SAM (500 µM) in 100 mM TRIS buffer (pH 8.3).
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Assays (200 µI) were maintained at 37 °C for one hour.

Note that the following

changes were incorporated into this experiment: no radioactive SAM was used,
2-MeNH+ concentration was reduced about 10-fold, and assay volume was
reduced from 370 µI to 200 µI. The SPE procedure was not included in the assay
work-up.

Three distinct types of "blank" assays were evaluated: one lacking 2-

Me NH+, one without SAM, and one with boiled homogenate.

Replicate reactions

(N=3-5) were prepared and analyzed at each condition.
Fluorescence detection of 2,9-Me 2NH+ was achieved using a PerkinElmer LC240 detector: excitation wavelength was 310 nm and emission
wavelength was 450 nm.

These wavelengths were optimal for detection of 2,9-

Dialysis of Guinea Pig Brain
Homogenate
Guinea pig brain was homogenized in 5 volumes of 10 mM Na2HP04 (pH
7.4) containing the protease inhibitor phenylmethylsulfonylfluoride (PMSF).
A 1.2 ml aliquot of this homogenate was dialyzed against 1 L of IO mM Na2HP04
(pH 7.4).

Dialysis was done at 0-5 °C using SpectraPor 3 (Scientific Products)

dialysis tubing with a 3500 molecular weight cutoff (m.w.c.o.).
Assays contained boiled homogenate or undialyzed homogenate (0.640
mg protein) or dialyzed homogenate (0.524 mg protein).

Substrates included

500 µM 2-MeNH+ and 500 µM SAM in 100 mM Na2HP04 buffer at pH 9.5. Volume
totaled 200 µI and final pH was 8.5.

Six replicates were prepared for each

condition, and assays were maintained at 37 °C for one hour.
terminated by the addition concentrated HCI04.

Reactions were

Strong-cation exchange
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chromatography with fluorescence detection was utilized to measure 2,9Me2NH+ in the reaction work-up.

BC-9-NMT activity was expressed as pmoles of

2,9-Me2NH+ formed per hour per mg protein (pmol/h/mg protein).

BC-9-NMT Activity in Frozen
Bovine Brainstem
Frozen bovine brain was purchased from Pel-Freez and stored at -80 °C.
Homogenation and subcellular fractionation was similar to the Mizoguchi et al.
procedure (Mizoguchi 1989).

Brainstem (pons and medulla oblongata) was

thawed, cut into small pieces, and homogenized at 0-5 °C in 4 volumes of buffer
at 0-5 °C in a glass homogenizer by 6 up-and-down strokes of a motor-driven
teflon pestle. Homogenation buffer consisted of 0.32 M sucrose, 1 mM NaHC0 3
(pH 7.2), 0.5 mM CaCl2, 1 mM MgCJi, and 1 mM PMSF. Homogenate was diluted to
10% (w/v) with homogenation buffer and filtered through 4 layers of gauze to
yield crude whole brainstem homogenate.
Homogenate was centrifuged at 1400g for 10 minutes, and the pellet was
resuspended in homogenation buffer to 10% (w/v) and re-homogenized.
Centrifugation at 7 lOg for 10 minutes afforded pellet "P1 ", comprised of nuclei
and cell debris. The "P 1" supernatants were pooled and centrifuged at 13,800g
for 10 minutes.

The resulting pellet was washed and centrifuged at 13,800g for

10 minutes, yielding "P2" -- theoretically a mixture myelin, mitochondria, and
synaptosomes.

Combined "P2" supernatants were centrifuged at 105,000g for

60 minutes to produce "P3" and "S 3", equivalent to microsomal and cytosolic
(soluble) fractions, respectively.

Pellets were diluted in 10 mM Na2HPO.i (pH
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7.4) prior to use in BC-9-NMT assays.

Dialysis of crude homogenate or

subfraction was accomplished in SpectraPor 3 (3500 m.w.c.o.) dialysis tubing
against 1 L of 10 mM Na2HP04 (pH 7.4).

Dialysis was carried-out overnight at

0-5 °C; dialysis buffer was changed 3-4 times.
For BC-9-NMT assays, 2-MeNH+ (500 µM) and SAM (370 µM) were
prepared in 100 mM Na2HP04 (pH 9.5).
was 200 µI.

Final assay pH was 8.3-8.5 and volume

Blank assays contained all substrates and boiled homogenate or

boiled subfraction.

Replicates (N=5-7) were prepared at each assay condition.

Reactions were maintained at 37 °C for one hour and then terminated by HCI0 4
addition.

Product 2,9-Me2NH+ was quantitated using SCX-HPLC and

fluorescence

detection.
BC-9-NMT Activity in Fresh

Bovine

Brainstem

Fresh bovine brain was obtained from Aurora Packing Company
(Aurora, IL).

Brainstem (medulla, midbrain, and pons) was cut into pieces and

homogenized briefly in a Waring blender at 0-5 °C with 0.32 M sucrose, 1 mM
NaHC03 (pH 7.2), 0.5 mM CaClz, 1 mM MgClz, 1 mM PMSF, and 1 µg/µI leupeptin.
Homogenation was subsequently continued in a glass homogenizer using 12
up-and-down strokes of a motor-driven teflon pestle (1000 rpm).

Crude

homogenate was stirred for 15 minutes in a plastic beaker and then
centrifuged at 1400g for 10 minutes.

The pellet was resuspended in buffer and

centrifuged at 600g for 10 minutes to yield the crude nuclear pellet ("P 1").
combined supernatants were saved but not assayed in this experiment.

The

Crude

homogenate or nuclear extract was dialyzed so that BC-9-NMT activity could be
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compared in undialyzed and dialyzed fractions.
Reactions (200 µl) at pH 8.3 in phosphate buffer, contained 500 µM 2Me NH+, 370 µM SAM, and 100 µl of dialyzed or undialyzed bovine brain fraction.
Assays were maintained for 1 hour at 37 °C and then terminated by the
addition of concentrated HCl04.

BC-9-NMT activity was calculated by measuring

2,9-Me2NH+ in the work-up using SCX-HPLC with fluorescence detection.

Note

that this experiment was repeated three times with variable results.

Results
First Experiment Replicating
the BC-9-NMT Activity
Reported by Matsubara
BC-9-NMT activity was 4.6 pmol/h/mg protein in guinea pig wholebrain homogenate.

This value is consistent with the activity (4.7 pmol/h/mg

protein) reported by Collins et al. (1992) under identical experimental
conditions.

Effect of S-Adenosyl-L-Methionine
Concentration on BC-9-NMT
Activity
Figure 8 represents the Lineweaver-Burk plot derived for guinea pig
whole-brain homogenate BC-9-NMT activity as a function of SAM
concentration.
33

Calculated kinetic constants with respect to SAM were:

± 12 pmol/h/mg protein and

KM, 997

± 113 µM.

Vmax,
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1/v

= (KM/ Vmax)(1/[SAM])

1/v

= 0.0292

+ (1/V max )

+ 29.9(1/[SAM]), r2 = 0.951
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Figure 8. Lineweaver-Burk plot for BC-9-NMT activity as a function of SAM
concentration.
Enzyme activity (pmol 2,9-Me2NH + formed/h/mg protein) was
determined in guinea pig whole-brain homogenate.
SAM concentration
varied from 20 to 400 µM while BC substrate (2-MeNH+) was fixed at 1.08 mM.
Assay was carried out for one hour at 37 °C at pH 8.05 in phosphate buffer. The
Lineweaver-Burk equation is shown as well as the equation and coefficient of
determination (r2) resulting from linear curve-fitting of the data. Values for
KM and Ymax are calculated values ±standard errors.
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Effect of TRIS Buffer on BC-9-NMT Assay, and
BC-9-NMT Activity in Yeast
Brain BC-9-NMT activity was comparable in TRIS buffer and phosphate
buffer.

Activity was detected in both brain and yeast extracts (Table 5).

This

table also compares the results obtained with and without the SPE work-up.
"Sample" SPE fraction represents the flow-through from the cartridge during
application of the initial basified sample to the SPE cartridge and "NH40H" is
the 1% (w/v) ammonium hydroxide wash fraction.
was detected in "Sample" and "NH4 OH" fractions.

Unexpectedly, 2,9-Me2NH+
As expected, no product was

found in the methanol fraction off the SPE cartridge.

"H+ I ACN" is the

acidified acetonitrile used to elute tritiated 2,9-Me 2 N H + from the cartridge
but no product was measured here. "Acid" represents the acidified supernatant
resulting from the reaction work-up that excluded SPE.

60

Table 5.--Brain and Yeast BC-9-NMT Activity in Solid-Phase Extraction
Cartridge Fractions and Acidified Supernatant
BC-9-NMT Activity (pmol

!him~

protein)

Fraction
Sample

NH40H

H+/ACN

I..ailll

A.ci.d

Brain

8.6

12.4

0

21.0

39.8

Yeast

0

15.0

0

15.0

5.0

Values are the number of pmoles of 2,9-Me 2 N H + in each fraction from the
solid-phase extraction cartridge.
Following BC-9-NMT assay, proteins were
precipitated by HCl04, resulting supernatant was basified with KOH/NH.iOH, and
then applied to SPE cartridge. "Sample" = fraction collected during sample
application to the cartridge, "NH40H" = fraction collected during ammonium
hydroxide wash, "H+/ACN" = fraction collected during the acidified acctonitrile
wash, and "Total" is the sum of the 3 fractions. "Acid" is the acidified
supernatant from assay that did not include the SPE work-up.
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BC-9-NMT Activity in Rat Organs

Compared to Guinea Pig Brain
Guinea pig brain and each of the rat organs tested has BC-9-NMT
activity (Table 6).

Rat thymus exhibited the highest BC-9-NMT activity at 44.6

pmol/h/mg protein. Note that in liver assays the chromatograms were
difficult to interpret due to "background" radioactivity; therefore, activity was
not reported in those fractions.

Total BC-9-NMT activity in guinea pig brain

(22 pmol/h/mg protein) is consistent with the brain "Total" in the previous
experiment (21 pmol/h/mg protein).

Consistent with previous experiment,

these data suggest that a substantial quantity of tritiated 2,9-Me2N H + was not
retained by the cartridge during sample application ("Sample") and that
product was present in SPE fractions other than the acidified methanol eluate
("H+/MeOH").

No product was found in the methanol wash.

The percentage of

total product recovered in all fractions is represented in parentheses (Table 6).
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Table 6.--BC-9-NMT Activity in Guinea Pig Brain
and Rat Organs

BC-9-NMT Activity (pmol/h/mg protein)
Fraction
Sample

NH40H

H+/MeOH

Total

Brain

4.2 (19%)

8.9 (40%)

9.1 (41%)

22.3

Lung

1.3 (7%)

8.8 (43%)

10.3 (50%)

20.4

Thymus

4.6 (10%)

23.7 (53%)

16.3 (37%)

44.6

Organ

Liver

2.8

Kidney

0.9 (5%)

9.6 (56%)

6.7 (39%)

17.2

Spleen

0 (0%)

7.5 (45%)

9.1 (55%)

16.6

Values are the number of pmoles of 2,9-Me 2 N H + in each fraction from the
solid-phase extraction cartridge.
Following BC-9-NMT assay, proteins were
precipitated by HCl04, resulting supernatant was basified with KOH/NH40H, and
then applied to SPE cartridge. SPE fractions, in order of collection were:
"Sample" = fraction collected during sample application to the cartridge,
"NH40H" = fraction collected during ammonium hydroxide wash, "H+/ACN" =
fraction collected during the acidified acetonitrile wash, and "Total" is the sum
of the 3 fractions.
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Fluorescence Detection of 2,9-Me2NH +Product
(Rather Than Radioactive Detection)
Fluorescence detection of 2,9-Me 2N H + in BC-9-NMT assays is possihle.
Figure 9 shows that BC-9-NMT activity in "blank" assays is statistically
different than complete assays when fluorescence detection is utilized to
measure 2,9-Me2NH+ formed.

"Activity" in blanks is due to 2,9-Me 2NH+ present

in the substrate 2-MeNH+ or other fluorescent compounds unrelated to 2,9Me2NH+, but with an identical retention time.

Additionally, 2,9-Me2NH+ product

present in the assays lacking 2-MeNH+ substrate may be due to endogenous 2,9Me 2NH+ present in the homogenate itself.

Net BC-9-NMT activity (complete

minus boiled) is 9.6 ± 3.1 pmol/h/mg protein.
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Figure 9. BC-9-NMT activity in guinea pig brain homogenate with 2,9-Me2NH+
measurement by fluorescence detection.
Error bars are s.e.m. Complete assay
is significantly different than assay containing boiled homogenate or assays
lacking substrate (* p<0.05). All assays were done at 37 °C for I hour at pH 8.3,
and included guinea pig brain homogenate (1.28 mg protein) that was not
boiled, except where noted. All assays contained 100 µM 2-MeNH+, except for
the "No 2-MeNH+" assay. All assays contained 500 µM SAM except for the "No
SAM" assay.
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Dialysis of Guinea Pig
Brain Homogenate
It appears that dialysis increases BC-9-NMT activity in guinea pig brain
homogenate, perhaps due to the removal of a low molecular weight inhibitor
(Figure 10).

Dialyzed - Boiled = Net BC-9-NMT Activity
(61.0 - 47.4)(pmol/h/mg) = 13.6 pmol/h/mg
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Figure 10. BC-9-NMT activity in dialyzed guinea pig brain homogenate. Error
bars are s.e.m. Dialyzed (3500 m.w.c.o.) homogenate is significantly different
than assay containing undialyzed. homogenate or boiled undialyzed
homogenate (p<0.0005). All assays were done at 37 °C for 1 hour at pH 8.5, and
included undialyzed guinea pig brain homogenate that was boiled
or not boiled (0.640 mg protein), or dialyzed/non-boiled homogenate (0.524 mg
protein). All assays contained 500 µM 2-MeNH+ and 500 µM SAM.
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BC-9-NMT Activity in
Frozen Bovine Brainstem
BC-9-NMT specific activity in undialyzed bovine brainstem homogenate

was 14.6 pmol/h/mg protein.
pmol/h/mg protein.

Dialysis increased the activity 3-fold, to 46.8

BC-9-NMT activity in undialyzed crude nuclear fraction

was 121.3 pmol/h/protein.

Dialysis of the crude nuclear fraction resulted in a

complete loss of enzyme activity.

No BC-9-NMT activity was detected in

undialyzed or dialyzed crude mitochondrial, microsomal, or cytosolic
subfractions.
BC-9-NMT Activity in Fresh

Bovine

Brainstem

BC-9-NMT activity in the crude homogenate from fresh bovine

brainstem was very high at 125.1 pmol/h/mg protein.

This activity is

equivalent to that found in the nuclear extract for the preceding experiment.
Inconsistent with the previous experiment,

undialyzed nuclear fraction

exhibited 5.9 pmol/h/mg protein BC-9-NMT activity.

Samples derived from

dialyzed crude homogenate or nuclear extract could not be assayed due to an
autosampler

malfunction.

Repeats of this experiment produced inconsistent results. In the second
experiment no BC-9-NMT activity was found in either undialyzed crude
homogenate or nuclear extract.

In third experiment, 14.2 pmol/h/mg BC-9-

NMT activity was found in undialyzed crude homogenate; dialysis increased
activity to 126.0 pmol/h/mg protein.
nuclear extract.

BC-9-NMT activity was not assessed in

In the fourth attempt, no activity was detected in undialyzed

or dialyzed crude homogenate.

However, the undialyzed crude nuclear extract

exhibited a BC-9-NMT specific activity 25.5 pmol/h/mg protein.

Dialysis of the
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nuclear extract abolished BC-9-NMT activity.

Discussion

BC-9-NMT activity was detected in guinea pig and bovine brain, several
rat organs, and even yeast extract.

Increasing SAM concentration or extract

dialysis increased BC-9-NMT activity.

Activity in the TRIS buffer was

comparable to activity in phosphate buffer.
As will be discussed below, it is speculated that BC-9-NMT activity is quite
variable from animal to animal.

There are indications that this enzyme is

temperature-labile and that its activity is modified by endogenous dialyzable
substances.

These speculations would explain (in part) the several failed

attempts, aimed at reproducing Matsubara's work, which preceded the first
experiment in which BC-9-NMT activity was successfully measured.
Difficulties in assessment of BC-9-NMT activity are summarized below,
beginning with a discussion of the solid-phase extraction procedure work-up.

Solid-Phase Extraction Protocol
The solid-phase extraction (SPE) protocol includes four steps: sample
application,

NH40H wash, methanol or acetonitrile wash, and finally an

acidified methanol (acetonitrile) eluate.

The SPE procedure was originally

developed as a means of increasing the sensitivity for detection of 2,9-Me2N H +.
Use of SPE decreases non-BC tritiated compounds in the sample that contribute
to background during HPLC analysis.

Lower apparent BC-9-NMT activity in

samples subjected to the SPE procedure versus non-SPE samples is probably
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due to a reduction tritiated background as a consequence of the SPE work-up.
The majority of this background radioactivity is 3H-SAM and its metabolites.
The three ring structure of BCs or MeBCs+ predicts that hydrophobic
forces drive the interaction between these compounds and the C 18 SPE
cartridge.

Since the cartridge is a silica-based packing-material, under basic

conditions the matrix silanol groups will be negatively charged.

It is

suspected that a secondary interaction occurs between the negatively charged
matrix and positively charged MeBCs+ (@ pH > 10).

This interaction is

apparently an important interaction, because when the column or sample is
not basified, MeBCs+ are not retained by the cartridge (data not shown).

The

NH40H wash is intended to remove unwanted compounds from the cartridge,
while MeBCs+ are retained.

However, if this wash is not basic, MeBCs+ are

eluted from the column during this step (data not shown).

In experiments

reported here in which 2,9-Me 2 NH+ was measured in the "Sample" and
"NH 40H" fractions,
a pH less than 10.

it is speculated that either the column or the sample was at
It is also possible, but not as likely,

that the radioactive

compounds detected in these fractions are not 2,9-MezBCs+, but rather
compounds the exhibit a HPLC retention time similar to that of 2,9-Me 2 NH +.
The methanol or acetonitrile wash (i.e., third step in the elution
protocol) disrupts hydrophobic interactions and causes elution of BCs (not
MeBCs+). In addition, this solvent serves as a transition solution between the
NH 40H and the acidified methanol (acetonitrile) wash.

It is surmised that

acidification of the final methanol or acetonitrile eluent is necessary in order
to protonate silanol groups on the matrix, thereby disrupting the proposed
electrostatic interaction between the silica matrix and MeBCs+.

The
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acetonitrile or methanol is included to further disrupt hydrophobic
interaction between the matrix and MeBCs+. This eluate effectively promotes
elution of 2,9-Me2NH+ from the C18 SPE cartridge.

Effect of SAM Concentration
on BC-9-NMT Activity
Matsubara evaluated the kinetic constants, KM and Vmax, with respect to
the BC substrate, but these parameters were not ascertained regarding SAM.
In the present study the KM for SAM was 560 µM, a concentration that is 70-fold
higher than the SAM concentration (8 µM) routinely utilized in BC-9-NMT
assays.

Consider the Michaelis-Menten (M-M) equation and the calculated

velocity under conditions of 8 µM SAM, using KM
pmol/h/mg

= 560 µM

and Vmax

= 20

protein.

M-M equation:

v

= Vmax

[S] I ( KM + [S] )

v = reaction velocity
V max

= maximal

velocity

[S] = substrate concentration
KM= Michaelis constant,

experimentally the substrate

concentration at which velocity is V maxi 2

The calculated velocity when SAM is 8 µM is 0.3 pmol/h/mg protein, a low
activity that may not be consistently detectable.

Therefore,

in subsequent

experiments SAM concentration was increased to 300-500 µM, 3H-SAM was also
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increased.

Problems associated with increasing assay 3H-SAM will be

addressed in a subsequent paragraph.

Buffer Comparison
TRIS buffer was evaluated as an alternative to phosphate buffer in the
BC-9-NMT assay.

TRIS is expected to be a better buffer than phosphate since

the TRIS pKa (8.2) is within the pH range (pH 8-8.5) of the BC-9-NMT assay,
while the pKa for phosphate buffer (pKa 7 .2) is not within the desired range
for the BC-9-NMT assay.

Results indicate that BC-9-NMT activity was higher in

pH 8.3 TRIS buffer (39.8 pmol/h/mg protein) compared to previous
experiments in Na2HP0 4 at pH 8.05. This suggests that BC-9-NMT activity may be
inhibited somewhat in the presence of phosphate ions and/or the enzyme is
more active at pH 8.3 compared to pH 8.05.

These issues were not addressed any

further, and TRIS buffer was employed in several of the experiments
presented

below.

Activity in Yeast and Rat Organs
BC-9-NMT activity was detected in several rat organs as well as yeast cell

extract.

Enzyme activity was assessed in these preparations in an effort to

identify a potential starting material for enzyme purification purposes.

Rationale for Use of Fluorescence
Detection of 2,9-Me2NH+
An unfortunate drawback to increasing SAM in these reactions is the
concomitant increase in 3H-SAM required so that tritiated 2,9-Me 2 NH+ could be
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detected.

Excessive use of tritiated SAM is quite expensive and contributes

significantly to background during HPLC analysis.

Therefore fluorescence

detection was investigated as an alternate method for measuring 2, 9-Me2 NH+
formed by the action of BC-9-NMT.
BCs, exhibit fluorescent properties

B-Carbolines, particularly N-methylated
especially at acidic HPLC conditions --

and are consequently amenable to fluorescent detection.

In contrast SAM is

very weakly fluorescent under these same conditions, so a large excess of nonradioactive SAM could be used in the BC-9-NMT assay with little effect on the
quality of the chromatogram.
The advantages of fluorescence detection of 2,9-Me2N H + are that it
circumvents the requirement for the SPE protocol, eliminates 3H-SAM

from

the J3C-9-NMT assay, and allows for the analysis of a greater number of samples
per day (use of an autosampler is possible).

Because of these advantages, the

fluorescent assay is much more efficient and more economical than the
radioactive assay.

One dis ad vantage of the fluorescent assay derives from the

discovery that the substrate 2-MeNH+ contains traces (<0.1 %, w/w) of product
2,9-Me 2NH+.

This "background" 2,9-Me 2NH+ is bothersome since its level often

exceeds that of the 2,9-Me2NH + formed by BC-9-NMT.

Because of this

background, 5-7 replicates each of blank and complete assays are required in
order to achieve statistically significant differences between these two
conditions.

This large number of replicates obviously precludes the use the

fluorescent assay during the proposed purification of BC-9-NMT.

Another

disadvantage of fluorescent detection is that when a large amount of 2-MeNH+
is used in the BC-9-NMT assay, the

2,9-Me2N H + product peak appears as a small

shoulder peak on the 2-MeNH+ substrate peak.

This poor resolution
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occasionally makes 2,9-Me2NH + quantitation difficult.

Attempts at purification

of 2-MeNH+ to remove trace 2,9-Me2NH+ were fruitless.

BC-9-NMT Activity as a
Function of Time
BC-9-NMT activity as a function of time offered some interesting clues
regarding the stability of the enzyme or its product.

Recall that activity

increased up to about 15 minutes and then decreased to below detection.

This

suggests that BC-9-NMT is either labile or that another enzyme system present
in the assay is catabolizing the 2,9-Me 2NH+ formed by BC-9-NMT.

However, a

similar time profile was not observed for BC-2-NMT activity (see Chapter 3),
implying that 2,9-Me2NH+ is not catabolized by endogenous enzymes under
similar conditions.

Unfortunately this BC-9-NMT time-study could not be

replicated; i.e., BC-9-NMT activity was often measured at the 30 or 60 minute
time-points

in

subsequent

experiments.

Inconsistent Detection of Activity
Over an 8 month period of study. BC-9-NMT activity became rather
elusive and could not be measured on a consistent basis.
factors on BC-9-NMT activity were assessed.

The effects of several

Factors evaluated included:

characteristics of guinea pig brain (vendor, sex and age of animal); SAM
vendor; reaction work-up; and removal of endogenous SAH by SAH hydrolase
plus adenosine deaminase.

Often BC-9-NMT activity could not be detected or at

least distinguished statistically from blanks (except occasionally in yeast
extracts).

Matsubara indicated that he experienced similar difficulties in
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assessment of BC-9-NMT activity upon his return to Japan. He suggested using
brain tissue harvested from older animals, increasing SAM concentration, and
dialysis of brain extracts (to remove endogenous BC-9-NMT inhihitors).

As

reported in this Chapter, increasing SAM concentration did increase BC-9-NMT
activity; however, increased SAM concentration had no effect on the
consistency of detection of BC-9-NMT activity.

Subsequent evaluation of brain

harvested from old and young guinea pigs did not affect BC-9-NMT activity.
Dialysis of brain homogenate was the only strategy that enhanced detection of
BC-9-NMT activity, and this effect was not dramatic. This is consistent with the

presence of a dialyzable inhibitor of BC-9-NMT; there are reports of dialyzable
low-molecular-weight inhibitors of methyltransferases (Park et al.

1993 ).

Bovine Brain BC-9-NMT Activity
BC-9-NMT activity was also evaluated in bovine brain -- a potential
inexpensive and abundant source of enzyme for purification purposes.

Bovine

brainstem was initially tested since Matsubara et al. (1992b) reported highest
BC-9-NMT activity in guinea pig brainstem.

Initial studies, using frozen

bovine brainstem, confirmed these published results, which showed a
primarily nuclear localization for BC-9-NMT activity.

It is intriguing that

dialysis of bovine-brainstem whole-homogenate increased BC-9-NMT activity,
while dialysis of nuclear extract reduced or abolished enzyme activity.

This

suggests that BC-9-NMT may exist in two forms: a non-nuclear form that is
inhibited by some dialyzable substance and a nuclear form that requires a
dialyzable

factor.

In contrast to the results for frozen bovine brainstem, in the

firs~

experiment using fresh bovine brainstem, very little nuclear activity was
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measured and there was a high level of BC-9-NMT activity rn wholchomogenate.

It is possible that subtle differences in homogenation between

this and the previous study may account for these results.

Perhaps in the

present study, nuclei were damaged or disrupted thereby releasing f3C-9-NMT
into

the

whole-homogenate.

Similar to activity from guinea pig brain, bovine brainstem f3C-9-NMT
activity could not be measured consistently.

It was suspected that freezing

may adversely affect BC-9-NMT activity, but this suspicion was not evaluated
systematically.
BC-9-NMT activity was aggressively pursued for at least a year.

After

that, BC-9-NMT and BC-2-NMT activities were re-evaluated in bovine and
guinea pig brain using RP-HPLC with radioactive detection (data not shown).
BC-9-NMT activity was undetectable in both samples, while BC-2-NMT activity

was present in both.

Consequently, the investigation of BC-2-NMT began (see

Chapter 3).
Noteworthy is the fact that BC-9-NMT activity was later consistently
measured in postmortem human brain tissue ( see Chapter 5).

Briefly, BC-9-

NMT activity in human brain was higher in the 10,000xg supernatant fraction
than it was in the corresponding particulate fraction.

In control tissue

particulate fraction activity was 7 .8 pmol/h/mg protein (range 0-45 .2
pmol/h/mg protein) across the brain regions tested, while supernatant
activity averaged 14.3 pmol/h/mg protein (range 0-67.7 pmol/h/mg protein).
Consistent measurement of BC-9-NMT in human brain suggests that it may be a
better source than bovine brain for study of BC-9-NMT activity.

CHAPTER3
CHARACTERIZATION OF BOVINE BRAIN
B-CARBOLINE-2N-METHYL TRANSFERASE

Back~round

This chapter describes experiments designed to characterize the
following

properties

of bovine

brain

B-carboline-2N-methyltransferase

(BC-2-NMT): (a) subcellular localization; (b) apparent kinetic constants,
Michaelis constant (KM ) and maximal velocity (V max) with respect to its
cosubstrates

9-methylnorharman

(9-MeNH)

and

S-adenosyl-L-methionine

(SAM); (c) dependence of activity on protein concentration;
for enzyme assay; (e) activity as a function of assay time;

(d) pH optimum
(f) inhibition by S-

adenosyl-L-homocysteine (SAH), a competitive inhibitor of SAM-dependent
methyltransferases; and (g) the effect of various metals on its activity.
Delineation of these properties was essential to the development of a sensitive
and reproducible enzyme assay for use in future studies, including the
purification of BC-2-NMT from bovine brain (Chapter 4) and comparison of
BC-2-NMT activity in parkinsonian and normal human brain (Chapter 5).
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Materials and Methods
Reagen ts
6-Carboline substrate, 9-methylnorharman, was synthesized in our
laboratory using two different methods:

according to Matsuhara (Matsubara et

al. 1992b) or a modification of the method described by Rubottom (Rubotlom et
al. 1974).

The modified Rubottom method is described in Appendix C. Unlahelcd

S-adenosyl-L-methionine (toluenesulfonate salt) and tritiated S[methyl-3H]-adenosyl-L-methionine (60-85 Ci/mmol) were purchased from
Sigma Chemical and Dupont NEN, respectively.

All other reagents were of

appropriate purity for their intended use and were utilized as purchased.

Subcellular

Fractionation

Bovine brain (including brainstem) was obtained fresh (Aurora
Packing Co., Aurora IL), divided sagittally into equal halves, and frozen at -80
°C for three months. Brain was quickly thawed in a 40 °C water hath, and
subsequently homogenized in 2 volumes (2 ml/g tissue) of cold buffer "HI"
using a chilled Waring blender at low speed (3 cycles x 30 seconds per cycle).
Buffer "'Hl" contained 150 mM potassium chloride (KCI), 1 mM dithiothreitol
(OTT), 1 mM ethylenediaminetetraacetic acid disodium (EDT A), and 20 mM
sodium phosphate dibasic (Na2HP04) at pH 7.4.

The homogenate was filtered

through two to four layers of gauze prior to centrifugation.

Centrifugation

was accomplished at 5-10 °C iri a Sorvall RC5B Superspeed centrifuge (SS-34
rotor) or a Beckman L8-M Ultracentrifuge equipped with a SW28 rotor.
Centrifugation at 900g (10 minutes), 9000g (15 minutes), and 100,000g (one
hour) afforded crude nuclear, mitochondrial, and microsomal plus cytosolic
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fractions, respectively.

Crude particulate fractions were diluted with 150 mM

KCl prior to inclusion in assays; crude cytosol was not diluted.
For experiments other than subccllular fractionation,

bovine brain

(including brainstem) was obtained fresh (Aurora Packing Co., Aurora IL),
divided sagittally into equal halves, and frozen at -80 °C for seven months.
Brain was quickly thawed in a 40 °C water bath, and subsequently
homogenized in 2 volumes (2 ml/g tissue) of cold "H2" using a chilled Waring
blender at low speed (3 cycles x 30 seconds per cycle).
150 mM KCl and 1 mM DTT.

Solution "H2" contained

The crude cytosolic supernatant was obtained from

filtered homogenate following sequential centrifugation at 15,000g
minutes) and 100,000g (one hour).

Cytosolic supernatant was stored at -80 °C

in polypropylene tubes in 2-3 ml aliquots.
needed for use in 6C-2-NMT assays.

(30

Frozen aliquots were thawed as

For some studies, fresh bovine brain was

homogenized in buffer "H3" which contained 20 mM K2HP04, 150 mM KCl, 1
mM DTT, 1 mM EDTA, 1 mM phenylmethylsulfonylfluoride, and 1 µg/ml each
leupeptin and pepstatin A.
buffer "H2".

Cytosol was obtained and stored as described for

Composition of the homogenation buffer had no obvious effect

on 6C-2-NMT stability or assay.
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Determination of BC-2-NMT Activity
This activity catalyzes the transfer of the tritiated methyl moiety from
SAM to 9-MeNH resulting in the formation of 2-(3H-methyl)-9-MeNH+ and SAH
(Figure 11) .

*
H

+

O-I3

I

HOOC-C-(CH2)2-S-Cl-I2
I
+
NH2

I SAM I

19-MeNH

Adenine

I

I

GI

Cl-I

(sc-2-NMT )

Adenine

H
I

HOOC-C-(CH2)2-S-CH2
I

+

NH2

GI

a-1

2,9-Me2NH+

Figure 11. BC-2-NMT assay. Site of tritium label in molecule marked with *.
Abbreviations: 9-methylnorharman (9-MeNH), 2-[3H-methyl]-9methylnorharmanium ion (2,9-Me 2 N H +), S-adenosyl-L-methionine (SAM),
S-adenosyl-L-homocysteine (SAH).

I
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Use of the norharman, a presumed physiological substrate, rn the assessment
of BC-2-NMT activity would have been confusing since the reaction product, 2MeNH + (refer to Figure 2) is subsequently 9N-methylated by BC-9-NMT;

i.e., it

would be difficult to quantitate the product 2-MeNH+ since it converted to 2,9Me2NH +.

Therefore, the BC substrate 9-MeNH was used to assess BC-2-NMT

activity since its

indole position (9N-) is already methylated, allowing for

measurement of methylation occurring exclusively at the 2N- position of the
BC.

It was assumed that 9-MeNH and norharman are similarly 2N-methylatcd

by BC-2-NMT.

This assumption was made based on similar enzyme activities

reported by Collins et al. (1992) for guinea pig brain catalyzed 2N-methylation
of 9-MeNH and norharman.

BC-2-NMT activity was 2.17 ± 0.17 pmol/h/mg

protein with 9-MeNH as the substrate.

Total BC-2-NMT activity with

norharman as the substrate was 7 .85 pmol/h/mg protein) -- the total was
calculated by summing the 2-MeNH+ (4.80 ± 0.06 pmol/h/mg protein) and 2,9Me2NH + (3.05 ± 0.05 pmol/h/mg protein) present in the assay.
The assay was carried out as previously reported by Matsubara ct al.
(1993) with modifications as detailed below.

Enzyme assays were prepared in

1.5 ml polypropylene microcentrifuge tubes by mixing concentrated stock
solutions of 9-MeNH and SAM with whole brain homogenate or subfraction.
Stock solutions of SAM were prepared in water,

and 9-MeNH was dissolved in a

buffer mixture consisting of 50 mM sodium phosphate (Na 2HP04) and 50 mM
bicine at pH 6 to 9.

Brain homogenate or subcellular fraction containing 0.014

to 3.33 mg protein per assay tube was present in buffer "Hl", "H2", or "H3".
Stock solution volumes remained constant across studies, whereas stock
solution concentrations and final pH varied depending upon the experiment.
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Assay volume was 370 µl, comprised of the following stock solutions: 50 µl
3H-SAM, 20 µl non-radioactive SAM,
solution.

200 µl 9-MeNH, and 100 µI enzyme

The final assay pH, as well as the final substrate and protein

concentrations are indicated below for each experiment.

The assay was gently

vortexed and subsequently maintained at 37 °C in a shaking water bath for one
hour, except in the time study.
Following incubation at 37 °C the assay tube was placed on ice and
protein precipitated by the addition of 200 µl 0.5 N perchloric acid (HC10 4 ).

The

mixture was centrifuged to pellet precipitated protein (7000g for 5 minutes);
supernatant was transferred to a glass culture tube containing one ml I%
(w/v) ammonium hydroxide (NH 40H, pH IO ± 0.2) and 100 µ1 I N potassium
hydroxide.

The protein pellet was vigorously resuspended in 500 µI 0.01 N

H C 10 4 and centrifuged (1 O,OOOg

for 5 minutes);

the resulting supernatant was

combined in the glass tube with the initial supernatant.

Contents of the glass

tube were slowly applied to a Sep-Pak® Cl8 Plus solid-phase extraction
cartridge (Millipore-Waters part no. 20515, 360 mg). The cartridge was
pretreated with 5 ml each of methanol :5 N acetic acid (3: I, v/v ), methanol, and
1% NH40H (w/v) in that sequence.

Slow application of all solutions to the

cartridge (2 to 5 drops per second) was achieved using a vacuum manifold.
Following sample application, the extraction cartridge was washed with 8 ml of
1% NH40H followed by 5 ml methanol; these washes were discarded since they
contained undesired compounds that contributed significantly to background
radioactivity during subsequent analysis.

The final wash (5 ml), containing

3:1 (v/v) methanol:5 N acetic acid, promoted elution of tritiated 2,9-Me 2 NH+
product from the cartridge into a clean glass culture tube. This eluate was
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evaporated to dryness at 30 - 40 °C using a Speed Vac concentrator

(Savant

Instruments Inc., Hicksville NY).

Reverse-Phase High Performance
Liquid Chromatography
(RP-HPLC)
Activity of BC-2-NMT was quantitated by RP-HPLC analysis of
2-(3H-methyl)-9-MeNH+ present in the Speed Vac residue.

Residue was

dissolved in 200 µI HPLC mobile phase by sonication and vortexing. Samples
were filtered through a 0.45 µm nylon membrane filter (Micro-Spin, ChromTech Inc.) prior to

injection (150 µI) onto the HPLC system.

Isocratic HPLC

analysis was carried out under ambient conditions on a Bondclone I 0 µ C 18
column (Phenomenex™, 300 mm x 3.9 mm).

Mobile phase consisted of 17%

(v/v) HPLC grade acetonitrile mixed with 83% (v/v) aqueous buffer.

The

buffer contained 50 mM triethylamine in 250 mM sodium phosphate monobasic
adjusted to pH 3 with phosphoric acid (final mobile phase was pH 3.4 ± I). The
HPLC system consisted of a Shimadzu SIL-9A programmable autosampler, a
Beckman 1 lOA pump (0.8 ml/minute), and an in-line radioactive flow detector
(Radiomatic Instruments

Flo-One\B ).

Ultima-Flo™ AP (Packard Instruments)

liquid scintillation cocktail was used at a flow rate of 2.8 ml per minute
resulting in a scintillation fluid to mobile phase mixing ratio of 7:2.

The

radioactive flow detector was equipped with a 2.5 ml flow cell and an automatic
stream splitter.

It was necessary to bypass the radioactive flow detector by

splitting the HPLC column effluent to waste until about ten minutes into the
run in order to reduce interference due to tritiated materials (e.g.,
present in the sample.

3 H - SAM)

Radioactive peak area corresponding to 2,9-Me2NH+
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(retention time 12-13 minutes) was calculated using Radiomatic Flo-One\B
system software and resulting integrated peak area was reported as total cpm
under the 2,9-Me2N H + curve (see Figure 12 for representative radiogram).

+

I
0

·s.w .~~ s.r.d.- ~

I
I
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10
Time (minutes)

Figure 12. Rendition of representative HPLC radiogram. Peak represents
radioactivity due to 2,9-dimethylnorharmanium ion (2,9-Me2NH+) formed at pH
8.5 by BC-2-NMT in the presence of9-methylnorharman (9-MeNH), Sadenosyl-:methionine (SAM), and 3H-SAM. Background represents
radioactivity in the absence of 9-MeNH. Chromatographic separation was
performed using RP-HPLC as described in text. Column effluent was split to
waste (s.w.) from 0-9 minutes into analysis, and then split to radioactive
detector (s.r.d.) from 9-20 minutes.
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Determination of pH Optimum
for BC-2-NMT Assay
Buffers composed of 50 mM bicine (pKa 8.3 ) plus 50 mM Na2HP04
(pKa 7.2) spanning the range pH 6.6-9.0 were utilized to prepare 9-MeNH stock
solutions (1 mM); final 9-MeNH concentration in the assay was 540 µM.
Duplicate samples were prepared to contain 0.6 mg protein from bovine brain
cytosol (in "H2"), and SAM at a final concentration of 105 µM (3.6 µCi)
addition to 9-MeNH stock at the indicated pH.

in

Final assay pH was determined to

be identical to the pH of the buffer used to prepare 9-MeNH stock solutions.
BC-2-NMT activity, expressed as pmoles of 2,9-Me 2 NH+ formed per hour per mg

protein (pmol/h/mg protein), was plotted as a function of assay pH.

Assessment of BC-2-NMT Activity as a Function
of Protein Concentration
Bovine brain cytosol in "H2" was concentrated using a Centricon® 30
concentrator (Amicon ®, Beverly MA).

Concentrated cytosol was then serially

diluted with 150 mM KCl to provide solutions containing various protein
concentrations for use in the BC-2-NMT assay.
contain:

protein (0.014 -3.33 mg per assay),

(105 µM, 4.5 µCi) at pH 8.5.

Assays were prepared to

9-MeNH (540 µM),

and SAM

BC-2-NMT-catalyzed formation of 2,9-Me2NH+

(pmol/h) was plotted as a function protein concentration in the assay.

The Effect of Length of Assay Time
on BC-2-NMT Activity
Assays contained bovine brain cytosol (0.687 mg protein in buffer
"H3"), 540 µM 9-MeNH, and 105 µM SAM (2.88 µCi) at pH 8.5. Duplicate samples
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were maintained at 37 °C for 0, 15, 30, 60, 120, and 180 minutes prior to
termination of assay.

The BC-2-NMT-catalyzed formation of 2,9-Me2NH+ was

plotted as a function of time at 37 °C.

Determination of Apparent Kinetic Constants
With Respect to the Methyl Donor
SAM
Assays contained bovine brain cytosol in "H2" (0. 79 mg protein),
9-MeNH (540 µM, pH 8.5), 3H-SAM (2.3 or 6.0 µCi), and SAM at a final
concentration ranging from 2.6 - 520 µM.

BC-2-NMT activity -- expressed as

pmoles of 2,9-Me2N H + formed per hour per mg protein (pmol/h/mg protein)
was plotted as a function of SAM concentration.

Plotting and curve-fitting

were accomplished using Kaleidagraph™ data analysis/graphics application
software (Abelbeck and Synergy Software, Reading PA).

Nonlinear curve

fitting was employed to fit the data to the Michaelis-Menten equation for the
determination of apparent kinetic parameters, the Michaelis constant (KM)
and maximal velocity (V max).

This program uses the Levenberg-Marquardt

algorithm to fit data to a user-defined nonlinear equation.

Data were also

analyzed using a Hanes plot, a linear transformation of the Michaelis-Menten
equation.

Determination of Apparent Kinetic Constants
With Respect to the 8-Carboline
9-MeNH
Assays included bovine brain cytosol (0.79 mg protein), SAM (260 µM,
5.6 µCi), and 9-MeNH at a final concentration ranging from 5 µM to 1 mM at pH
8.5.

Data analysis was achieved as described above.
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Effect of S-Adenosyl-L-Homocysteine (SAH)
on BC-2-NMT Activity
The effect of SAH on BC-2-NMT activity was determined in preparations
containing bovine brain cytosol in "H3" (1.33 mg protein), 540 µM 9-MeNH, 105
µM SAM (2.77 µCi), and SAH at pH 8.5.

Cytosol was concentrated, and

endogenous SAH theoretically removed by ultradiafiltration using a
Centricon® 30 concentrator; ultradiafiltration was carried out against IO mM
Na2HP04

(pH 7) containing 150 mM KCI.

Assays were prepared in duplicate

and contained SAH ranging from 1 µM to 1 mM.

Results are reported as

percent of control .BC-2-NMT activity in the absence of added SAH.

Only the

linear range of the curve is shown (1 µM - 100 µM) for ease in determination
of the ICso following linear curve-fitting of the data.

Effect of Various Metals
on .BC-2-NMT Activity
The effect of a number of transition metals on .BC-2-NMT activity was
determined by adding chloride salts of metals or EDT A at a final concentration
of 1 mM.

Activity was measured in bovine brain cytosol in "H2" or

"H3" (0.721

mg protein) at pH 8.5; substrates were present at 540 µM and 105 uM (3.4 µCi)
for 9-MeNH and SAM, respectively.

Results are reported as percent of control

.BC-2-NMT activity, control activity is activity in the absence of added EDTA or
metal chloride.

Data were obtained from two different experiments, each with

its own control.

Composition of homogenation buffer ("H2" or "H3") did not

appear to affect results between studies.
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Protein

Measurement

Protein was determined using a modified Lowry method as described in
Scopes (1994a).

Details of this method are provided in Appendix A.

Results
Subcellular Distribution of
BC-2-NMT Activity
Bovine brain BC-2-NMT activity (Table 7) resides predominantly in the
cytosolic supernatant (72% of total activity), although there is also notable
nuclear activity (26% of total activity).
the highest specific activity.

The cytosolic subfraction also exhibits

Comparable results -- with respect to fraction

specific activity and subcellular distribution of total activity -- were obtained
upon subcellular fractionation of guinea pig brain (data not shown).
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Table 7 .--Subcellular Localization of
BC-2-NMT Activity in Bovine Brain
Subcellular
fraction

% Recovered

Actiyity

Specific Activity
Cpmol/hr/m2 protein)

Crude

--------

4.1

Nuclear

26.5

1.4

Mitochondrial

0.7

1.6

Microsomal

0.5

3.7

Cytosolic

72.3

21.9

Bovine brain was homogenized in 2 volumes (2 ml/g tissue) of cold buffer
containing 150 mM potassium chloride (KCI), 1 mM dithiothreitol (DTT), I mM
ethylenediaminetetraacetic acid disodium (EDT A), and 20 mM sodium phosphate
dibasic (Na 2 HP0 4 ) at pH 7.4. Homogenate was filtered through 2-4 layers of
gauze prior to centrifugation. Centrifugation at 900g (10 minutes), 9000g ( 15
minutes), and 100,000g
(one hour) afforded crude nuclear, mitochondrial, and
microsomal plus cytosolic fractions, respectively.
Crude particulate fractions
were diluted with 150 mM KCl prior to inclusion in assays; crude cytosol was
not diluted.
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pH Optimum for BC-2-NMT Assay
Under Lhe assay conditions utilized, BC-2-NMT activity increased
linearly from pH 6.6 to approximately pH 8.0, where activity reached a plateau
that extended to pH 9.0 (Figure 13).
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Figure 13. BC-2-NMT activity as a function of assay pH. Buffer system was
50 mM bicine plus 50 mM Na2HP0 4 . Components present included: 0.6 mg
protein from bovine brain cytosol, 9-MeNH (540 µM), and SAM (105 µM, 3.6 µCi).
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Linearity of BC-2-NMT Activity as a Function of
Time and Protein Concentration
Under assay conditions in which product formation was much less than
substrate concentration, BC-2-NMT activity increased linearly with respect to
time (Figure 14) and protein concentration (Figure 15).

Least squares curve-

fitting to a linear equation of activity as a function of total protein or time
showed a highly linear relationship (r=0.996 and 0.980 respectively).
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Figure 14. BC-2-NMT-catalyzed formation of 2,9-Me2NH + as a function of assay
time. Assays contained bovine brain cytosol (0.687 mg protein in bicinephosphate buffer), 540 µM 9-MeNH, and I 05 µM SAM (2.88 µCi) at pH 8.5.
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Apparent

Kinetic Constants With Respect to Substrates,
SAM and 9-MeNH

The high correlation coefficients (r>0.96) obtained following nonlinear
curve fitting of the data to the Michaelis-Menten equation indicate that
BC-2-NMT obeys Michaelis-Menten kinetics with respect to both 9-McNh
(Figure 16) and SAM (Figure 17) when the non-varied substrate is fixed near
saturation.

Values for KM and Vmax are reported as parameter value ± standard

error of that parameter value.

Graphical analysis of the data calculates KM and

V max values of 75 ± 20 µM and 48 ± 3 pmol/h/mg protein with respect to 9MeNH (Figure 16).

Regarding SAM,

estimates of KM and Ymax are 81 ± 21 µM

and 53 ± 4 pmol/h/mg protein (Figure 17).

As shown in Figures 18 and 19,

linear transformation of the Michaelis-Menten equation and data analysis in
the form of a Hanes plot generates KM and Vmax estimates similar to those
obtained following nonlinear regression analysis of the data.
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Equation for Nonlinear Curve-Fitting
BC-2-NMT Activity = Vmax [9-MeNH]/(KM + [9-MeNH])
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Figure 16. BC-2-NMT activity as a function of 9-MeNH concentration. Assays
included bovine brain cytosol (0.79 mg protein), SAM (260 µM, 5.6 µCi), and 9MeNH at a final concentration ranging from 5 µM to 1 mM at pH 8.5.
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S-Adenosyl-L-Homocysteine (SAH)
Inhibits BC-2-NMT Activity
The activity of bovine brain BC-2-NMT is inhibited
concentration-dependent manner (Figure 20).

hy SAH

The ICso for SAH,

111

a

i.e., the

concentration of inhibitor producing a 50% reduction in BC-2-NMT aclivity
compared to control, is 14.8 µM.
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Figure 20. SAH inhibition of BC-2-NMT activity. Assays (pH 8.5) contained
bovine brain cytosol (1.33 mg protein), 540 µM 9-MeNH, 105 µM SAM (2.77 µCi),
and SAH.
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Effects of Transition Metals
on BC-2-NMT Activity
Certain transition metals affected BC-2-NMT activity (Table 8).
BC-2-NMT activity was increased 2-fold in the presence of iron (p<0.05) and
manganese (p<0.05).

Increased BC-2-NMT activity in the presence of calcium

did not reach statistical significance. Nickel, magnesium and copper did not
appear to affect BC-2-NMT activity, but zinc completely inhibited formation of
2,9-Me2NH+.

BC-2-NMT activity was 139% of control in the presence of the

chelating agent EDT A (1 mM).

Table 8.--Effect of Transition Metals on BC-2-NMT Assay

Mllil.a

% of Controlc

Iron

209 ± 0.7 (2)
b

231 ± 13 (2)

Manganese

192 ± 13 (2)

Cobalt

146

Calcium

121 ± 0 (2)

Nickel

116

Magnesium

101

Copper

101

Zinc

0±0 (2)

Iron

a
b

c
d

As chloride salt, 1 mM,
3 + oxidation state

d
d

2+ oxidation state

Values are mean ± s.d. for (N) replicates
Significantly different than control (p<0.05),
ANOV A followed by Tukey-HSD post-hoc test
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Discussion
Enzyme

Kinetics

Fitting of kinetic data to the Michaelis-Menten (M-M) equation indicates
that BC-2-NMT obeys M-M kinetics with respect to both 9-MeNH and SAM, when
one substrate is fixed and the other is varied.

For guinea pig brain, previous

studies from this laboratory reported kinetic constants with respect to 9-McNH
of 17.8 µM and 2.2 pmol/h/mg protein, for KM and Vmax values,

respectively

(Matsubara et al. 1992b), results that differ from those reported here. Kinetic
parameters with respect to SAM were not determined in previous studies.
In addition to species differences (guinea pig vs. bovine), two factors
may contribute to the difference in kinetic constants reported by Matsubara
(1992b) and those reported here:

(a) SAM concentration utilized between

studies, and (b) the method of data analysis utilized in each investigation.
Regarding the effect of SAM concentration, Matsubara determined kinetic
parameters with respect to 9-MeNH with SAM fixed at 8 µM. The present study
indicates that 8 µM SAM is well below its KM of 81 µM. In fact, if 8 µM SAM is
inserted into the M-M equation using the present KM and Vmax values for SAM,
the calculated activity is about 5 pmol/h/mg protein,
the Vmax described by Matsubara (l 992b ).
concentration was fixed at 260 µM,

a value comparable to

In the present study,

SAM

equivalent to a concentration three times

its KM; the literature suggests (Dixon et al. l 979a) that a higher SAM
concentration is more appropriate for testing the adherence of BC-2-NMT to
M-M kinetics with 9-MeNH as the variable substrate.

Increasing SAM

concentration from 8 µM (the concentration used by Matsubara) to 260 µM (the
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concentration used in this dissertation), while 9-MeNH is varied,

increased the

V max estimate approximately 20-fold, from 2.2 pmol/h/mg protein for guinea
pig brain (Matsubara et al. 1992b) to the value reported in this dissertation, 48
pmol/h/mg protein for bovine

brain.

In addition to the effect of SAM concentration discussed above, data

analysis methods employed between studies may contribute to the discrepancy
in the KM for 9-MeNH reported by Matsubara (1992b) and the value reported in
this dissertation.

These researchers utilized a non-weighted Lineweaver-Burk

linear transformation (double-reciprocal plot) of the M-M equation in data
analysis.

Though commonly used,

this plot does not reflect experimental

error accurately, a point discussed by Cornish-Bowden (Cornish-Bowden 1979).
In fact, when kinetic data presented here are fitted to the Lineweaver-Burk
equation, the estimated KM with respect to 9-MeNH was nearly identical to the
17 .8 µM value obtained by Matsubara.

It is noteworthy that close scrutiny of a

Lineweaver-Burk plot of these data revealed a marked downward curvature of
data points near the y-axis (data not shown).

This observed deviation from

linearity in the double-reciprocal plot prompted an investigation of other
options regarding data analysis.
Nonlinear curve- fitting, which fits the data directly to the MichaelisMenten equation, i.e., without linear transformation of the original equation,
was therefore employed.

Use of nonlinear cure-fitting circumvents certain

problems associated with the use of linear transformation and subsequent
graphical analysis of nonlinear data.

For a review of the applicability of

nonlinear regression in the analysis of nonlinear data (e.g., enzymatic data)
the reader is directed to papers by Wilkinson et al. (1961) and Motulsky et al.
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(1987).

Hanes plots of the kinetic data were generated, following the more the

more familiar linear transformation of the M-M equation, as refere need in
Cornish-Bowden (1979).

As shown in Figures 13 and 14,

Hanes plots yield

kinetic parameters that are reasonably close to those obtained with nonlinear
curve-fitting.
The Vmax of bovine brain BC-2-NMT with respect to both substrates is
quite small.

Since Vmax is derived from the product of enzyme concentration

and kcat> the small magnitude of Vmax may indicate that 6Cs are poor substrates
for this N-methyltransferase (i.e., low turnover number), or that the amount
of BC-2-NMT present in brain tissue is quite small.

BC-2-NMT-catalyzcd

formation of neurotoxic products in relatively low amounts due to the
enzyme's low Vmax•

would be consistent with the hypothesis that this N-

methyltransferase could participate

in

the

neuropathogenesis of Parkinson's

disease -- a disease that takes years to manifest symptoms related to the
underlying neurodegeneration.

It is postulated that the low activity of BC-2-

NMT could result in the generation of small quantities of neurotoxic 2-MeBCs+,
which over a period of many years would cause the death of sufficient
neurons to elicit the clinical characteristics of PD.

Other Properties of BC-2-NMT
Linearity of BC-2-NMT activity as a function of time and protein
concentration is fundamental to reliable monitoring of enzyme activity
during protein purification.

Note that enzyme activity was not linear, but

instead plateaued, with respect to time or protein concentration in
preliminary experiments which utilized SAM at 8 µM instead of 105 µM (data

IOI

not shown).

The linearity of BC-2-NMT activity through 180 minutes al 37 °C is

also an indication that the enzyme is thermally stable under these conditions.
All SAM-dependent methyltransferases studied to date are inhibited by
S-adenosyl-L-homocysteine (SAH) in a competitive manner (Deguchiand
Barchas 1971; Lawrence and Robert-Gero 1990).

This is not surprising since

products often inhibit the enzyme responsible for their formation, and SAH is
a product of SAM-dependent methylation reactions.

Inhibition by SAH varies

depending upon the specific methyltransferase affected,
the 100 nM to 12 µM range.

with Ki's falling into

Fifty percent inhibition of BC-2-NMT activity is

observed when added SAH is present at about 14.5 µM, which corresponds to a
Ki of 4.5 µM (data not shown),
SAM-dependent

consistent with the behavior of other

me thy I transferases.

The manganese and iron effects, although not dramatic, are intriguing
since both metals are associated with parkinsonism (Irwin et al. 1995).
Manganese miners occasionally display parkinsonian symptoms such as
bradykinesia.

Neuropathologically, the globus pallidus shows extensive cell

loss but other basal ganglia components, including the substantia nigra may
also be affected (Mena 1979); however, manganese poisoning is not clinicalJy
classified as PD.

In contrast, aberrant iron metabolism has been suggested to

play a role in Parkinson's disease (PD);

persons afflicted with PD exhibit

higher than normal free iron (Dexter et al. 1989), and decreased ferritin
protein in the substantia nigra (Dexter et al. 1990).

Hypothetically,

if iron is

indeed elevated in the substantia nigra of persons with PD, this high iron
concentration could conceivably increase BC-2-NMT activity in that brain
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region -- leading to local formation of neurotoxic N-methylated B-carholinium
compounds and subsequent cell death.

Previously Characterized N-Methyltransferases
It is possible that BC-2-NMT represents a previously characterized

enzyme for which B-carbolines were not evaluated as substrates.

Saavedra et

al. (1973) described the distribution of a non-specific N-methyltransferase
present in the brain of several species, including human postmortem brain
tissue.

That SAM-dependent enzyme utilizes tryptamine as well as several

other amines as substrates.

Similar to BC-2-NMT, the enzyme exhibited a KM

with respect to SAM of 52 µM and a Ymax
protein, depending upon the tissue.

in the range 2

-15 pmol/h/mg

The subcellular distribution and specific

activity of the non-specific N-methyltransferase described by Saavedra are
similar to those reported here for BC-2-NMT.

However, the regional

distribution of this enzyme differed from that for BC-2-NMT described by
Matsubara et al. (1992b).
Ansher and Jakoby (1986b, 1987) purified amine N-methyltransferases
A and B from rabbit liver.
N-methylating activities
azaheterocycles.

The enzymes exhibited broad, overlapping

toward numerous amines, including several

The azaheterocycles tested included derivatives of pyridine

and isoquinoline, but B-carbolines were not tested as substrates.

It is

noteworthy that both N-methyltransferases A and B were purified from
cytosol and both exhibited pH profiles with respect to desmethylimipramine
and tryptamine that were similar to that of BC-2-NMT toward
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9-MeNH.

Ansher et al. (1986a) also found these amine N-methyltransfcrase

activities in human, monkey, and rodent cytosolic brain extracts; suhstrates
included

4-phenyltetrahydropyri<line

precursors of neurotoxic MPP+.

and

4-phenylpyridine,

potential

Specific activities toward these substrates

were in the range 0.17-23 pmol/h/mg protein, similar to the values reported
in the present study.
In addition, Naoi, et al. (1989a) reported the presence of

a cytosolic

N-methyltransferase activity in human brain homogenates that forms
potentially

neurotoxic

N-methyl-1,2,3 ,4-tetrahydroisoquinoline

tetrahydroisoquinoline (TIQ).

from

The TIQ-methylating activity exhibited kinetic

parameters and a pH optimum similar to those of BC-2-NMT.

Likewise,

Matsubara et al. (1992a) identified a cytosolic N-methyltransferase activity
present in rodent brain that catalyzes methylation at the 2N-nitrogen of
tetrahydro-B-carbolines.

It is conceivable that BC-2-NMT and any of the

N-methyltransferases described above are the same or least similar enzymes.
Interestingly, evidence presented in Chapter 6 of this dissertation
indicates that BC-2-NMT may be due to the epinephrine-synthesizing enzyme,
phenylethanolamime-N-methyl transferase

(PNMT).

Cytosolic or Nuclear Localization
of BC-2-NMT Activity?
The cytosolic location of BC-2-NMT disagrees with the primarily nuclear
location of the enzyme previously reported from this laboratory,

in which

guinea pig brain cytosolic activity was undetectable (Matsubara et al. 1992b).
However, subcellular fraction of guinea pig brain (data not shown) showed a
subcellular distribution and specific activities that were similar to those
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reported here for bovine brain.
to

This discrepancy between studies could be due

variation in the intensity of homogenation preceding subcellular

fractionation.

Since subcellular enzymatic markers were not utilized to

monitor fractionation, the cause of the discrepancy remains unknown.
However, cytosolic BC-2-NMT activity is consistent with the subccllular
distribution of the N-methyltransferases previously described by Saavedra et
al. (1973), Ansher et al. (1986a),

Naoi et al. (1989a), and Matsubara et al.

(1992a).

Conclusions
The studies presented in this chapter define experimental conditions to
be utilized in subsequent investigations; specifically BC-2-NMT purification
from bovine brain cytosol (Chapter 4) and measurement of its activity in
normal and parkinsonian human brain (Chapter 5). For the proposed studies,
cosubstrates 9-MeNH and SAM will be present at 540 µM and 105 µM (2-6 µCi)
respectively;

assays will be maintained at 37 °C for 60 minutes at pH 8.5.

CHAPTER4
PARTIAL PURIFICATION OF B-CARBOLINE-2N-METHYLTRANSFERASE
FROM BOVINE BRAIN

General

Comments

Difficulties
The assay at present is very labor- and time-intensive and is not
amenable to utilization in the purification of BC-2-NMT. Only 12 samples may
reasonably be prepared and analyzed per day.

This number is incompatible

with the number of potential column fractions generated in a typical column
chromatography procedure, even if alternate fractions are analyzed.
Moreover, the low activity of BC-2-NMT in combination with the dilute nature
of column fractions necessitates concentration of each fraction prior to
incorporation into the BC-2-NMT assay.

Concentration using Centricon

concentrators requires 1-4 hours depending upon the composiLion of the
fraction.

Once the concentrated fraction is prepared, the time required to

obtain BC-2-NMT activity results for those fractions is detailed below.
For the maximum of 12 samples:
•
•
•
•
•
•
•
•

preparation of substrate solutions
prepare tubes and BC-2-NMT assays
incubation at 37 °C
protein prec1p1tation and centrifugation
solid-phase extraction procedure
Speed Vac drying
HPLC analysis (baseline, 3H-SAM, 12 samples)
protein assays (another day)
Total time required (minimum)

105

0.5 h
0.5 h
1.0 h
0.5 h
0.5 h
2.0 h
5.0 h
.LlLh_
11 h
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Recommendations
It is recommended that a new work-up of the BC-2-NMT assay be

developed.

The incubation of substrates with enzyme is acceptable; however,

the subsequent work-up and analysis of 2,9-Me2N H + should be modified.

The

new work-up/analysis should be simple, e.g., spectrophotometric analysis of
2,9-Me2NH+ formed or liquid scintillation counting of tritiated 2,9-Me2NH +
product.

This can only be accomplished if radioactive substrates and products

can be completely separated either physically (using SPE, liquid extraction) or
"analytically" based on differences in spectral properties.

Separat.ion based

on spectral characteristics is probably not possible unless a coupled assay is
developed since BCs, MeBCs+, and SAM exhibit overlapping ultraviolet and
fluorescent

spectra.

Purification
General

Overview

Backi:round

A series of laboratory guides published by Pharmacia will be the
primary references utilized during the chromatographic isolation of BC-2NMT (Pharmacia 1991; Pharmacia 1993a; Pharmacia 1993b; Pharmacia ).

These

guides describe in detail the practical aspects of preparing, using, and
maintaining various chromatographic resins.

The books "Protein

Purification: Principles and Practice" by Scopes (1994a) and "Guide to Protein
Purification" by Deutscher (1990) were utilized throughout BC-2-NMT
partial-purification.
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Summary of Results

A graphical summary of the experimental results to be discussed
further in this chapter is presented in Figure 21.

The starting material for BC-

2-NMT purification was the 100,000xg supernatant from whole bovine-brain
homogenate.

This cytosolic supernatant generally exhibited a BC-2-NMT

specific activity of 15-20 pmol/h/mg protein, using the assay conditions
defined in the "Conclusions" of Chapter 3.
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Summary of BC-2-NMT purification results (details in chapter).
Key: each bar represents 1-2 steps ju sequence

.LJ::il4..l.2,.S..Q.:i. .!i0-80%/DEAE: 60-80% ammonium sulfate fraction from bovine brain cytosol
dissolved in pH 7 imidazole buffer, then subjected to batch chromatography on DEAESephadex (anion exchange matrix). BC-2-NMT activity (represented by bar) was eluted
from the matrix with pH 7 imidazole buffer containing 0.3 M NaCl.
Green 19/Green 5: Bovine brain cytosol was applied to a Green 19 dye column. eluate from
this column was applied to a Green 5 dye column. BC-2-NMT activity (represented by bar)
was eluted from Green 5 dye column using pH 7.4 Na2HP0 4 containing 3 M NaCl.
DEAE/SAH-Affinjty: DEAE-Sephadex batch chromatography elute (above) applied to an Sadenosyl-L-homocysteine affinity column. BC-2-NMT activity (represented by bar) was
eluted from the column with pH 7 imidazole buffer containing I M NaCl.
BC-Affinity: Bovine brain cytosol in 20 mM Na2HP0 4 (pH 7.3)/150 mM KC! was applied to
a 8-carboline affinity column. BC-2-NMT activity (represented by bar) was eluted from the
column using a I mM buffered norharman solution .
.LJ::il4..l.2,Sil:t~ supernatant from 40% ammonium sulfate fractionation was applied to a
octyl-agarose (C8) hydrophobic interaction chromatography column.
BC-2-NMT activity
(represented by bar) was measured in application flow-through.
lli!Li..l.2,£14~ supernatant from 40% ammonium sulfate fractionation was applied to a
pentyl-agarose (CS) hydrophobic interaction chromatography column.
BC-2-NMT activity
(represented by bar) was measured in application flow-through.
Green 19: column chromatography (same conditions as above) on a Green 19 dye column
60-80% CNH1 12,s.14.:. the 60-80% ammonium sulfate fraction (desalted)
40-60% CNH!~s.14.:. the 40-60% ammonium sulfate fraction (desalted)
Cytosol: bovine brain cytosol, typically the starting material for each step above
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Ammonium

Sulfate

Precipitation

Experiments

Theory
This technique exploits the effect of salt on protein conformation and
therefore solubility; proteins with variable amino acid compositions can be
separated based on their behavior at different electrolyte concentrations. This
method is discussed in detail by Scopes (1994b).

In practice, ammonium

sulfate is added at low temperature and in small portions.

The mixture is

centrifuged to pellet precipitated proteins and additional precipitant is added
to the resulting supernatant; the mixture again centrifuged, and so on.
Proteins are fractionated (precipitated) based on their individual solubilities
in progressively more concentrated salt solutions or organic solvents.

Materials and Methods
Preparation

of Fractions

Bovine brain cytosol (12 ml) -- containing 20 mM Na2HP0 4 (pH 7.4),
150 mM KCl, 1 mM OTT, 1 mM EDTA, 1 mM PMSF, leupeptin (1 µg/ml), and
pepstatin A

(1 µg/ml) -- was thawed from -80 °C.

at -80 °C for 2 months prior to use.

A sample, representing "control cytosol",

was retained for protein and BC-2-NMT assays.
ml of thawed cytosol.

The aliquot had been stored

The starting material was 11.0

Ammonium sulfate precipitation of cytosolic proteins

was accomplished at 5-10 °C with constant stirring, by adding solid (NH 4 hS 0 4
to either cytosol ("0-40% cut") or the supernatant resulting from the previous
cut.

Supernatant and pellet (cut) were separated by centrifugation at 10,000 xg
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for 10 minutes at 0-5 °C.
prepared:

The following ammonium sulfate fractions were

0-40%, 41-60%, and 61-80% saturation with respect to (NH.1)2S O.t. The

resulting (NH4)2S 04 pellets were dissolved in 2.0 ml of l 50 mM KCI containing
10 mM Na2HP04 at pH 7.

If necessary, fraction pH was adjusted to pH 7.

Solutions were filtered through a 0.2 µm polysulfone syringe filter to remove
particulates and denatured protein.

The turbid solution resulting from

reconstitution of the 0-40% pellet could not be filtered,

probably due to the

presence of large particles or protein aggregates that clogged the filter;
therefore, the sample could not be desalted and assayed as such.

The filtered

solutions derived from the 41-60% and 61-80% samples (0.5 ml of each) were
desalted using ultradiafiltration against buffer (150 mM KCI, 10 mM Na 2HPO.t at
pH 7) on a Centricon 30 concentrator.

Total protein and BC-2-NMT activity

were determined in desalted and non-desalted samples, except as noted.

BC-2-NMT Assay

Details of the assay and work-up are described in Chapter 3.

In this

experiment reactants were present at the following concentrations: 9-McNH
(540 µM), SAM (105 µM, 2.98 µCi), and 100 µI of indicated fraction containing
BC-2-NMT activity.

Protein

Determination

Protein was assessed using a modification of the Lowry method as
described in the Appendix A.

III

Results
"Control cytosol" contained 81 mg of total protein and 2146 pmol/h of
BC-2-NMT activity -- therefore, its specific activity was 26.6 pmol/h/mg

protein.

Figure 22 depicts BC-2-NMT specific activity present in cylosol and

indicated (NH4)i S 0 4 fraction prior to desalting the fraction. The sum of lhe
protein in each (NH4)iS 04 fraction (excluding the 60-80% supernatant) was 41
mg;

this represents 51 % of the protein present in the original cytosol.

respect to BC-2-NMT activity,

With

1023 pmol/h (48% of the original cytosolic

activity) was recovered in the summed (NH 4)zS 0 4 fractions.

>80%

0
66.6

22.9

40-60%
0-40%

0

10

20
30
40
50
60
BC-2-NMT SPECIFIC ACTIVITY
(pmol/h/mg protein)

70

Figure 22. BC-2-NMT activity in crude cytosol and fractions resulting from
precipitation with ammonium sulfate.
Fractions were not desalted prior to
assays. Values next to bars represent BC-2-NMT activity in that fraction.
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The results presented in Figure 23 indicate that desalting (NH4)2S 04
fractions prior to use in BC-2-NMT assays increases the measured BC-2-NMT
activity.

Total protein was affected less drastically by desalting.

83.9

~
0
00

~-

66.6

42.2

~

0

\0

~.
0

22.9

Not Desalted
Desalted

20
40
60
80
BC-2-NMT SPECIFIC ACTIVITY
(pmol/h/mg protein)

100

Figure 23. The effect on BC-2-NMT activity of desalting ammonium sulfate
fraction.
Fractions were desalted using ultradiafiltration on a Ccntricon 30
concentrator.
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Discussion
The presence of ammonium sulfate affects both the Lowry protein and
the BC-2-NMT assays.

The Bradford assay would be a better choice regarding

protein measurement in these samples since it is not affected by the presence
of (NH4)iS04 (Petersen 1983).

This experiment shows that removal of (NH.ihSO.i

from the fraction prior to its utilization in the BC-2-NMT assay increases the
measured specific activity 1.2 to 1.8-fold.

Screenin~

Experiment for Bindin~ of BC-2-NMT to Ion-Exchani;e
ChromatoJi:raphy Matrices in Batch Mode
as a Function of Buffer pH
Theory

Ion exchange chromatography allows for separation of molecules based
on charge;

anion exchangers contain positively charged groups such as

quaternary amines or diethylaminoethyl (DEAE),

which interact with sample

molecules possessing negative charges. Cation exchangers, possess negatively
charged groups such as a sulfonic acid or carboxymethyl (CM) side-chains;
these resins interact with sample molecules that are positively charged.

Both

pH and ionic strength are manipulated in order to affect the interaction of
sample molecules with the anion exchanger. In general, low ionic strength
conditions favor binding to ion exchangers.

Lower pH buffers (pH 4-8) are

used in cation chromatography, and higher pH buffers (pH 5-9) are used in
anion chromatography.
gradient.

Proteins are then eluted using an increasing salt

Fractions from the column are collected and assayed for total protein

content and protein of interest.
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Materials and Methods

Ion-Exchange

Resins

Ion-exchange resins were obtained in the dry-state from Pharmacia.
Technical information pertaining to each of the Sephadex resins is
summarized in Table 9.

Table 9.--Properties of Evaluated Ion-Exchange Resins
Ion-Exchange Resin
DEAE Sephadex A-50

CM Sephadex C-50

weakly basic
anion exchanger

weakly acidic
cation exchanger

diethyl aminoe th yl

carboxymethyl

Matrix

cross-linked

cross-linked

Particle size

40 - 120 µ

40 - 120 µ

Capacity

3.5 ± 0.5 mmoles/g

4.5 ± 0.5 mmoles/g

Swelling Ratio

varies with pH
and ionic strength

varies with pH
and ionic strength

Description
Functional

group

dextran

dextran

Sephadex resins (10 g) were swelled in about 500 ml of IO mM Na 2 HP0 4
(pH 7.4) and subsequently stored in a capped jars at room temperature.
resins were equilibrated in other buffers as indicated in subsequent
experiments.

These
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Ion-Exchange

Buffers

Buffers were prepared as 1 M stock solutions that were diluted to the
required strength for individual procedures.

The respective buffer salt was

dissolved in Milli-Q water, the pH was adjusted using either NaOH or HCI, and
the solution was diluted with Milli-Q water to the final volume.

The huffcr and

corresponding pH utilized in anion and cation exchange chromatography
protocol are summarized in Table 10.

Table

10.--lon-Exchange

Anion Exchange Buffers
Piperazine

chloride

Chromatography

Buffers

llH

Supplier

5

Sigma

Bis-tris

chloride

6

Sigma

Bis-tris

chloride

7

Sigma

hydrochloride

8

Sigma

9

Sigma

Sodium acetate

5

Merck

Sodium malonate
(di basic)

6

Eastman

Sodium phosphate
(mono basic)

7

Fisher

HEPES (sodium salt)

8

Sigma

Tris

Ethanolamine

chloride

Cation Exchange Buffers
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Batch

Chromatof;raphy
Bovine brain cytosol (6 ml) -- containing 20 mM Na2HPO.i (pH 7.4),

150 mM KCI, 1 mM DTT, 1 mM EDTA, 1 mM PMSF, leupeptin (1 µg/ml), and
pepstatin A (1 µg/ml) -- was thawed from -80 °C.
-80 °C for 3 days prior to use.

The aliquot had heen stored at

The sample was concentrated 4-fol<l to 1.25 ml

using a Centricon 30 concentrator.
Ion-exchange resins were equilibrated at room temperature using the
buffers (diluted to 0.05 M) listed in Table 11.

Approximately 1.5 ml of each

Sephadex slurry was transferred to a 1.5 ml microcentrifuge tube.

The tubes

were centrifuged briefly in order to pack the gel, and the resulting
supernatant was

discarded.

The appropriate buffer (100 µI) and 100 µI of

concentrated cytosol were added to each of the tubes containing packed resin.
The contents of the tubes were mixed on a lab rocker for 15 minutes at room
temperature.

Sephadex gel was settled with a brief centrifugation, and 150 µI

of the resulting supernatant was transferred to a clean microcentrifuge tube.
Supernatants were analyzed for BC-2-NMT activity and total protein.

BC-2-NMT Assay
Assay components were present as follows: 9-MeNH (540 µM), SAM (150
µM, 3.72 µCi), and 100 µI of concentrated cytosol or 100 µI of supernatant
derived from one of the nine ion-exchange chromatography conditions
described above.

Assay volume was 370 µI, pH was 8.5, and assay was

maintained at 37 °C for one hour.
in Chapter 3.

Details of the BC-2-NMT assay may be found
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Protein

Determination

Protein was determined as described in the Appendix A.

Results
DEAE-Sephadex

Chromato~raphy

As depicted in Figure 24,

BC-2-NMT activity is retained by the anion

exchange resin more extensively than total protein, and retention of BC-2NMT activity increases as pH increases.

The largest difference between BC-2-

NMT activity bound and total protein bound occurs at pH 7.
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Figure 24. Binding of total protein and BC-2-NMT to DEAE-Sephadex as a
function of equilibration buffer pH.
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CM-Sephadex

Chromato~raphy

As shown in Figure 25,

BC-2-NMT activity binds to the cation exchanger

to a lesser degree than total protein.

BC-2-NMT binding appears to increase as

a function of increasing equilibration pH.

The greatest difference between

percentage of BC-2-NMT activity and total protein bound occurs at
pH 5.

[]

D

100

% BC-2-NMT Activity Bound
% Total Protein Bound

.....>.
.....
>

·..:i

u >.

< .0 .s
E--o "O

80

VJ

0

~ g~

z .....

0

I
~ OJ)
No=

60

I~~

u

..=

c:Q

= u

o

BIJ,.:I

"O ..... ~

40

..... 0

-0.. ii.
.... =
0
0..

< "O

.....

~

...... ~u
0

20

~

0

5

(acetate)

6

(malonate)

7

(phosphate)

pH of Resin Equilibration

@

8

(HEPES)

0.05 M Buffer

Figure 25. Binding of total protein and BC-2-NMT to CM-Sephadex as a function
of equilibration buffer pH.
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Discussion
BC-2-NMT generally sticks to both cation and anion exchange resins,
suggesting that this enzyme is relatively hydrophilic and probably possesses
both positively and negatively charged patches in its structure.

The ideal

circumstance would be chromatographic conditions in which most of the BC-2NMT activity is bound along with very little total protein, or conversely, a
condition that binds BC-2-NMT activity inefficiently and total protein to a high
degree.

In the screening experiment, at least 60% of applied total protein and

BC-2-NMT activity are bound by these resins at each pH evaluated.

However,

the greatest difference between BC-2-NMT activity and total protein bound was
observed at pH 7 for the anion exchanger, and at pH 5 for the cation exchange
resin.

Since a higher percentage of applied BC-2-NMT activity was retained by

the anion-exchange resin than by the cation-exchange resin, anion exchange
chromatography at pH 7 was investigated in subsequent experiments.

Screening Experiment for Binding of BC-2-NMT to
DEAE-Sephadex in Batch Mode at pH 7
as a Function of Ionic Strength
Materials and Methods
Batch

Chromato~raphy

Bovine brain cytosol (8 ml)

containing 20 mM Na2HP04 (pH 7.4), 150

mM KCl, 1 mM DTT, 1 mM EDTA, 1 mM PMSF, leupeptin (1 µg/ml), and pepstatin
A (1 µg/ml) -- was thawed from -80 °C.
for 1.5 months prior to use.

The aliquot had been stored at -80 °C

Prior to concentration on a Centricon 30, the

aliquot was filtered through a 0.22 µ polysulfone syringe filter (13 mm
diameter).

The filtered sample was concentrated to 25-30 µI overnight in the
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coldroom.

The Centricon retentate was diluted and quantitatively transferred

to a clean microcentrifuge tube using 600 µl of equilibration buffer (0.05 M
BIS-TRIS buffer at pH 7).
Equilibration buffers #2 -#10, of increasing ionic strength (I), were
prepared as detailed in Table 11 by mixing 5.0 ml of 0.5 M BIS-TRIS buffer (pH
7) with the listed volume of NaCl stock solution (0.45 M).
brought to a final volume of 50 ml using Milli-Q water.

All solutions were
The pH of each buffer

solution was between pH 6.9-7.

Table 11.--Preparation of NaCl-BIS-TRIS Buffer Solutions
for DEAE-Sephadex Batch Chromatography
I = Final Ionic
Strength CM)

Buffer
#

0.45 M NaCl

1

0

0.05

2

5

0.10

3

10

0.15

4

15

0.20

5

20

0.25

6

25

0.30

7

30

0.35

8

35

0.40

9

40

0.45

10

45

0.50

(ml)
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Initially 25 ml of DEAE-Sephadex was equilibrated in buffer #1 and then 2 ml
of this slurry was transferred to each of ten 13 x 75 mm glass culture tuhes.
The tubes were centrifuged briefly in order to pack the gel (1 ml), and the
resulting supernatant was discarded.

The gel in each of the ten tuhes was then

equilibrated using one of the ten buffers listed in Table 11, transferred to a 1.5
ml microcentrifuge tube, centrifuged briefly, and the supernatant from gel
was discarded.

The appropriate buffer (80 µl) and 40 µl of concentrated cytosol

were added to each of the tubes containing packed resin.

The contents of the

tubes were mixed on a lab rocker for 15 minutes at room temperature. The
resin in each tube was packed by brief centrifugation, and then 50 µl of the
resulting supernatant was transferred to a clean microcentrifuge tube.
Supernatants were analyzed for BC-2-NMT activity and total protein.

BC-2-NMT Assay
Assay components were present as follows: 540 µM 9-MeNH (275 µl of a
727 µM stock), 150 µM SAM (20 µL of a 1.928 mM stock), 3.35 µCi 3H-SAM (in 50
µL), and 25 µl of control cytosol or supernatant derived from one of ten anionexchange chromatography conditions described above.

Control cytosol was

prepared by mixing 40 µl of concentrated cytosol with 80 µl of 150 mM KCI.
Total assay volume was 370 µl,
75 minutes.

pH was 8.5, and assay was maintained at 37 °C for

Details of the BC-2-NMT assay and subsequent analysis described

in Chapter 3.

Protein

Determination

Total protein was determined using a modified Lowry method as detailed
in Appendix A.
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Results

The sample equilibrated at 0.05 M ionic strength could not be analyzed
due to a technical problem; therefore results begin with the 0.1 M condition.
As Figure 26 shows, 70% of the applied BC-2-NMT activity and 45% of total
protein was retained by DEAE-Sephadex at pH 7 when the ionic strength was
0.1 M (0.05 M bis-tris buffer plus 0.05 M NaCl).

= 0.25

decreased as ionic strength increased (except at I
I

= 0.4

BC-2-NMT binding generally

M) up to

M, where BC-2-NMT retention by the matrix appeared to decrease.

D
ml!

Total Protein
BC-2-NMT Activity

100 ..-

80 ,_

Buffer:
0.05 M Bis-Tris
at pH 7

60 '""

-

100

-

80

-

60

40
20

0.1

0.15 0.2 0.25 0.3 0.35 0.4 0.45 0.5
Buffer Ionic Strength (M)

Figure 26. Binding of total protein and BC-2-NMT activity to DEAE-Sephadex at
pH 7 as a function of equilibration buffer ionic strength.
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Discussion
A high salt concentration is required to disrupt the electrostatic
interaction between BC-2-NMT and the positively charged chromatography
matrix.

About 25% of the applied BC-2-NMT activity remains bound to the

anion-exchange chromatography matrix at I=0.3 M, this suggests that BC-2NMT is a relatively hydrophilic, negatively-charged protein.

Increased

binding of BC-2-NMT to the matrix at I > 0.35 M may be due to a change on BC-2NMT structure at the

higher ionic strength resulting in an exposure of ionic

groups that may then interact with the matrix.
also be the result of experimental error.

The increased binding could

Based on these results a proposed

DEAE-Sephadex batch chromatography protocol might begin with
equilibration of matrix and cytosol application at pH 7 in 0.05 M bis-tris buffer
containing 0.05 M NaCl.

The resin would then be washed with equilibration

buffer to remove loosely bound proteins.

Elution of BC-2-NMT could be

accomplished using 0.05 M BIS-TRIS buffer (pH 7) containing 0.25-0.30 M NaCl
(total I = 0.30 - 0.35 M).

This idea was evaluated in the subsequent experiment.

DEAE-Sephadex Batch Chromato~raphy
Scale-Up
Materials and Methods
Bovine brain cytosol (55 ml) in 20 mM Na2HP0 4 (pH 7.4), 150 mM KCl, 1
mM OTT, 1 mM EDTA, 1 mM PMSF, leupeptin (1 µg/ml), and pepstatin (1 µg/ml)
was used in this study; the aliquot had been stored at -80 °C for 2 months prior
to thawing.

An 1 ml aliquot was retained for control assays, and the remaining

54 ml was stirred magnetically in a polypropylene beaker in an ice-water
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bath.

A 60 - 80% ammonium sulfate pellet was obtained according to

fractionation procedures previously described.
ml 0.05 M imidazole buffer at pH 7.

The pellet was dissolved rn 8

The solution was filtered through a 0.2 µm

polysulfone syringe filter prior to simultaneous ultradiafiltration and
concentration on a Centriprep 30 concentrator to a final volume of 1.85 ml.

An

150 µl aliquot was retained for assays, and the remaining 1.7 ml was mixed with
about 20 ml of DEAE-Sephadex that had been previously equilibrated in 0.05 M
imidazole buffer (pH 7).

The BIS-TRIS buffer used in previous studies was not

available in sufficient quantity for this study, so imidazole buffer was
substituted.

The mixture was agitated gently on a lab rocker for 20-30 minutes

at room temperature.

Resin was recovered by vacuum filtration on a Buchner

funnel and the resulting filtrate saved (9.9 ml).

The resin was washed while

on the funnel with 5 ml of equilibration buffer; filtrate volume was 4.4 ml.
The resin was transferred to a polypropylene tube containing 3 ml of 0.05 M
imidazole buffer (pH 7) plus 3 M NaCl.
as described above.

The mixture was agitated for 30 minutes

The slurry was filtered to recover eluate (7 ml).

Initial

cytosol and subsequent fractions were analyzed for total protein and BC-2-NMT
activity.

BC-2-NMT Assay
Assays were done according to details presented elsewhere (Chapter 3).
Duplicate assays were prepared for each fraction evaluated; assays contained
9-MeNH (540 µM), SAM (105 µM, 3.65 µCi) at pH 8.5 plus 100 µl concentrated
column fraction or initial cytosol.

In addition, blank assays were prepared

which lacked 9-MeNH, but contained all other components.
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Protein

Determination

The modified Lowry method was used in the assessment of total protein
in cytosol and column fractions (Appendix A).

Results
The overall yield of BC-2-NMT activity from this procedure was poor
(7%).

The purification from cytosol to the final 0.3 M NaCl eluate was 14.4-fold.

Results are summarized in Table 12 and include initial cytosol,

desalted 60-80%

(NH4 )zS04 fraction ("60-80%"), and high salt eluate from the DEAE-Sephadex
("0.3 M NaCl").

The percentages in parentheses in Table 13 represent the

fraction yield from initial cytosol. The purification factor is the increase in
specific activity from the previous step.

Table 12.--Purification Results for Ammonium Sulfate Fractionation
Followed by DEAE-Sephadex Batch Chromatography

Fraction

Protein
Cmi:)

BC-2-NMT
(pmole/h)

Specific Activity
Cpmol/h/m ~)

Purification
Factor

Cytosol

396

10098

25.5

60 - 80%

28

1056 (10%)

37.7

1.5

0.3 M NaCl

1.96

721 (7.1 %)

368

9.8

A 60%-80% (NH4)zS 04 fraction prepared from bovine brain cytosol (100,000 x g
supernatant) was dissolved in pH 7 imidazole buffer (equilibration buffer),
and applied in batch-mode to DEAE-Sephadex resin. After washing the resin
with equilibration buffer, BC-2-NMT was eluted with pH 7 imidazole containing
0.3 M NaCl.
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Discussion
Excessive loss in total BC-2-NMT (90%) suggests that the 60-80%
(NH4)2S04 fractionation-step should be excluded from subsequent studies.
These results are encouraging with respect to purification using batch
chromatography on DEAE-Sephadex.

A nearly IO-fold purification was

achieved during batch chromatography, and the yield for this step alone was
reasonable at 68%.

Suggestions for future studies include:

DEAE-Sephadex

batch chromatography under these conditions except exclude the (NH4)2S 0 4
fractionation step, and to use dialysis to bring bovine brain cytosol to resin
equilibration conditions (0.05 M imidazole buffer, pH 7) prior to mixing with
resin.

Binding of BC-2-NMT Activity to
Dye Chromatography Columns
Background
Dye chromatography is a subset of affinity chromatography, in which
polycyclic-aromatic dyes are covalently attached to a chromatography matrix
such as agarose.

Interaction between dye and enzyme may occur

biospecifically as a result of the structural similarity between certain dyes and
nucleotide cofactors required by the enzyme.

Conversely, interaction between

the immobilized dye and protein of interest may be nonspecific, via ionic or
hydrophobic

mechanisms.
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Materials and Methods:
Dye Screening Experiment
Column

Chromatoi:raphy

Dye resin Test Kit No. RDL-9 was purchased from Sigma Chemical
Company (St. Louis, MO).

Column bed volumes were pre-packed at 2.5 ml;

the

multi-dye test kit contained nine columns with different dye-agarose
substitutions.

Characteristics of the nine columns supplied in the kit are listed

in Table 13.

Table 13.--Components of Multi-Dye Test Kit

Cataloi: #

Dye Substitution

Identification

CB-5

Cibacron Blue

Cib. Blue

RG5-5

Reactive Green

Green 5

RBI0-5

Reactive Brown

Brown 10

RB72-5

Reactive Blue 72

Blue 72

RB4-5

Reactive Blue 4

Blue 4

RY86-5

Reactive Yellow 86

Yellow 86

RY3-5

Reactive Yellow 3

Yellow 3

RR-120-5

Reactive Red 120

Red 120

RG-19-5

Reactive Green 19

Green 19
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Each dye column was equilibrated with 5-10 column volumes of
equilibration buffer in the coldroom at 0-5 °C; buffer contained 10 mM
Na2HP04 at pH 7.3.

It was necessary that bovine cytosol be present in the same

buffer prior to application to dye columns; therefore, solvent exchange on a
PDlO desalting column (Sephadex G-25M, Pharmacia) was utilized to prepare
cytosol in equilibration buffer.
Bovine brain cytosol in 20 mM Na 2HP0 4 (pH 7.4), 150 mM KCl, 1 mM OTT,
1 mM EDTA, 1 mM PMSF, leupeptin (1 µg/ml), and pepstatin (1 µg/ml) was used
in this study; the aliquot had been stored at -80 °C for 5 months prior to use.
Details of solvent exchange procedure follow:

each of three Pharmacia PDlO

columns was equilibrated with equilibration buffer.

Cytosol (2.5 ml) was added

to each desalting column, and protein was eluted using 3.5 ml of equilibration
buffer.

Eluates (10.5 ml total) from these columns were collected and

combined; 1.5 ml was retained and represented "control cytosol".
One ml (3 .2 mg protein) of "control cytosol" was applied to each of the
nine equilibrated dye columns at 0-5 °C.

Flow-through from each column was

collected independently into 13 x 100 mm polypropylene tubes.

Columns were

washed with 6.0 ml of equilibration buffer; this wash was combined with the
previous column flow-through (total volume 7.0 ml).

A control sample was

prepared by mixing 1.0 ml of "control cytosol" with 6.0 ml of equilibration
buffer to yield 7 .0 ml total sample volume.

Samples were evaporated to dryness

using a Speed Vac concentrator at ambient temperature.
reconstituted using 500 µI of Milli-Q water.
range 7-8 as expected.

Each residue was

The pH of each sample was in the

These solutions were assayed for total protein and BC-2-

NMT activity as described below.
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The goal of the screening experiment was to identify one "positive (+)"
column and one "negative (-)" column.

By definition the "positive" column

binds most of the BC-2-NMT activity and less total protein, whereas the
"negative" column binds very little BC-2-NMT activity and a relatively high
quantity of total protein.

BC-2-NMT Assay
Assay components were present as follows: 9-MeNH (540 µM),
µM, 3.69 µCi), and 100 µl of concentrated cytosol or column fraction.
volume was 370 µl,

SAM (150
Assay

pH was 8.5, and assay was maintained at 37 °C for one hour.

Details of the BC-2-NMT assay are in Chapter 3.

Protein

Determination

Total protein was determined using a modified Lowry method as detailed
in the Appendix A.

Results:

Dye Screening Experiment

As Figure 27 shows, the "Green 19" column retained approximately 60%
of the total protein applied and did not bind any detectable BC-2-NMT activity;
therefore, the "Green 19" column was defined as the "negative" column.

The

"Green 5" column bound all of the applied BC-2-NMT activity and 60% of the
applied protein; the "Green 5" column was therefore designated the "positive"
column.

"Yellow 86" and "Yellow 3" dye columns retained little if any protein

or BC-2-NMT activity.
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Figure 27. Total protein and .BC-2-NMT activity retained by various dye
chromatography columns.
Values above the bars represent .BC-2-NMT activity
(pmol/h/mg protein) of column eluate.
"Green 19" is designated "negative"
since it does not bind .BC-2-NMT. "Green 5" is designated "positive" since it
retains 100% of the applied activity.
Discussion: Dye Screening Experiment
These results suggest that the "Green 19" and "Green 5" dye
chromatography columns may be used in sequence for the purification of BC2-NMT activity from bovine brain cytosol.

Specifically, bovine brain in

equilibration buffer could be applied to the "Green 19" column.

The "Green

19" column flow-through combined with the column wash could subsequently
be applied to a "Green 5" column.

.BC-2-NMT activity could then be eluted from

the "Green 5" column using a high salt buffer or other eluent.
experiment is presented below.

The proposed
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Materials and Methods:
Chromatography on Green Dye Columns
Experiment 1
Chromato~raphy

Column

Cytosol used in this experiment contained 20 mM Na2HP04 (pH 7.4), 150
mM KCl, 1 mM DTT, 1 mM EDTA, 1 mM PMSF, leupeptin (1 µg/ml), and pcpstatin
(1 µg/ml); the aliquot had been frozen at -80 °C for 14 months.

PDIO desalting

columns were utilized to bring bovine brain cytosol to equilibration buffer
conditions (10 mM Na 2HP0 4 at pH 7.3).
the coldroom at 0-5 °C.

All subsequent steps were carried-out rn

"Green 19" and "Green 5" columns (2.5 ml) were

equilibrated using 5 column volumes of equilibration buffer.

A portion of Lhe

PD 10 column eluate was reserved for control assays.
The PDlO column eluate (5.4 ml) was applied to the "Green 19
(negative)" column and the column was washed with 5 ml of equilibration
buffer.

Sample application flow-through and wash were combined (10.0 ml

total).

A 2.0 ml aliquot of this solution was concentrated using a Centricon 30

concentrator.

The remaining solution (8.0 ml) was applied to the "Green 5

(positive)" column.

This column was washed with 5 ml of equilibration buffer,

and the wash was combined with flow-through from sample application (12.0
ml total).

A 2.0 ml aliquot was concentrated completely using a Centricon 30

concentrator.

BC-2-NMT activity was eluted from the "Green 5 (positive)"

column with 5 ml 10 mM Na 2HP0 4 containing 2 M NaCl (pH 7.3).

Eluate was

collected (5.0 ml) and a 2.0 ml aliquot was concentrated as described above.
Centricon 30 concentration was achieved overnight in the coldroom.
Centricon retentates (25-30 µl) were diluted in 300 ul of equilibration buffer;
these concentrated solutions were used in the BC-2-NMT and protein assays.
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BC-2-NMT Assay
Assay components were present as follows: 9-MeNH (540 µM),
µM, 3.01 µCi), and 100 µl of concentrated cytosol or column fraction.
volume was 370 µl,

SAM (105
Assay

pH was 8.5, and assay was maintained at 37 °C for one hour.

Details of the BC-2-NMT assay are in Chapter 3.

Protein

Determination

Total protein was determined using modified Lowry method as detailed
in the Appendix A.

Results:
Chromatography on Green Dye Columns
Experiment 1
Results are shown in Table 14.

Table 14.--Recovery of BC-2-NMT Activity and Total Protein During
Reactive Green Dye Column Chromatography
Volume

BC-2-NMT

Protein

Specific Activity

Lmll

Cpmol/h)

~

(pmol/h/mg)

Cytosol (applied to
"Green 19" column)

5.4

426

13.46

31.6

"Green 19" wash plus
flow-through (W/FT)

10

583

7.68

75.9

"Green 19" W/FT
applied to "Green 5"

8

466

6.14

75.9

""Green 5" wash plus
flow-through

12

301

4.09

73.6

"Green 5" eluate
(2 M NaCL/buffer)

5

82

0.63
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Fraction
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These data are summarized graphically in Figure 28.

"Green 19

(negative)" column results were similar to the results obtained in the
screening experiment: in the present study 43% of the total protein applied to
the column was retained by the "Green 19" column, since 57% of applied
protein was measured in the flow-through plus wash from this column.

As

predicted from the screening experiment, none of lhe applied BC-2-NMT
activity was bound by the "Green-19" column.

However, the "Green 5

(positive)" column results differed from those in the screening experiment:
in this study 67% of applied protein (compared to 40% previously) and 64% of
applied BC-2-NMT activity (0% previously) were present in the flow-through
plus wash from the

"Green 5" column.

In other words, in this experiment

only 36% of the BC-2-NMT activity that was applied to the "Green 5" column
was retained by that column, whereas in the screening experiment 100%
retention was observed.

Most of the BC-2-NMT activity retained by the "Green

5" column was effectively eluted from that column by the buffered 2 M NaCl
wash, while 18% of the applied activity remained bound to the "Green 5"
column after 2 M NaCl elution.
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Step (1):
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to "Green 19"
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apply "Green 19"
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"Green 5" column

Step (3):
wash "Green 5"
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Figure 28. BC-2-NMT activity in fractions from reactive green dye columns.
Chromatographic steps: (1) Cytosol was applied to the "Green 19" column. (2)
Flow-through and wash from the "Green 19" column was applied to the "Green
5" column. (3) "Green 5" column was washed with buffered 2 M NaCl to elute
BC-2-NMT activity.
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Discussion:
Chromatography on Green Dye Columns
Experiment 1
The major difference in from this study compared to the screening
experiment is the lack of complete retention of BC-2-NMT by the "Green
(positive)" column. There are three possible explanations for this observation:
(1) the previous experiment is not reproducible, (2) the "Green 5" column
capacity was exceeded in this study with respect to protein and specifically BC2-NMT binding, or (3) the column was contaminated from previous study and
binding efficiency consequently decreased.

A new "Green 5" column with an

8-fold greater bed volume will be utilized in "Experiment 2".

If the steps

beginning with the "Green 5" sample application are considered:

77% of the

protein applied to the column is accounted for in either the "Green 5" flowthrough/wash (67%) and salt elution (10%) from the column.
activity recovered in those two fractions were 82%;

BC-2-NMT

i.e., 64% of the BC-2-NMT

activity applied to the "Green 5" column was found in the column flowthrough plus wash, while 18% of the applied activity resided in the high salt
eluate from the column.

This suggests that 23% of the total protein and 18% of

the BC-2-NMT activity, respectively -- actually applied to the "Green 5" column
remained bound to that column after the high salt wash.
A modification of this experiment incorporated the use of clean
Reactive Green Dye columns, each with an 8-fold greater bed volume.
addition, the final NaCl wash was increased from 2 M to 3 M NaCl.
that experiment are described below.

In

The details of
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Materials and Methods:
Chromatography on Green Dye Columns
Experiment 2: Scale-Up
Column

Chromato~raphy

Reactive Green 19 on 4% beaded agarose (catalog no. R-2882) and
Reactive Green 5, crosslinked on 4% beaded agarose were obLained from Sigma
Chemical Company (St. Louis, MO).

Slurries of each dye chromatography

matrix were filled into each of two empty 12 cm x 1.5 cm EconoPrep
polypropylene columns (BioRad); each bed volume was approximately 20 ml.
Dye columns were equilibrated with 5-10 column volumes of equilibration
buffer in the coldroom (0-5 °C); buffer contained 10 mM Na2HP04 at pH 7.3. It
was necessary that bovine cytosol be present in the same buffer prior to
application to dye columns; therefore, solvent exchange on a PDlO desalting
column (Sephadex G-25M, Pharmacia) was utilized to prepare cytosol in
equilibration buffer.

Bovine brain cytosol in 20 mM Na2HP0 4 (pH 7.4), 150 mM

KCl, 1 mM DTT, and 1 mM EDT A was used in this study;
stored at -80 °C for 1 month prior to use.

the aliquoL had been

The solvent exchange procedure was

identical to previous experiments.
Brain cytosol (9.4 ml) was applied to the equilibrated "Green 19" dye
column at 0-5 °C.

The column was washed with 20 ml of equilibration buffer.

Flow-through from sample application was combined with column wash (27
ml), and a 5.0 ml aliquot was concentrated to 500 µl using a Ccntricon 30
concentrator. The concentrate was used for total protein and BC-2-NMT assays.
The remaining unconcentrated eluate from the "Green 19" column (22 ml) was
applied to the equilibrated "Green 5" column.

This column was washed with 20

ml of equilibration buffer, and this wash was combined with the sample
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application flow-through (41 ml total).

A 5.0 ml aliquot was concentrated to

500 µ1 using a Centricon 30 concentrator.

BC-2-NMT activity was eluted from

the "Green 5" column with 10 mM Na2HP04 (pH 7.4) containing 3 M NaCl, and a
5.0 ml sample of this eluate was concentrated to 500 µI.

BC-2-NMT Assay
Assays were done according to details presented elsewhere (Chapter 3).
Duplicate assays were prepared for each fraction evaluated; assays contained
9-MeNH (540 µM), SAM (105 µM, 3.65 µCi) at pH 8.5 plus 100 µl concentrated
column fraction or initial cytosol.

In addition, blank assays were prepared

which lacked 9-MeNH, but contained all other components.

Protein

Determination

The modified Lowry method was used in the assessment of total protein
in cytosol and column fractions (Appendix A).
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Results:
Chromatography on Green Dye Columns
Experiment 2: Scale-Up
As summarized in Table 15,

this 2-step procedure resulLed in a 17-fold

purification from cytosol and an overall 9% yield of BC-2-NMT activity.

Table

Fraction

15. --Purification Results:

BC-2-NMT
(pmol/h)

Green Dye Chromatography

Protein Specific Activity
(mg)
(pmol/h/mg)
Purification

Yield (%)

Cytosol

846

45.3

18.7

-------

100

"Green 19"

859

11.3

76.0

4

102

"Green 5"
(wash)

16

5.2

3.1

-------

"Green 5"
(NaCl)

62

0.2

310

17

9

Bovine brain cytosol in equilibration buffer (10 mM Na2HP04 at pH 7.3) was
applied to a "Green 19" column. The column was washed with equilibration
buffer. This wash combined with initial eluate was applied to a "Green 5"
column, the column was washed. BC-2-NMT was eluted using 10 mM Na 2HP0 4
containing 3 M NaCl.

Note that since a 5 ml aliquot was removed from the "Green 19" column
flow-through, actual BC-2-NMT activity applied to "Green 5" column was 700
pmole/h (9.2 mg protein).

Very little BC-2-NMT activity (16 pmolc/h or 2% of

applied) was removed from the "Green 5" column as a consequence of washing
the column with equilibration buffer.

In contrast, 56% (5.2 mg) of the total

protein applied to the "Green 5" column was eluted from the column during
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the wash step.

The final wash, composed of 20 mM Na2HP0 4 (pH 7.4) and 3 M

NaCl, eluted 62 pmoles/h BC-2-NMT activity (9% of applied) in 0.2 mg of
protein.

This indicates that 622 pmole/h BC-2-NMT activity and 3.8 mg protein

remained bound to the "Green 5" column.

Discussion:
Chromatography on Green Dye Columns
Experiment 2: Scale-Up
This study indicates that dye chromatography on Reactive Green 19 and
Reactive Green 5 matrices may be useful in the purification of J3C-2-NMT.
expected,

As

none of the BC-2-NMT activity was retained by the "Green 19

(negative)" column.

Total protein bound to the "Green 19" column was 34 mg,

equivalent to 75% of applied protein; this value is higher than the expected 4060%.

The increased retention of total protein is likely due to the ratio of

applied protein to column bed volume between studies. In this study this ratio
was 2.3 (mg protein:column volume) and in the previous investigations the
ratio of applied protein to column volume was greater.
The larger column volume probably accounts for the poor yield of BC-2NMT activity from the "Green 5" column.

Improved recovery from the "Green

5 (positive)" column may be possible by using (1) a larger wash volume, (2) a
"Green 5" column with a smaller bed volume, (3) an alternate eluent (e.g.,
dilute acetic acid, reactive green dye 5).
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Hydrophobic Interaction Column
Chromatography of BC-2-NMT
Background
Hydrophobic

interaction

chromatography

of molecules based on their hydrophobicity.

(HIC)

enables

the

separation

Hydrophobic interactions

between sample components and the HIC matrix are favored under conditions
of high salt.

Therefore, samples are usually applied to HIC columns in a high

salt buffer, with the same buffer being utilized to equilibrate the column.
Successive elution of bound protein is achieved using a either a step or
continuous gradient of decreasing salt concentration.

Collected fractions are

assayed for total protein and protein of interest.

Materials and Methods: Screening Experiment
at Low Ionic Strength
Column

Chromatography

A "Hydrophobic Interaction Chromatography Test Kit" (kit no. MAA-8)
containing eight pre-packed 2.5 ml columns was obtained form Sigma
Chemical Company (St. Louis, MO).

Columns were manufactured to contain

hydrophobic ligands of a discrete carbon number covalently attached to
agarose

(agarose--(CH2)nCH3) as indicated in Table 16.
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Table 16.--Components of HIC Test Kil

Car hons

(#)

Catalog

HJC Matrix

#

2

E 1879

ethyl

agarosc

3

p 5268

propyl

4

B 6882

butyl

5

p 5393

pentyl

6

H 1882

hexyl

8

0 6376

octyl

agarose

10

D 3013

decyl

agarose

12

D 2264

dodccyl

agarose
agarose
agarose
agarose

agarose

Columns were conditioned with 10 column volumes of equilibration buffer
at room temperature and then stored in the coldroom.

Equilibration buffer

contained: 150 mM KCl, 20 mM Na2HP04 (pH 7.4), 1 mM EDTA, 1 mM DTT, and 10%
glycerol.

A 50 ml aliquot of bovine brain cytosol (in equilibration buffer) was

thawed from storage at -80 °C ( 1 month).

In the coldroom,

cytosol was applied to each HIC column.

a 2.5 ml sample of

The sample application flow-through

(''S") from each column was collected into polypropylene tubes and placed on
ice.

Each column was subsequently washed with 3 column volumes (7 .5 ml) of

cold equilibration buffer.

The washes ("W") were collected into

polypropylene tubes and saved on ice.

Finally, each column was eluted with

2.5 ml of dilute buffer containing 20 mM Na2HP04 (pH 7.4),
mM DTT.

Eluates ("E") were saved as above.

1 mM EDTA, and 1

All fractions (''S", "W", and "E")
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were analyzed for total protein content, but only "S" and "E" fractions were
assayed for BC-2-NMT activity.

BC-2-NMT Assay

Assays were done according to details presented elsewhere (Chapter 3 ).
Assays contained 9-MeNH (540 µM), SAM (105 µM, 3.208 µCi) at pH 8.5 plus 100 µl
column fraction or original cytosol.

Protein

Determination

The modified Lowry method was used in the assessment of total protein in
cytosol and column fractions (Appendix A).

Results:
Screening Experiment
at Low Ionic Strength
Figures 29 and 30 show the percentage of applied protein or BC-2-NMT that
was not retained by each HIC column; i.e., the plot shows the percentage of
applied protein or BC-2-NMT found in the sample application flow-through
(''S") or final eluate ("E") fractions for each column.
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Table 17 shows the percentage of applied total protein that was recovered in
column fraction (''S", "W", and "E"), the sum total of those fractions, and the
calculated amount of total protein remaining on the column.

Table 17 .--Total Protein Recovered in Each Fraction
From HIC Columns

% of Applied Total Protein in Fraction

Column

On Column

C-2

7

97

0

104

0

C-3

3

110

0

113

0

C-4

3

96

2

101

0

C-5

0

0

4

4

96

C-6

0

123

8

131

0

C-8

0

6

2

8

92

C-10

4

8

6

18

82

C-12

0

3

4

7

93

Bovine brain cytosol in 150 mM KCI, 20 mM Na2HP04 (pH 7.4), 1 mM EDTA, 1 mM
DTT, and 10% glycerol (equilibration buffer) was applied to each column, and
the column flow-through collected (''S").
Columns were washed with
equilibration buffer ("W").
Final eluate ("E") consisted of equilibration
buffer lacking 150 mM KCI.
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Discussion: Screening Experiment
at Low Ionic Strength
This experiment would have been more meaningful and complete if BC2-NMT activity had also been measured in the wash ("W") fraction, since
without those values it is impossible to conclude if this activity was in the wash
fraction or was retained by the column after all treatments.

As Table 17

indicates much of the total protein was removed from the shorter-carbon
chain HIC columns by the initial wash, whereas the longer-chain HIC columns
retained total protein quite efficiently.

It is possible that substantial BC-2-NMT

activity may have been removed from the columns during the wash. The
cytosolic samples were applied under relatively low ionic strength conditions
because doing so would allow for cytosol to be used directly after subcellular
fractionation, without the need for solvent exchange, thereby eliminating one
step.

The results with this approach were discouraging since much of the BC-

2-NMT activity did not bind to the HIC columns under these conditions, and that
loosely bound protein (and possibly BC-2-NMT) was removed from several of
the columns during the wash step. Therefore, the experiment was repeated
under conditions which favor hydrophobic interactions,

namely sample

application under high ionic strength conditions.

Materials and Methods:
Screening Experiment
at High Ionic Strength
Column

Chromato2raphy

HIC columns were equilibrated in the coldroom with buffer composed of
2 M (NH 4)iS0 4, 150 mM KCl, and 20 mM Na2HP04 (pH 7.3). An aliquot of bovine
brain cytosol (30 ml, 89 mg protein, 2296 pmol/h BC-2-NMT) in 150 mM KCl,

20
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mM Na2HP04 (pH 7.4), 1 mM EDTA, 1 mM DTT, and 10 % (v/v) glycerol was
thawed from -80 °C; the aliquot had been frozen for 2 months.

The cytosol was

stirred magnetically and maintained in an ice-water bath while solid
ammonium sulfate was added to the cytosol to make it 2 M with respect to
(NH4)zS04

-- equivalent to 45% saturation with respect to (NRi)zS 0

4.

Subsequent steps were conducted as described previously in this chapter.

The

supernatant resulting from the 0-45% (NH4)zS 0 4 fraction was applied to
equilibrated HIC columns (2 ml per column), and sample application flowthrough was collected into polypropylene tubes on ice.
washed with 6 ml of equilibration buffer.

Columns were then

This wash was combined with

sample application flow-through (8 ml total).

A "control" sample was

prepared by mixing 2 ml of the 0-40% (NH4)zS 0 4 supernatant with 6 ml of
equilibration buffer.

These solutions were concentrated completely on

Centricon 30 overnight.

Control solution did not concentrate completely

(volume = 750 µl); therefore 750 µl of 10 mM Na2HP04 (pH 7.4) was added to the
other Centricon retentates.

The concentrated samples were utilized in total

protein and BC-2-NMT assays.

BC-2-NMT Assay
Assays were done according to details presented previously (Chapter 3).
Assays contained 9-MeNH (540 µM), SAM (105 µM, 3.325 µCi) at pH 8.5 plus 100 µl
concentrated column fraction or concentrated control cytosol.
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Protein

Determination
The modified Lowry method was used in the assessment of total protein

in cytosol and column fractions (Appendix A).

Results:
Screening Experiment
at High Ionic Strength
Figure 31 reflects the quantity of total protein and BC-2-NMT activity,
represented as percent of applied, present in the combined sample application
flow-through plus wash fractions

that is total protein and BC-2-NMT not

bound by the HIC columns.
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Figure 31. Total protein and BC-2-NMT activity not bound by HIC columns at
high ionic strength conditions.
Values above bars represent BC-2-NMT
activity in a given fraction.
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Discussion:
Screening Experiment
at High Ionic Strength
Since the control solution did not concentrate completely (750 µI
remained), 750 µI of IO mM Na2HP04 (pH 7.4) was added to the other retentates.
The control should have been concentrated completely like the other samples,
because the control was really no longer a true control since it contained a
high concentration of ammonium sulfate compared to other samples.

As a

consequence, "control BC-2-NMT activity" was low, due to presence of the high
salt concentration.

Therefore, based on previous experience, an assumption

was made that about 50% of original cytosolic activity was recovered in the 046% (NH4)2S04 supernatant (31 ml), giving 1150 pmol/h BC-2-NMT (calculated)
and 52.4 mg protein (measured).

This is equivalent to 3.4 mg protein and 74

pmole/hr BC-2-NMT activity applied to each column (per 2 ml).

These values

were used to calculate the percentage of applied protein or BC-2-NMT residing
in respective column fractions.
Data indicate that total protein was more effectively retained by the HIC
matrices than BC-2-NMT in nearly all cases.

At high salt conditions, greater

than 100% of the applied BC-2-NMT activity did not stick to the C3, C4, C6, CS,
and CIO columns, suggesting that BC-2-NMT is not a very hydrophobic protein.
The observation that more than 100% recovery was obtained in these fractions
suggests that: the assumptions in the preceding paragraph are incorrect (i.e.,
applied activity was higher than calculated) or that an inhibitor of BC-2-NMT
was retained by these columns.

No blank BC-2-NMT assays were analyzed in

this study, therefore it is also possible that the reported BC-2-NMT activity is
inflated due to a high amount of nonspecific background.

Furthermore it is

possible that column capacity for BC-2-NMT may have been exceed under these
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conditions.

The next section describes experiments in which blank assays

were prepared, and chromatography repeated under these conditions using C5
and CS columns with larger bed volumes.

Materials and Methods:
C5 and CS HIC Column Chromatography
Scale-Up
Column

Chromato~raphy

Pentyl-agarose (catalog #P-5393) and octyl-agarose (catalog #0-6376)
HIC matrices were obtained from Sigma and filled into each of two 20 ml
polypropylene EconoPrep columns (BioRad).

Columns were equilibrated in the

coldroom with buffer containing: 2 M (NH4)zS04, 150 mM KCI, 20 mM Na 2 HP0 4 , 1
mM EOTA, and 1 mM OTT.
A 35 ml aliquot of bovine brain cytosol in 150 M KC!, 20 mM Na 2 HP0 4 , 1
mM EOTA, and 1 mM OTT was thawed from -SO °C (stored 1 month).

The aliquot

was stirred and chilled in an ice-water bath during the addition of 9 .17S g of
solid (NH 4)zS 0 4 (equivalent to 45% saturation).
adjusted to pH 7 .3.

The pH of the mixture was

Ammonium sulfate precipitation was accomplished as

previously described in this chapter. A two ml aliquot of the supernatant (3S
ml total) was ultradialyzed and concentrated on a Centricon 30 (final volume =
300 µl).
The remaining 0-45% (NH4)zS04 supernatant was applied to each of the
two HIC columns (1 S ml per column).

Sample application flow-through was

collected and saved on ice in a 150 ml polypropylene container with lid.

Each

column was washed with 40 ml (2 column volumes) of equilibration buffer,
and this wash was combined with the original column fraction (total volume =
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55 ml).

A 4 ml aliquot of each column fraction was ultradialyzed and

concentrated on a Centricon 30 concentrator.

Final volume of each

concentrate was 350 µI in 10 mM Na2HP0 4 buffer at pH 7.3. Total protein and BC2-NMT activity were measured in each concentrated column fraction, desalted
0-45% (NH4)2S 04 supernatant, and original cytosol.

BC-2-NMT Assay
Assays were carried out according to details presented previously
(Chapter 3).

Assays were prepared in duplicate to contain

9-MeNH (540 µM),

SAM (105 µM, 2.445 µCi) at pH 8.5 plus 100 µI concentrated column fraction,
desalted/concentrated

Protein

(NH 4h S 0 4 fraction, or initial cytosol.

Determination
The modified Lowry method was used in the assessment of total protein

in cytosol and column fractions (Appendix A).

Results:
CS and C8 HIC Column Chromatography
Scale-Up
These results are inconsistent with those in the previous experiment
where a tremendous increase in specific activity was observed with HIC.
Purification from cytosol through HIC column eluate was 4.4-fold for the C5
column eluate, and 5.2-fold C8 column eluates.

BC-2-NMT and total protein

present at each step of purification is summarized in Table 18.

Fractions

include initial cytosol, the supernatant resulting from the 0-45% (NH4)iS 04
"precipitation step ("0-45%), the material applied to each HIC column, and the

1S2
quantity of protein and BC-2-NMT measured in the column flow-through plus
wash ("Ff/W") fractions from each of the HIC columns ("CS" and "C8).

Table

18.--Hydrophobic Interaction Chromatography
Purification Results
Protein

Fraction

BC-2-NMT
Cpmol/h)

Specific

Activity

Cpmol/h/m~)

Cytosol

331.4S

9800

29.6

0 - 45%

86.42

4236

S0.1

HIC applied

40.93

2049

S0.1

cs

(Ff/W)

2.743

3SS

129.4

C8 (Ff/W)

1.829

281

1S3.7

Supernatant ("0-4S%") obtained following 0-4S% (NH4hS 0 4 fractionation of
bovine brain cytosol was divided in half and applied to equilibrated pentyl (CS)
and octyl (C8) columns ("HIC applied"). Composition of equilibration buffer
was 2 M (NH4)zS04, lSO mM KCl, 20 mM Na2 HP0 4, 1 mM EDTA, and 1 mM OTT. The
column flow-through and subsequent wash were combined and analyzed ("CS
Ff/W" and "C8 Ff/W").

As expected, ammonium sulfate precipitation resulted in a 1.7-fold
purification of BC-2-NMT activity from bovine brain cytosol; yield of enzyme
activity was 44%.

For the "CS" column, approximately 83% of the applied BC-2-

NMT activity, and 93% of the total protein remained in association with the
column following the wash-step.

For the C8 column 86% of the applied BC-2-

NMT, and 96% of applied total protein remained bound to the column.
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Discussion:
CS and CS HIC Column Chromatography
Scale-Up
The enhanced binding of BC-2-NMT activity relative to total protein may
be due to the increase in bed volume utilized in this study compared lo the
previous experiment.

Based on this experiment, which incorporated better

controls, it is concluded that the previous experimental results which showed a
tremendous increase in BC-2-NMT using this protocol were in error.

Preparation and Evaluation of S-Adenosyl-L-HomocysteineSepharose Affinity Chromatoi;raphy Column
Materials and Methods:
SAH-CH-Sepharose Affinity Chromatography
Couplin~

Reaction

The goal was to prepare an affinity chromatography matrix in which
SAH was covalently attached to CH-Sepharose 4B.

This was accomplished at

acidic conditions by reacting CH-Sepharose-4B with SAH in the presence of a
carbodiimide (Figure 32).
SAH-CH-Sepharose column was prepared according to Harvima et al.
(1985) and Pharmacia technical literature (Pharmacia l 993a).

The primary

reactants were purchased from Sigma Chemical Company (St. Louis, MO):
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Reactant

FWT

Catalog #

S-adenos yl-L-homoc ysteine

384.4

A-9384

1-e thyl-3-(3-di methyl ami nopropyl)carbodiimide (HCl salt)

191.7

E-1769

6-Aminohexanoic acid-Sepharose
(CH-Sepharose 4B)

4B

A-8769

The supplier provided the following information regarding the CH-Sepharose
4B

chromatography matrix:

Matrix:

Sepharose 4B

Activation:
Spacer:

cyanogen

bromide

provides an 8-atom spacer when ligands are coupled to free

carboxy groups using a carbodiimide coupling agent
Extent of Activation:
Form:

10-14 µmoles per ml of gel (40-56 µmoles/g dry)

lyophilized powder stabilized with lactose and dextran

Swelling Ratio:

1 g swells to approximately 4 ml of gel
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generic
carbodiimid

6-aminohexanoic acid
Sepharose 4B

~
,.NR1
Sepharose-NH-(CHz)5-C-O-C
'NR2

+

HzN..,
fH-(CHz)z-SHXC

ID

a-1

0

II

Sepharose-NH-(CHz)5-C-NH-CH-(CHz)z-S-CHz

+

I
CXDH

ID

GI

I

SAH-C H-Sepharose Affinity Column

Figure 32.
Preparation of S-adenosyl-L-homocysteine (SAH) Sepharose
affinity chromatography column.
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The CH-Sepharose 4B (2 g, 80-112

µmoles active groups) was swollen in

20 ml of 0.5 M NaCl, and then washed on a scintered glass funnel with 500 ml
0.5 M NaCl followed by 100 ml Milli-Q water at pH 6.

SAH (100 mg, 260 µmoles)

was dissolved in 15 ml of Milli-Q water at pH 4.6-6.

The SAH solution was added

to the CH-Sepharose 4B with minimal stirring on a magnetic stir plate.

The

carbodiimide (235 mg, 1.23 mmoles) was added as a solid in small amounts to the
stirred SAH and CH-Sepharose mixture.

The mixture was transferred to a tube,

capped, and mixed by rocking on a lab rocker plate.

The pH of the coupling

reaction was checked during the first hour to assure that it remained between
pH 4.6 and pH 6.
20 hours).

The reaction was rocked at room temperature overnight (15-

No blocking reaction was done, and the affinity gel was washed

extensively with Milli-Q water to remove urea product, unreacted SAH, and
carbodiimide.
6.5).

The gel was stored at 0-5 °C in 2 M KCl and 10 mM K 2 HP0 4 (pH

The extent of coupling of SAH to CH-Sepharose 4B was not determined.

Column

Chromato~raphy

Approximately 1 ml of the SAH-CH-Sepharose 4B affinity gel was filled
into a polypropylene 1 cc tuberculin syringe fitted with a stopcock and
silanized glass wool plug at the outlet.

The column was equilibrated with 10 ml

of 0.05 M imidazole buffer (pH 7) containing 0.3 M NaCl.

The sample (3.5 ml)

that was applied to the affinity column was the 0.05 M imidazole buffer (pH 7)/
0.3 M NaCl eluate derived from DEAE-Sephadex batch chromatography protocol
described previously in this chapter.

The sample application flow-through

was collected, and a 1.5 ml portion concentrated to 150 µI on a Centricon 30
concentrator.

The column was washed with 2 ml of

(pH 7) containing 1 M NaCl.

0.05 M imidazole buffer

This wash was collected and a 1.5 ml aliquot
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concentrated to 150 µI.

The concentrated solutions were analyzed for BC-2-NMT

activity and total protein.

BC-2-NMT Assay
Details of the assay, work-up, and RP-HPLC analysis are discussed in
Chapter 3.

Assays (pH 8.5) were maintained at 37 °C for one hour.

The

reactions consisted of 9-MeNH (540 µM), SAM (105 µM, 3.30 µCi), and 100 µI of
respective

Protein

concentrated

column

fraction.

Determination

Protein measurements were carried-out using a modified Lowry method
as detailed in Appendix A.
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Results: SAH-CH-Sepharose 4B
Affinity Chromatography
Total protein and BC-2-NMT activity recovered in each fraction are
summarized in Table 19.

Table

19.--SAH-CH-Sepharose Affinity Chromatography

BC-2-NMT
Cpmol/h)

Specific Activity
(pmol/h/mg)

Fraction

Protein
(mg)

Applied

0.756

102

135

Flow-through

0.525

12.3

23.4

1 M NaCl wash
(buffered)

0.166

32.2
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SAH column equilibrated in 0.05 M imidazole buffer contanung 0.3 M NaCl.
Sample "Applied" to column was the 0.3 M NaCl eluate from DEAE-Scphadex
chromatography discussed in a previous section of this chapter.
Column
"Flow-through" was collected, and then BC-2-NMT was eluted from the column
with 0.05 M imidazole buffer containing 1 M NaCl ("l M NaCl wash").
Regarding total protein: 91 % of the applied protein was accounted for in
the initial flow-through fraction (0.525 mg, 69%), and following the buffered 1
M salt wash (0.166 mg, 22%).

These results indicate that 0.065 mg (9%) of the

total protein applied to the column remained bound to the SAH-CH-Sepharose
4B affinity matrix.
In contrast,

55% (57 pmol/h) of the applied BC-2-NMT activity remained

in association with the SAH affinity column, since 12% (12.3 pmol/h), and 32%
(32.2 pmol/h) of the applied activity was recovered in the flow-through and
wash

fractions,

respectively.
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Discussion: SAH-CH-Sepharose 4B
Affinity Chromatography
These results are discouraging since a mere 1.4-fold purification was
achieved with respect to BC-2-NMT activity, beginning with application to the
SAH column (specific activity, 135 pmol/h/mg protein) and ending wilh the
buffered 1 M NaCl elution (specific activity, 194 pmol/h/mg protein).
Typically purification by ligand-specific affinity methods is much greater.
The final eluate did not remove all of the remaining BC-2-NMT activity.

In

fact, 57 pmol/h BC-2-NMT activity and 0.068 mg of total protein remained
bound to the affinity column. This is equivalent to 838 pmol/h/mg protein BC2-NMT specific activity stiII retained by the SAH-CH-Sepharose column.
These results indicate that a more efficient means of eluting BC-2-NMT
activity from the SAH-CH-Sepharose 4B affinity column is required, such as
dilute acetic acid, or affinity elution with SAH or SAM.

Due to the high cost of

SAH and SAM, affinity elution would be quite expensive compared to elution
with acid.

In addition,

= 14 µM)

than SAM (KM

since BC-2-NMT exhibits a higher affinity for SAH (IC5 o

= 85 µM),

it may be impractical to elute BC-2-NMT

activity from the SAH column using affinity elution with SAM.
Regarding the preparation and use of SAH-CH-Sepharose affinity
columns in future studies, the following suggestions are made:
( 1) preparation of a new affinity matrix, since literature indicates
that efficiency of an SAR-column decreases as a function of storage
time (Harvima et al. 1985)
(2) utilization of more SAH in the coupling reaction
(3) evaluation of the efficiency of coupling using the method
described by Harvima et al. (1985), in which a small aliquot of
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coupled gel was hydrolyzed and the liberated SAH analyzed
using HPLC
(4) "affinity" elution using an adenosine solution.

Preparation and Evaluation of B-Carboline-Sepharose
Affinity Chromatography Column

Materials and Methods:
Couplin~

Experiment I

Reaction

The goal was to prepare an affinity chromatography matrix in which a
BC was covalently attached to Sepharose 6B.

This was done by reacting harmol

with epoxy-activated Sepharose 6B (EAS) under basic conditions (Figure 33).
The methods were similar to those described by Hermanson et al. (1992) and in
the Pharmacia technical literature (Pharmacia

1993a).
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Sepharose-O-Ch:-CH-CHz-CHz-O-(CHz)4-CHz-,lH2

~
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IEpoxy-activated Sepharose 6B I
(coupling conditions)
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Sepharose-o-q1-12-CH-CHz-CHz-O-(CHz)4-CHz-1H-C~~~
OH
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Figure 33.

Affinity Column

H

CH3

l

Scheme for preparation of BC-affinity chromatography column.
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Epoxy-activated Sepharose 6B was purchased as a lyophilized powder
Sigma Chemical Company,

St. Louis, MO (Catalog # E-6754).

from

The following

information was provided by the manufacturer:
Activated group:

Sepharose-(1,4-bis(2 :3-epoxypropoxy)butane

Extent of activation: 19 - 40 µmole per ml of gel
Spacer-arm
Swelling
Harmol

length:

12 atoms

properties: 1 g swells to 3 ml of gel

(1-methyl-9H-pyrido[3 ,4-b ]indol-7-ol)

hydrochloride

dihydrate

was

purchased from Sigma (FWT 270.7, Catalog #H-1000).
Sodium carbonate buffer (100 ml, 0.1 M, pH 10) was prepared by
dissolving 1.06 g of sodium carbonate (Na2C03, FWT 105.99, Sigma Chemical Co.)
in 80 ml of Milli-Q water.

The solution pH was adjusted to pH 10 and the

solution brought to 100 ml using Milli-Q water.
Lyophilized epoxy-activated-Sepharose 6B (1 g) was suspended in 10 ml
of Milli-Q water and then transferred to a scintered glass funnel.

The gel was

washed with 200 ml of Milli-Q water, exercising care to keep the gel moist.

The

rinsed gel (3 ml) was then washed with 20 ml of Na2C03 buffer and
subsequently transferred as a slurry (5 - 6 ml) to a small amber vial.
Due to the limited solubility of BCs under alkaline conditions, harmol
was dissolved in dimethylformamide (DMF) prior to addition to Na 2C 0 3 buffer.
Harmol (162 mg, 600 µmoles) was dissolved in 2.5 ml of DMF followed by the
slow addition of Na2C03 buffer (2.5 ml).

The pH of the mixture (pH 7-8) was

adjusted to pH 10 using 8 N and 1 N sodium hydroxide.

Harmol (600 µmole) was

present in a 5-fold excess relative to the maximum number of epoxy-activated
sites (120 µmole on 3 ml of gel).
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Harmol solution was combined with the EAS gel slurry in the amber vial
and capped.

The vial contents (10-12 ml total) were maintained for 18 hours at

40 °C in a shaking water bath.
this procedure.

The gel settled to the bottom of the vial during

Ideally the gel should have been maintained as a suspension

in order to improve the efficiency of the coupling reaction.

Determination of

Couplin~

Efficiency

The maximum theoretical quantity of harmol that could be covalently
attached via the epoxy-activated groups was 40 µmoles of harmol per ml of gel
(40 nmoles harmol per µl gel).
A 100 ul aliquot of the coupled gel slurry was transferred to a 1.5 ml
microcentrifuge tube, and then washed repeatedly with Milli-Q water to
remove free harmol.

The gel was washed with 0.1 M HCl,

Milli-Q water, and

finally 10 mM Na2HP04 (pH 7.4). The rinsed gel (30 µl of settled gel) was
suspended in 970 µL 10 mM Na2HP04 (pH 7.4).

Assuming 100% efficiency of the

coupling reaction, maximally 1200 nmole (1.2 µmoles) of harmol would be
covalently bound to the 30 µl of gel.

Therefore a standard solution was

prepared to contain 1.2 µmole/ml of harmol in 10 mM Na2HP04 (pH 7.4).

This

standard was serially diluted with buffer to yield standards ranging from
0.00012 - 0.12 µmole/ml harmol.

The wavelength of maximal absorbance of the

harmol solution was determined by scanning from 220-500 nm using the
Gilford Response spectrophotometer.

This wavelength was used to measure the

absorbance for each standard, and linear curve-fitting of the data was used to
define the equation for the standard curve.

Samples were also analyzed at this

wavelength in small volume quartz cuvettes with a 1 cm path, where buffer
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was used as in the reference cuvette.

Absorbance of the coupled gel was

determined

spectrophotometrically,

and

coupling

efficiency

subsequently

calculated.

Coupling efficiency appeared to be low, and therefore in an effort

to improve coupling, the reaction pH was increased from 10.2 to pH 12.7 by the
addition of 8 N NaOH.

The coupling reaction was mixed at room temperature on

a rocker plate until absorbance values for samples of the mixture reached a
plateau and then began to decline.

Blockin~

of Unreacted Activated Sites

The coupled gel was transferred to a scintered glass funnel and washed
extensively with Milli-Q water (200 ml) in order to remove free harmol.

In

addition, the gel was washed with 50 ml each 0.5 N HCl and Milli-Q water.
Blocking of any remaining epoxy-activated sites was accomplished by shaking
the gel at 40 °C for 14 hours with 20 ml 1 M ethanolamine (pH 9.4).
washed with 100 ml each Milli-Q water and 150 mM KCI.

The gel was

Gel was stored in the

refrigerator in 150 mM KCl until it was filled into a column (2-3 days).

BC-Sepharose

Column

Chromato~raphy

The BC-Sepharose affinity matrix was filled into an empty PolyPrep
chromatography column (BioRad); this polypropylene column had a IO ml
reservoir on top of a bed volume of about 2.5 ml (0.8 cm x 4 cm bed).

The

column was equilibrated with 50 ml of IO mM Na2HP04 containing 1 M NaCl (pH

7.4).
A 2 ml aliquot of bovine brain cytosol was thawed and ultradialyzed on a
Centricon 30 concentrator against equilibration buffer.

The cytosol had been

stored at -80 °C for 1 month in 150 mM KCl, 1 mM OTT, and 10% (w/v) glycerol.
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Ultradialyzed cytosol (2.5 ml) was applied to the equilibrated BC-Sepharose
column by gravity flow.

The column flow-through was collected and a 1.0 ml

aliquot concentrated to 300 µI on a Centricon 30 concentrator.

The column was

washed (with the add of a vacuum) using 25 ml of equilibration buffer.
wash was collected and a 2.0 ml sample concentrated to 300 µI.

The

BC-2-NMT

elution was attempted using 2 ml of 10 mM Na2HP04 buffer (pH 7.4) containing
2 M NaCl and 3 M NaCl in succession.
concentrated to 300 µI.

Aliquots (2.0 ml) of these eluates were

Total protein and BC-2-NMT activity were measured in

each column fraction.

BC-2-NMT Assay
Details of the assay, work-up, and RP-HPLC analysis are discussed in
Chapter 3.

Assays,

at pH 8.5, were maintained at 37 °C for 45 minutes;

reactions consisted of 9-MeNH (540 µM), SAM (105 µM, 2.194 µCi), and 100 µI of
the

concentrated

Protein

column

fractions.

Determination

Protein measurements were carried-out using a modified Lowry method
as detailed in Appendix A.
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Results:

Coupling

BC Affinity Chromatography
Experiment 2

Procedure

The coupled and rinsed gel was yellow under alkaline conditions and
colorless in an acidic environment.

This suggests that at least some 13C is

bound to the gel, since free harmol exhibits similar properties.
The harmol standards exhibited an intense absorbance maxima at 320.5
nm (A320,5).

Therefore, this wavelength was utilized to determine the

concentration of harmol present in the standards and samples. The harmol
standard curve is represented in Figure 34.
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Standard curve for harmol in 10 mM Na2HP04 (pH 7.4).
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Analysis of these data resulted in the following equation:
A32o.5

= 0.03

+ 13.251( µmoles/ml harmol).

The 30 µl sample of coupled gel (in 1 ml total volume) exhibited an A320.5 of
0.2107,

corresponding to 0.013 µmoles harmol per 30 µl gel.

quantity of harmol coupled per ml of gel was 0.45 µmoles.
represented only 1-2% of theoretical quantity.

Therefore, the

This value

The reaction pH was increased

from pH 10.2 to pH 12.7 in an effort to improve coupling efficiency.

After

mixing for one hour at room temperature a 30 µl aliquot was analyzed for
harmol bound to gel as described above.

For this sample, A32o.5

corresponds to 2.33 µmoles harmol per ml gel.
theoretical value of 19-40 µmoles/ml.
hours at room temperature.

= 0.6802,

which

This value represents 6-12% of

The reaction was allowed to proceed 20

Analysis showed a decrease in A310.s to 0.3956 (i.e.,

0.92 µmoles harmol/ml gel), therefore coupling reaction was terminated and
the blocking reaction was initiated.

BC-Sepharose

Column

Chromatography

The results of this experiment were very difficult to interpret because
the HPLC traces appeared similar--much like background, with no discernable
peaks.

Approximately 10.6 mg of total protein was applied to the column;

9.9

mg (93%) of that was retained by the column initially and subsequent washing
removed 4.2 mg protein (40% of applied).

This indicates that 5.7 mg of total

protein (54% of applied) remained bound to the BC-Sepharose column after
washing with equilibration buffer.

No additional protein was eluted by

subsequent buffer solutions containing 2 M or 3 M NaCl .
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Discussion:

BC-Sepharose Affinity
Experiment 1

Chromatography

It is possible that the BC-2-NMT activity was removed from the column

during the first wash step, but that its presence there was undetectable due to
dilute nature of the wash.

It is more reasonable to speculate that the BC-2-NMT

activity remained bound to the BC-Sepharose column, since 54% of the protein
applied remained in association with the column foIIowing extensive washing.
It is conceivable that the high salt buffers used in this experiment -- a
condition that favors hydrophobic interaction -- may have actually
strengthened the interaction between the hydrophobic HC (attached to the
matrix) and protein or HC-2-NMT -- rather than lessened the interaction as
planned.

FoIIow-up experiments were carried out using buffers of lower ionic

strength in order to address this concern.

Materials and Methods:
BC-Sepharose Affinity Chromatography
Experiment 2

Column

Chromato~raphy

The HC-Sepharose column prepared in "Materials and Methods: BCSepharose Affinity Chromatography (Experiment 1) was utilized in
"Experiment 2".

The major differences in this experiment compared to

"Experiment 1" were, (1) sample was applied under lower ionic strength
buffer conditions,

(2) wash volume was decreased, and (3) an attempt was

made to elute BC-2-NMT activity from the column with norharman ("affinity
elution").

The column was equilibrated in buffer containing 20 mM Na2H PO 4
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(pH 7.3) and 150 mM KCI.

Bovine brain cytosol (5 ml), in the same buffer was

applied to the column by gravity flow.

Column flow-through was collected and

filtered through a 0.22 µm polysulfone syringe filter (13 mm diameter). The
entire fraction was concentrated completely on a Centricon 30 concentrator.
The column was washed with 6 ml of equilibration buffer, and the wash was
collected and treated like previous fraction.

Norharman (2.0 ml, 1 mM in

equilibration buffer) was used to elute BC-2-NMT from the column.
norharman (NH) wash was repeated three additional times.

The

These fractions

were ultradialyzed (three solvent exchanges) to remove norharman, and
simultaneously concentrated on a Centricon 30 concentrator.
Centricon 30 concentration proceeded overnight at 0-5 °C.
Equilibration buffer (300 µI) was added to each retentate;

buffer was not added

to the initial column flow-through since its volume measured 450 µ1 "as-is".
These concentrated solutions were used in the BC-2-NMT assay and for protein
de termination.

BC-2-NMT Assay
Details of the assay, work-up, and RP-HPLC analysis are discussed in
Chapter 3. Assays,

at pH 8.5, were maintained at 37 °C for one hour;

reactions

consisted of 9-MeNH (540 µM), SAM (105 µM, 3.112 µCi), and 100 µl of respective
concentrated

Protein

column

fraction.

Determination

Protein measurements were carried-out using a modified Lowry method
as detailed in Appendix A.
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Results:

BC-Sepharose Affinity Chromatography
Experiment 2

The results of this experiment are summarized in Table 20.

Table 20.--BC-Sepharose Affinity Chromatography Results
Column
Fraction

Protein
(mg)

BC-2-NMT
(pmol/h)

Specific Activity
(pmol/h/mg)

Cytosol

34.0

671

19.7

Flow-through

6.8

65.7

9.5

Wash

4.3

145

33.8

NH (1st)

0.37

38.8

101

NH (2nd)

0.27

32.5

122

NH (3rd)

0.14

40.8

283

NH (4th)

0.09

16.6
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The BC-Sepharose column was equilibrated in 20 mM Na2HP04 (pH
containing 150 mM KCI. Bovine brain cytosol ("Cytosol") in same
applied to the column and "Flow-through" collected. Column was
equilibration buffer ("Wash"), and BC-2-NMT subsequently eluted
sequential volumes of 1 mM norharman solution (NH 1st - 4th).

7.3)
buffer was
washed with
using four

Approximately 35% (12.0 mg) of the total applied protein was accounted
for in all fractions, indicating that 65% of total protein remained on the
column.

With respect to BC-2-NMT activity,

60% of the applied activity was

accounted for (405 pmol/h), with 31 % of the applied activity in the combined
flow-through and wash fractions (211 pmol/h), suggestive of poor hinding of
BC-2-NMT under these conditions.

Affinity elution of BC-2-NMT activity with
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norharman solution resulted in the release of 19% of the applied activity
(129.0 pmol/h), and approximately 50% of the applied BC-2-NMT activity
remained in association with the BC-Sepharose column (339 pmol/h).

The

specific activity of the combined norharman fractions was 148 pmol/h/mg
protein; therefore, the overall purification from cytosol to norharman eluates
was 7.5-fold with a 19% yield.

Discussion:

BC-Sepharose Affinity Chromatography
Experiment 2

More total protein remained bound to the column in this experiment
compared to "Experiment 1'',

65% compared to 54%, respectively.

This may

indicate that non-specific binding of protein is increased at lower ionic
strength used in "Experiment 2" or that other interactions -- such as ionic
interaction with the ethanolamine used to block reactive sites -- may be
occurring.

The lack of BC-2-NMT binding during cytosol application to the

column and subsequent washing indicates that binding of BC-2-NMT may be
favored under conditions of higher ionic strength utilized in "Experiment 1".
The incomplete elution of bound BC-2-NMT by a 1 mM NH solution was
unexpected, and the 7 .5-fold purification atypical for a true affinity column.
These data suggest that a more concentrated NH solution may be required for
complete BC-2-NMT displacement from the column.

It is also possible that a pH

change may facilitate complete elution of BC-2-NMT activity.
experiments have not been done.

These
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Discussion:
Affinity Chromatography
General Comments
Purification of BC-2-NMT activity using SAH and BC affinity columns in
sequence would likely be a powerful approach to BC-2-NMT purification.

In

theory the SAH-column could be used bind SAM-dependent
methyltransferases, including BC-2-NMT.

Obviously it is necessary to identify

an efficient means of eluting BC-2-NMT activity from the SAH-CH-Sepharose
4B affinity column.

The BC-2-NMT-containing fraction from the SAH-column

could subsequently be applied to the BC affinity column under conditions that
bind this activity efficiently -- perhaps at a pH similar to pH optimum for
enzyme assay (pH 8.5).

In theory a tremendous purification of BC-2-NMT could

be achieved at this step, since a relatively small number of proteins are
presently known to specifically interact with BCs.

A few proteins expected to

bind to a BC-affinity column include, (1) those that catabolize BCs, (2)
monoamine oxidase (BCs inhibit MAO), and (3) the benzodiazepine receptor to
which BCs bind.

As with the SAR-column, an effective procedure for elution

of BC-2-NMT from the BC-column is fundamental to the success of this method.
Consideration should also be given to the possibility that the BC-column may
act as a nonspecific hydrophobic matrix due to the hydrophobic nature of the

BC molecule.
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Overall

Purification

Summary

Ammonium sulfate fraction followed by DEAE-Scphadcx batch
chromatography resulted in a nearly 20-fold purification of BC-2-NMT activity
-- from a cytosolic activity of 20 pmol/h/mg protein to nearly 400 pmol/h/mg
protein.

Purification of BC-2-NMT varied depending upon the purification

protocol utilized (Figure 35).
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Summary of BC-2-NMT purification (see this chapter for details).

Key: each bar represents 1-2 steps in sequence
llil4lz.Si4_60-80%/DEAE: 60-80% ammonium sulfate fraction from bovine brain cytosol
dissolved in pH 7 imidazole buffer, then subjected to batch chromatography on DEAESephadex (anion exchange matrix). BC-2-NMT activity (represented by har) was eluted
from the matrix with pH 7 imidazole buffer containing 0.3 M NaCl.
Green 19/Green 5: Bovine brain cytosol was applied to a Green 19 dye column, eluate from
this column was applied to a Green 5 dye column. BC-2-NMT activity (represented by bar)
was eluted from Green 5 dye column using pH 7.4 Na 2 HP0 4 containing 3 M NaCl.
DEAE/SAH-Affinity: DEAE-Sephadex batch chromatography elute (above) applied to an Sadenosyl-L-homocysteine affinity column. BC-2-NMT activity (represented by bar) was
eluted from the column with pH 7 imidazole buffer containing I M NaCl.
BC-Affinity: Bovine brain cytosol in 20 mM Na 2 HP0 4 (pH 7.3)/150 mM KC! was applied to
a B-carboline affinity column. BC-2-NMT activity (represented by bar) was eluted from the
column using a l mM buffered norharman solution .
.LN141.i.Sl4~ supernatant from 40% ammonium sulfate fractionation was applied to a
octyl-agarose (C8) hydrophobic interaction chromatography column.
BC-2-NMT activity
(represented by bar) was measured in application flow-through.
!Nli.4_lz.Sl4lC.i.:. supernatant from 40% ammonium sulfate fractionation was applied to a
pentyl-agarose (C5) hydrophobic interaction chromatography column.
BC-2-NMT activity
(represented by bar) was measured in application flow-through.
Green 19: column chromatography (same conditions as above) on a Green 19 dye column
60-80% fNH!lz.SJ4,;_ the 60-80% ammonium sulfate fraction (desalted)
40-60% CNH!lz.SJ4.:. the 40-60% ammonium sulfate fraction (desalted)
Cytosol: bovine brain cytosol, typically the starting material for each step above.

CHAPTERS
MEASUREMENT OF 6-CARBOLINE-2N-METHYLTRANSFERASE
AND 6-CARBOLINE-9N-METHYLTRANSFERASE ACTIVITIES
IN POST-MORTEM HUMAN BRAIN FROM CONTROL AND
PARKINSON'S DISEASE SUBJECTS

Back~round

6-carboline-N-methyltransferases (6C-NMTs) and

the products of their

catalytic activities, neurotoxic N-methylated 6-carbolinium cations (Me6Cs+),
may play a role in the pathogenesis of idiopathic Parkinson's disease (Collins
1994; Collins and Neafsey 1985).
particulate

fraction

To explore this hypothesis, supernatant and

6C-2N-methyltransferase

and

6C-9N-methyltransferase

activities were measured in human postmortem brains.

These activities were

assessed in substantia nigra, putamen, and frontal cortex from control (N= 11)
and Parkinson's disease (N=12) cases.

If 6C-2N- and/or 6C-9N-

methyltransferase contributes to the development of PD, the hypothesis
predicts that these activities may be increased relative lo control brain
activities -- probably early in the disease process.

In addition, it is predicted

that these activities may be elevated in brain areas primarily affected in PD,
namely the substantia nigra and/or putamen.

However, if these enzyme

activities are indeed elevated early in pre-symptomatic PD, that elevation may
be undetectable since the tissue used here was obtained from patients with
well-developed PD.
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Materials and Methods

Brain Tissue
Frozen sections of postmortem human brain were obtained from three
different brain banks: (1) National Neurological Research Specimen Bank,
VAMC Wadsworth Division, Los Angeles, CA 90073 (supported by NINDS/NIMH,
National Multiple Sclerosis Society, Hereditary Disease Foundation,
Comprehensive Epilepsy Program, Tourette Syndrome Association, Dystonia
medical Research Foundation, and Veterans Health Services and Research
Administration, Department of Veterans Affairs); (2) The Rush Brain Bank,
Chicago, IL (supported by NIA AG09466 and AG10161); and (3) The Loyola
University/Hines VA Brain Bank, Loyola University Medical Center, Maywood,
IL (supported by the Department of Pathology).
Sections evaluated in this study included substantia nigra, putamen, and
frontal cortex obtained at autopsy from control subjects and patients diagnosed
with Parkinson's disease.

Table 21 shows pertinent information regarding

these tissues by region, including: subject age, postmortem interval, and sex.
Due to the limited availability of Parkinson's tissue it was not possible to obtain
samples that were strictly age-matched to control tissue, although the age
ranges were roughly equivalent for the two groups.
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Table 21.--Characteristics of Postmortem Brain Tissue

Group
Brain Region

Control

Parkinson's

N

6

8

Male/Female

214

414

Age

73±9 (64-88)

76±4 (69-81)

PMI

16.6±6.9 (8-25.5)

12.9±5.0 (6.5-23.5)

N

7

7

Male/Female

611

512

Age

68±3a(64-73)

76±5 (69-83)

PMI

14.9±7.lb (7-25.5)

8.6±2.8 (5.5-13)

N

7

7

Male/Female

611

512

Age

67±3C (64-73)

77±4 (72-83)

PMI

13.3±5.5 (7.0-20.0)

10.2±6.3 (5.5-23.5)

Substantia nigra

Putamen

Frontal cortex

Note: Values for age (years) and PMI (hours) represent mean ± s.d., with the
range in parentheses.
Superscripts indicate (a) significantly different than
PD (p<0.005), (b) significantly different than PD (p<0.05), (c) significantly
different than PD (p<0.0005).
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A total of 48 different samples were evaluated in random order; each day
three tissue samples were prepared for the BC-NMT assays.

The frozen sections

were thawed slightly, and approximately 100 mg of tissue was removed using a
clean tissue punch.

In sections of substantia nigra or pulamen this sample

was taken from the center of the structure. In coronal sections of frontal
cortex, samples were removed from the superficial surface of the middle
frontal gyrus.

The tissue sample was weighed, placed in a 2 ml glass

homogenizer on ice, and homogenized at 0-5 °C in 5 volumes of homogenation
buffer (5 µ1 buffer per mg tissue).

Homogenation buffer (pH 7 .2) consisted of

150 mM potassium chloride, 20 mM sodium phosphate (Na2HP04), 1 mM
dithiothreitol, and 1 mM ethylenediaminetetraacetic acid disodium.
Homogenation was achieved with five up and down strokes of a motor-driven
(300 rpm) teflon pestle.
microcentrifuge

tube

Homogenate was transferred to a 1.5 ml

where centrifugation at

10,000g for thirty minutes

yielded crude particulate and supernatant fractions.

Particulate fraction was

diluted with 200 - 400 µI of homogenation buffer prior to use in BC-NMT assays,
and supernatant was used "as-is".

Reagents
6-Carboline

substrates,

2-methylnorharmanium

iodide

9-methylnorharman

(9-MeNH)

hydrochloride

(2-MeNH+), were synthesized in our laboratory

according to Rubottom (Rubottomand Chabala 1974) or Matsubara (Matsubara
et al. 1992b), respectively.
(toluenesulfonate salt)

or

Unlabeled S-adenosyl-L-methionine

was purchased from Sigma Chemical (St. Louis, MO),

and tritiated S-[methyI-3H]-adenosyl-L-methionine

(60-85

obtained from Dupont (New England Nuclear, Boston, MA).

Ci/mmol)

was
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The

BC-N-Methyltransferase

Assays

These activities catalyze the transfer of the tritiated methyl moiety from
S-adenosyl-L-methionine (SAM) to 9-MeNH or 2-MeNH+ to form SAH and
2(3H-methyl)-9-McNH+ or 2-9(3H-methyl)-NH+ (Figure 36).

~-()J/+ce,

I SAM I
H

! 9-McNH

*C~l3

Adenine

HOOC·~·(Cllz)z1..C~l2
O
NH2

H

ij.9-MczNH+

Figure 36.

H

I

Human brain BC-NMT assay scheme.

H

180
The BC substrates, 9-MeNH and 2-MeNH+, were used to assess BC-2-NMT
and BC-9-NMT activities, respectively, in both particulate and supernatant
fractions from each brain region.
polypropylene microcentrifuge

Enzyme assays were done in 1.5 ml

tubes by mixing concentrated stock solutions

of B-carboline (540 µM final), SAM (105 µM final), and 3H-SAM (4.6 µCi) with
supernatant or diluted particulate fraction.

Stock solutions of SAM were

prepared in water, and BC was dissolved in a buffer mixture consisting of 50
mM Na2HP0 4 plus 50 mM bicine at pH 8.5. Assay volume was 370 µl (pH 8.5),
comprised of the following stock solutions:
non-radioactive SAM (1.943 mM),
or particulate

50 µl 3H-SAM (4.6 µCi), 20 µl

200 µl BC (1 mM), and 100 µl of supernatant

fraction.

Each tube was gently vortexed and incubated at 37 °C in a shaking water
bath for one hour.

Following this incubation each sample was placed on ice

and protein precipitated by the addition of 200 µl 0.5 N perchloric acid (HC10 4).
The mixture was centrifuged to pellet precipitated protein (7000g for 5
minutes), with the supernatant transferred to a glass culture tube containing
1 ml of 1% (w/v) ammonium hydroxide (NH40H) and 100 µl of 1 N potassium
hydroxide.

The protein pellet was vigorously resuspended in 500 µl 0.01 N

H C 10 4 and centrifuged at 10,000g for 5 minutes, with the resulting supernatant
combined with the initial supernatant.

This solution was then slowly applied

to a Sep-Pak® C18 Plus solid-phase extraction (SPE) cartridge (360 mg,
Millipore-Waters part no. 20515).

The cartridge was pretreated with 5 ml of

methanol:5 N acetic acid (3:1, v/v), methanol, and 1% (w/v) NH40H in that
sequence.

Slow application (2 to 5 drops per second) of all solutions to the SPE

cartridge was achieved using a vacuum manifold.

Following the initial sample
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application, the SPE cartridge was washed with 8 ml of 1% (w/v) NH.iOH and
then by 5 ml methanol; these washes were discarded since they contained
compounds that could contribute to the background radioactivity during
subsequent analysis.

The final wash (5 ml), consisting of 3: 1 (v/v) methanol:5

N acetic acid, promoted elution of tritiated 2,9-Me2N H + from the cartridge into a
clean glass culture tube. This eluate was evaporated to dryness at 30-40 °C
using a Speed Vac concentrator (Savant Instruments Inc., Hicksville NY).

Reverse-Phase
Liquid

High

Performance

Chromatography

Activities of BC-NMTs were quantitated by measuring tritiated 2,9Me2NH + product using reverse-phase HPLC.

The residues from the Speed Vac

concentration step were dissolved in 200 µI HPLC mobile phase by sonication
and vortexing. Samples were filtered through a 0.45 µm nylon membrane filter
(Micro-Spin, Chrom-Tech Inc.) prior to injection (150 µI) onto the HPLC
system.

Isocratic HPLC analysis was carried out under ambient conditions on a

Bondclone 10 µm C18 column (Phenomenex™, 300 mm x 3.9 mm).

The mobile

phase was a mixture of 17% (v/v) HPLC grade acetonitrile and 83% (v/v)
aqueous buffer.

The buffer contained 50 mM triethylamine in 250 mM sodium

phosphate adjusted to a pH of 3 with phosphoric acid (final mobile phase pH
3.4).

The HPLC system included a Shimadzu SIL-9A programmable autosampler,

a Beckman 1 IOA pump (0.8 ml/minute), and an in-line radioactive flow
detector (Radiomatic Instruments Flo-One\B).

Ultima-Flo™ AP (Packard

Instruments) liquid scintillation cocktail was used at a flow rate of 2.8 ml per
minute, resulting in a scintillation fluid to mobile phase mixing ratio of 7:2.
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The radioactive flow detector was equipped with a 2.5 ml liquid flow cell and an
automatic stream splitter.

It was necessary to bypass the radioactive flow

detector by splitting the HPLC column effluent to waste until about ten minutes
into the run.

Splitting to waste reduced interference due to tritiated materials,

primarily 3H-SAM and its degradation products, present in the samples.
Radioactive peak area corresponding to 2,9-Me 2 NH+ (retention time 12 - 13
minutes) was calculated using Radiomatic Flo-One\B system software; the
resulting integrated area was reported as total cpm under the 2,9-Me 2 N H + peak.
BC-NMT activities are reported as pmoles 2,9-Me 2 N H + formed per hour per mg

protein (pmol/h/mg protein)

and

were calculated using experimentally

defined values for detector counting efficiency and the quantity of 3 H - SAM
added to the BC-NMT assay.

Counting efficiency and 3H-SAM added to BC-NMT

assays were determined on each day of HPLC analysis.

Total protein was

determined in particulate and supernatant fractions using a modified Lowry
method as described by Scopes (1994d) and in Appendix A.

Data Analysis
Kaleidagraph™ (Abelbeck/Synergy Software, Reading, PA) was used for
graphical analysis, and for determination of correlation coefficients for each
BC-NMT activity as a function of age or PMI.

done using SPSS for Windows.

Statistical analysis of data was

A three-way factorial ANOVA was used to

compare BC-2-NMT or BC-9-NMT activity as a function of fraction (particulate
vs. supernatant), disease-state (control vs. PD), and brain region (substantia
nigra vs. putamen vs. frontal cortex).
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Results

Analysis of Variance
(ANOVA)
The detailed results of the factorial ANOV A for BC-2-NMT activity and BC9-NMT activity as a function of fraction, brain region, an<l disease-state arc
presented in Appendix D.

BC-2-NMT Activity
The three-way ANO VA was significant (F(4,79)=4.037, p=0.005), but of the
three factors tested only the fraction factor had a significant main effcct (F
(1,79)=11.997, p=0.001), consistent with the generally higher level of activity
in the supernatant fraction that can be seen in Figures 32-34.

No significant

F-value was found for disease-state or brain region factors with respect to BC2-NMT activity.

A one-way ANOVA run on the 12 distinct "conditions"

(fraction*disease-state*brain region; see Figure 37) failed to reach statistical
significance (F(l 1, 79)=1.7427, p=0.0824), and Bonferroni post-hoc mulliple
comparisons tests revealed that no two groups were significantly different
with respect to BC-2-NMT activity.

Thus the higher BC-2-NMT activity in the

supernatant fraction appears to be a general effect.
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BC-9-NMT Activity
The three-way ANOVA was significant overall (F(4,83)=4.947, p=0.001),
with a significant main effect for fraction (F(l,83)=14.354, p=0.0003) and a
significant interaction effect for brain region and disease-state (F(2,83)=5.020,
p=0.009).

No significant main effects were found for disease-state or brain

region regarding BC-9-NMT activity.

A one-way ANOVA run on the 12

"conditions" (fraction*disease-state*brain region; see Figure *) was
significant (F(l 1, 83)=3.4806, p=0.0006).

Post-hoc Bonferroni multiple

comparison tests found that frontal cortex supernatant BC-9-NMT activity in
Parkinson's disease was significantly higher than control frontal cortex BC-9NMT activity (p<0.05) as can be seen in Figure 38.

In fact, Parkinson's frontal

cortex supernatant BC-9-NMT activity was significantly higher than BC-9-NMT
activity for all other groups (p<0.05), except for control substantia nigra and
control

putamen

activity.
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Discussion
This is the first description of BC-9N-mcthyltransfcrasc activity in
human brain; only rat and guinea pig brain activity was previously described
(Collins et al. 1992; Matsubara et al. 1992b).

The 13-fold higher SAM

concentration used in the BC-9-NMT assay in this study likely accounted for
the detection of BC-9-NMT activity; i.e., Matsubara ct al. (1993) use of 8 µM SAM
may have been insufficient for detection of BC-9-NMT activity.

These data

confirm the presence of BC-2N-methyltransferase activity in postmortem
human brain, a finding originally reported by Matsubara ct al. (Matsubara ct
al. 1993).

The study presented here expands upon Matsubara's work by

examining BC-NMT activities in Parkinson's
distinguishing

between

particulate

and

disease brain, as well as

supernatant

fraction activities.

It was

found that both BC-NMT activities were higher in the supernatant compared to
the particulate fraction, indicating a predominantly cytosolic localization for
these enzymes.

Higher supernatant BC-2-NMT activity is consistent with the

results reported in Chapter 3 for bovine brain BC-2-NMT activity.

Most

importantly, the data reported here indicate that frontal cortex supernatant
BC-9-NMT activity is significantly elevated in Parkinson's disease compared

LO

controls (p<0.05).

Age and Postmortem Interval Effccts
The significant age differences between the control and Parkinson's
groups for putamen and frontal cortex specimens arc unfortunate, but likely
not important since BC-NMT did not vary with subject age.

In contrast, PMI

could be considered a confounding variable in our study, since particulate
fraction BC-9-NMT activity varied with PMI in control tissue from putamen
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and frontal cortex.

This suggests that there may in fact be a difference

between control and PD cases for pellet BC-9-NMT activity in putamen, but that
a significant difference was not found due

to

the effect of PMI this activity

(i.e., a Type II statistical error may have been committed).

Basal Ganglia Findings
No assumptions were made a priori that BC-NMT activities would be the
same across the brain regions evaluated.

However, since the nigrostriatal

system is most dramatically affected in PD, the hypothesis logically predicts
that BC-2-NMT and/or BC-9-NMT activity may be higher in the substantia
nigra and/or putamen relative to the frontal cortex.

These data do not directly

support this prediction, because although mean BC-2-NMT activity in the
substantia nigra of control tissue is higher than in PD tissue, the difference is
not statistically significant.

It is possible that in the PD brain, regional

distribution of measurable BC-NMT activity is confounded by the MeBC+induced death of the neurons that, before death, possessed high BC-NMT
activity.

Note that selective elevation of BC-NMT activity in the nigrostriatal

system is not a requirement in this model since selective uptake of neurotoxic
MeBCs+ into this system would also confer neurotoxic selectivity to the
nigrostriatal system.

Consistent with the idea of selective uptake, MeBCs+ do

modestly inhibit dopamine uptake into rat synaptosomes (Drucker et al. 1990),
implying that these compounds are substrates for the dopamine transporter.

Frontal Cortex Findings
The significant elevation of supernatant BC-9-NMT activity in the
frontal cortex of PD brain compared to controls (p<0.05) was unexpected.
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Furthermore, considering only Parkinson's tissue, frontal

cortex supernatant

BC-9-NMT activity was significantly higher compared to suhstantia nigra or
putamen activity. It is believed that these differences are real and arc not
accounted for by differences between group age or PMI, since supernatant BC9-NMT activity did not correlate with PMI or age in any tissue.

It is speculated

that this observation may reflect both a general elevation of supernatant BC9-NMT activity in PD brain, and a selective, local vulnerability of the
nigrostriatal neurons to the effects of resultant 2,9-Me2BC s +.

Death of the

nigrostriatal neurons, originally containing the BC-9-NMT activity, would lead
to a commensurate loss of detectable BC-9-NMT activity in the nigrostriatal
nuclei.

Perhaps early in the disease process, well before profound cell-death,

BC-NMT activities are higher in PD relative to controls.

Cortical neurons that

exhibit increased supernatant BC-9-NMT activity, but are resistant to the toxic
effects of resultant MeBCs+, would remain viable and consequently make
measurement of enzyme activity possible.

Consistent with the postulate that

cortical neurons may be resistant to these toxins, it is interesting to note that
dopaminergic neurons projecting to the frontal cortex from the ventral
tegmental area are spared in PD.
However, it is equally conceivable that elevated supernatant BC-9-NMT
activity in the frontal cortex is a compensatory response to the death of
adjacent dopaminergic nigral

neurons occurring in Parkinson's disease.

Parkinson's

Disease

The hypothesis in this lab implies that BC-2-NMT and/or BC-9-NMT
activity is higher in Parkinson's disease compared to controls, resulting in the
formation of excessive neurotoxic MeBCs+ in PD brain and consequent
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neuronal death.

Furthermore, one would expect that BC-NMT activity would be

elevated during the subclinical or early stages of PD -- a hypothesis that can
not be readily investigated.

As discussed above the original hypothesis is

partially supported by elevated supernatant BC-9-NMT activity in the frontal
cortex of PD tissue.

Since MeBCs+ are able to penetrate the blood-brain barrier,

these compounds probably cross plasma membranes.

Therefore, MeBCs+

formed in the frontal cortex could enter the CSF, and subsequently exert toxic
effects on the nigrostriatal system.
Conversely, if elevated BC-9-NMT activity in the frontal cortex is truly a
local effect it is proposed that formation of MeBCs+ in the frontal cortex may
result in the death of a discrete population of vulnerable cortical neurons at
the site of MeBC+ formation.

Perhaps cells that exhibit high BC-9-NMT activity

are resistant to resultant MeBCs+, while other cells in close proximity are
vulnerable.

It follows that the death of these vulnerable cells could manifest

clinically as dementia or depression -- two nonmotor symptoms documented in
many PD patients (Koller and Pahwa 1995).
While these data certainly do not provide compelling evidence for a
global elevation of BC-NMT activity in Parkinson's brain, a role for MeBCs+ m
the neuropathogenesis of idiopathic PD remains viable considering the
following parallel hypothesis.

If MeBCs+ are elevated in PD, it is conceivable

that their BC-NMT-catalyzed formation is similar to that of controls, but that
catabolism of MeBCs+ is impaired in PD.

In PD brain a deficiency in the

catabolism of MeBCs+, to nontoxic compounds, could also lead to elevated levels
of these compounds -- culminating in cell death in brain regions where this
hypothetical catabolic deficiency occurs.

Indeed, studies have been reported
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which indicate that abnormalities in xenobiotic metabolism may contribute to
the development of PD (Williams 1995).
It is also possible that persons afflicted with PD are exposed to higher

levels of substrates of BC-NMT, and consequently form higher levels of toxic

MeBCs+ throughout life, until sufficient neurons are killed to manifest in the
clinical symptoms of PD.

This is consistent with a recent report indicating that

plasma levels of norharman and barman -- substrates of the BC-2-NMT activity
investigated in this report -- are elevated in individuals diagnosed with
Parkinson's disease (Kuhn et al. 1995).

Studies are underway in our laboratory

in which levels of MeBCs+ will be compared in postmortem human brain tissue
from PD and control individuals.

Those experiments, in combination with the

results reported here, should clarify the picture regarding the contribution of
N-methylated-6-carbolines to the pathogenesis of Parkinson's disease.

CHAPTER6
EVIDENCE THAT B-CARBOLINE-2N-METHYLTRANSFERASE
ACTIVITY IS DUE TO A PHENYLETHANOLAMINE
N-METHYLTRANSFERASE-LIKE ENZYME

It was hypothesized that BC-NMT activity may be due to a previously
characterized CNS-residing N-methyltransferase -- such as
phenylethanolamine-N-methyltransferase

(PNMT)

the formation of epinephrine from norepinephrine.

--

this

enzyme

catalyzes

PNMT is a cytosolic SAM-

dependent enzyme that is found in the adrenal medulla, brain, and other
tissues (Kennedy et al. 1995).

To test this hypothesis that BC-NMT activity may

be due to PNMT several experiments were performed.
The first experiment was designed to determine if purified bovineadrenal PNMT catalyzes N-methylation of either 9-MeNH or 2-MeNH+, for the
assessment of BC-2-NMT and BC-9-NMT activity, respectively.
The second experiment confirmed the presence of PNMT catalytic
activity in bovine-brain cytosol by measuring the conversion of
norepinephrine to epinephrine in the presence of tritiated-SAM.
The third experiment evaluated the effect of L Y134046 on BC-2-NMT
activity;

LY134046 is a selective inhibitor of brain and adrenal PNMT.

If BC-2-

NMT is the same as PNMT, one would expect an inhibition of BC-2-NMT in the
presence of L Y134046.
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In the fourth and fifth experiments several PNMT substrates were
evaluated for their ability to inhibit BC-2-NMT activity.

If BC-2-NMT is PNMT,

then substrates of PNMT should inhibit BC-2-NMT activity,

since these

substrates would compete with the BC for PNMT.
The sixth experiment assessed BC-2-NMT activity in human medulla
oblongata and human adrenal medulla. Both tissues exhibit documented PNMT
activity, particularly the adrenal medulla.

If BC-2-NMT is PNMT one would

expect BC-2-NMT activity in these tissues.
In the final experiment PNMT was immunoprecipitated from bovinebrain cytosol.

The resulting supernatant was evaluated for BC-2-NMT activity,

with the expectation that activity would be reduced or absent following PNMT
immunoprecipi ta ton.
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Experiment I:
BC-N-Methylation by PNMT
Materials and Methods
This experiment was repeated twice, and in each study replicate samples
were prepared at each condition.

Assay conditions were as follows:

9-MeNH or 2-MeNH+
SAM
3H-SAM
PNMT

540 µM
105 µM
3.60 µCi (study I)
6.74 µCi (study 2)
3.3 units

Stock solutions used were:
9-MeNH or 2-MeNH+ (1 mM stock in buffer "A")
SAM (1.943 mM stock in Milli-Q water)
3H-SAM (3.60 or 6.74 µCi in Milli-Q water)
PNMT Solution (0.033 units/~})
Total volume

200 µl

20 µl
50 µl
100 ul
370 µl

Buffer "A" contained 50 mM bicine and 50 mM Na2 HP0 4 dibasic at pH 8.5.
Sources of substrates are described in Chapter 5.
prepared to contain either 2-MeNH+, 9-MeNH,
assay pH was 8.5.

Replicate assays were

or no BC (blank assay).

Final

PNMT (25 units per vial) was obtained as a lyophilized

powder in a rubber-stoppered vial from Sigma Chemical Company (St. Louis,
MO).

The contents of the vial were dissolved in 800 µl Milli-Q water.

information regarding this enzyme is listed in Appendix E.
were maintained at 37 °C for one hour.

Label

BC-2-NMT assays

The assay work-up and measurement

of 2,9-Me 2 NH+ by RP-HPLC were performed as described in Chapter 5.
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Results
Bovine adrenal PNMT catalyzes the 2N-methylation of 9-McNH, but does
not carry-out 9N-methylation of 2-MeNH+ (Table 22).

Within each experiment,

a 2-tailed t-test was used to compare the assay results without
assays containing

~C.

~C

(blank) to

The reaction with 2-MeNH+ as substrate did not differ

from the blank reaction with respect to 2,9-Me 2N H + formation.

However, the

reaction with 9-MeNH was statistically different than the blank assay
(Study 1 **p<0.0005, Study 2 *p<0.005).
Table 22.-- Bovine Adrenal PNMT-Catalyzed
2N- and 9N-Methylation of ~Cs
6C-N-Methylation Activity (mean ± s.e.m,, N=2)
Conditions
Study 1

2,9-Me2NH+ Formed
(pmol/h)

2,9-Me2NH+ Formed
Cpmol/h/unit PNMT)

~C)

2.7 ± 0.9

0.8 ± 0.3

plus 2-MeNH+

1.4±0.7

0.4 ± 0.2

plus 9-MeNH

58.8 ± 1.4**

17.8 ± 0.4**

~C)

18.1 ± 5.6

5.7 ± 1.7

plus 2-MeNH+

26.6 ± 0.5

8.1 ± 0.2

plus 9-MeNH

80.1 ± 0.4 *

24.3 ± 0.1*

Blank (no

Study 2
Blank (no
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Recall that 2N-methylation is activity measured when 9-MeNH is used as
the substrate, and that 9N-methylation represents activity determined with 2Me NH+ as the substrate.

Net 2N-methylation activity was calculated for each

experiment by subtracting 2N-methylation in the blank assay from 2Nmethylation in the presence of 9-MeNH.

Net 2N-methylation of 9-McNH in

Study 1 was 17.0 ± 0.5 pmol/h/unit PNMT, and net 2N-mcthylation in Study 2
was 18.6 ± 1.7 pmol/h/unit PNMT.

Conclusion
These data show that PNMT can 2N-methylate a BC-substrate and
therefore do not refute the hypothesis that BC-2-NMT and PNMT are the same
or similar enzymes.
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Experiment 2:
PNMT Activity in Bovine Brain Cytosol

Materials and Methods

PNMT activity in bovine brain cytosol was assessed using
L-norepinephrine as the substrate.

Similar studies were not done with

octopamine and phenylethanolamine due to difficulties encountered with the
extraction procedure for their N-methylated derivatives.
concentrations

The final substrate

were:

SAM
3H-SAM
L-norepinephrine

105µM
1.034 µCi
0, 10, 40, 100, and 250 µM

The total volume of the assay was 370 µl and the final pH was 8.5.

Duplicate

assays were prepared in 1.5 ml polypropylene microcentrifuge tubes as
follows:
SAM (1.943 mM stock in Milli-Q water)
3H-SAM (1.034 µCi in Milli-Q water)
L-norepinephrine (stock in buffer "A")
Bovine brain cytosol ( 1.156 mg protein)

20 µl
50 µl
200 µl
100 µl

L-norepinephrine bitartrate stock solutions utilized were:
µM, 462.5 µM.

18.5 µM, 74 µM, 185

A blank assay was prepared that lacked L-norepinephrine.

Assays were incubated at 37 °C for one hour.
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The assay work-up was done according to the method descrihed hy
Chatelain et al. (1990).

The PNMT assay was terminated by its transfer to a 13 x

100 mm glass culture tube containing 250 µI of 1 N HCI.

Solid NaCl (1 g) was

added, and the mixture was extracted with 6 ml of 1 N HCI-washed butanol.

A 5

ml portion of the butanol layer was evaporated to dryness in a Speed Vac
concentrator at 40 °C.

The residue was dissolved in 5 ml of EconoSafc liquid

scintillation cocktail, and subsequently transferred to 20 ml pol ypropy Jene
scintillation vial.

The culture tube was rinsed with 5 ml of EconoSafe, and this

rinse was added to the scintillation vial.

Additional EconoSafe (I 0 ml) was

added to each scintillation vial, and the contents were mixed on a lab vortexer.
Tritium was measured in these vials using a Beckman LS 6500 liquid
scintillation counter.

Background radioactivity (represented by the blank

assay) was subtracted from the results for each assay that contained
norepinephrine.
hour

Results are presented as pmoles of epinephrine formed per

(pmol/h/mg

protein).
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Results
Bovine brain cytosol exhibits PNMT activity as evidenced by the
conversion of norepinephrine to epinephrine (Figure 40). The
velocity (V max) was 1.8 nmol/h/mg protein, and the KM

maximal

for norepinephrine

was 63 µM.

[Substrate] I Velocity =
(KM/ VM ax) + (IN max )[Substrate]
Linear Regression Analysis
[Substrate]/Velocity =
35.18 + 0.55 [norepinephrine]
r = 0.94
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Figure 40.
Hanes plot for formation of epinephrine from norepinephrine in
bovine brain cytosol. Substrates were SAM (105 µM, 1.034 µCi) and Lnorepinephrine (0, 10, 40, 100, and 250 µM) at pH 8.5.

Conclusion
This study simply confirms the presence of PNMT in the same bovinebrain preparation that was utilized in experiments that evaluated BC-2-NMT
activity, indicating that BC-2-NMT and PNMT exist in the same cytosol.
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Experiment 3:
Inhibition of BC-2-NMT Activity by LY 134046
Materials and Methods
The final assay concentrations of substrates and the PNMT-inhihitor
LY134046 were:
9-MeNH
SAM
3H-SAM
LY134046
Assay

100 µM
105 µM
3.54 µCi
1 nM, 1 µM, 500 µM, 1 mM, or 5 mM

volume was 370 µl at a final pH of 8.5.

polypropylene microcentrifuge

tubes

Assays were prepared in 1.5 ml

as follows:

9-MeNH (740 µM stock in buffer "A")
SAM (1.943 mM stock in Milli-Q water)
3H-SAM (3.54 µCi in Milli-Q water)
L Yl34046 (stock in buffer "A")
Bovine brain cytosol (0. 711 mg protein)

50 µl
20 µl
30 µl
170 µl
100 µl

LY134046 stock solution concentrations utilized were: 2.176 nM, 2.176 µM,
1.088 mM, 2.176 mM, or 10.882 mM.

A control BC-2-NMT assay, in the ahsence of

L Y134046, contained 170 µl buffer "A"

in place of L Y134046.

Two distinct kinds

of blank assays were prepared in which each blank lacked 9-MeNH: one blank
contained 1 mM L YI 34046 ("inhibitor-control"), whereas the other blank
lacked L Y134046.

L Y134046 was purchased from Research Biochemicals

International (Natick, MA); information regarding the inhibitor is listed in
Appendix E.

BC-2-NMT assays were incubated at 37 °C for one hour.

The assay

work-up and measurement of 2,9-Me2NH+ by RP-HPLC were performed as
described in Chapter 5.

The appropriate blank N-methylation activity was

subtracted from values obtained in complete assays.
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The resulting data were plotted in three ways:
(1) percent of control BC-2-NMT activity as a function of LY 134046

concentration.
(2) percent of control J3C-2-NMT activity as a function of log
L Yl34046 concentration. The ICso was determined from this plot.
( 3 a Dixon plot,
concentration.

l/BC-2-NMT activity as a function of L Y134046
The Ki for L Yl34046 was determined from this plot.

Results
L Y134046 inhibited BC-2-NMT in a concentration-dependent

manner.

Enzyme activity was nearly completely inhibited at 500 µM LY134046, and
complete inhibition of activity was observed at L Y134046 concentrations
greater than or equal to 1 mM (Figure 41).
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Figure 41. Inhibition of bovine brain cytosol BC-2-NMT activity by L Y134046.
Substrates were 9-MeNH (100 µM), SAM (105 µM, 3.54 µCi), and inhibitor
L Y134046 (0-5 mM) at pH 8.5.
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A linear relationship exists between percent of control BC-2-NMT
activity and LY 134046 concentration when inhibitor concentration
(range 1 nM-1 mM) is plotted on a log scale.

The IC 50 value -- the

concentration of LY134046 required to inhibit BC-2-NMT activity hy 50 percent
-- was 1.2 µM LY134046 (Figure 42).

- - - % Control BC-2-NMT Activity =

51.19 + -13.62*log[LY134046]
r= 0.98
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Figure 42. Determination of ICso for L Yl34046 dependent inhibition of
BC-2-NMT activity. Assay at pH 8.5 for 1 hour at 37 °C. Substrates: 100 µM 9MeNH, 0-1 mM LY134046, 105 µM (3.54 µCi) SAM.
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The Dixon plot for competitive inhibition is defined by the following equation:

This equation predicts that slope

=

(KM/Vmax*[S]*Ki), when I/Velocity is

plotted against inhibitor concentration. In Chapter 3, Vmax and KM

for BC-2-

NMT with respect to 9-MeNH were determined to be 48 pmol/h/mg protein and
75 µM, respectively.

Graphical analysis of inhibition of BC-2-NMT activity by

L Y134046 predicts a Ki = 0.4 µM (Figure 43).

- - - I/Velocity = 0.04877 + 0.04215 [LY134046]
(r = 0.996)
Slope
0.12

= (~/ Vmax* K)(Il[S]) = 0.00024

KM = 75 µM, Vmax = 48 pmole/h/mg protein
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Figure 43. Dixon plot for LY134046 inhibition of BC-2-NMT activity. Assay at
pH 8.5 for 1 hour at 37 °C. Substrates: 100 µM 9-MeNH, 0-1.5 µM LY 134046,
105 µM (3.54 µCi) SAM.
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Conclusion
These results support the hypothesis that BC-2-NMT is PNMT or a PNMTlike enzyme.

However, the Ki for LY134046 inhibition of BC-2-NMT is higher

than its Ki (24 nM) for inhibition of brainstem PNMT (Fuller et al. 1981 ).

Experiment 4:
Inhibition BC-2-NMT by PNMT Substrates
Materials and Methods
PNMT

N-methylates

norepinephrine,

octopamine

and

normetanephrine

to form epinephrine, synephrine, and metanephrine, respectively.

If BC-2-

NMT and PNMT are equivalent, one would expect BC-2-NMT activity to be
reduced in the presence of these PNMT substrates.

Final concentrations of

substrates in this study were:
9-MeNH
SAM
3H-SAM
PNMT substrate

540 µM
105 µM
3.54 µCi
1 mM

Assay volume was 370 µl at a final pH of 8.5.

Assays were prepared in 1.5 ml

polypropylene microcentrifuge tubes using the stock solutions listed:
9-MeNH (1.332 mM stock in buffer "A")
SAM (3.89 mM stock in Milli-Q water)
3H-SAM (3.02 µCi in Milli-Q water)
PNMT substrate (stock in buffer "A")
Bovine brain cytosol (0.525 mg protein)

150 µl
10 µl
10 µl
120 µl
80 µl
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Blanks assays were prepared for each PNMT substrate as described in
Experiment 2 above.

BC-2-NMT assays were maintained at 37 °C for one hour.

The assay work-up and measurement of 2,9-Me 2 N H + by RP-HPLC were
performed as described in Chapter 5.
control BC-2-NMT activity.

Results are reported as percent of

Control activity represents BC-2-NMT activity in

the absence of PNMT substrate.

Results
The three PNMT substrates evaluated inhibited BC-2-NMT activity to
varying degrees.

BC-2-NMT activity was inhibited to 26% of control by

octopamine, to 74% of control by normetanephrine, and to 80% of control by
norepinephrine.
Conclusion
These data indicate that PNMT substrates are competing with 9-MeNH for
BC-2-NMT, consistent with the hypothesis that BC-2-NMT and PNMT are the
same enzyme.
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Experiment 5:
Concen trati on-Dependcn t I nhi bi ti on
of BC-2-NMT Activity
by PNMT Substrates

In this series of experiments a range of PNMT substrate concentrations
was utilized -- this range bracketed the Ii terature KM of the rcspecti ve
substrate for PNMT.

Note that the concentration of 9-MeNH was reduced Lo 100

µM, from the 540 µM concentration used in Experiment 3, since an inhibitor
(i.e., the PNMT substrate) is more effective when the substrate (9-MeNH) is
present at or below its KM (75 µM).

For each of the PNMT substrates evaluated,

the data were plotted in two ways:

( 1) percent of control BC-2-NMT activity as a function of PNMT
substrate

concentration

( 2) a Dixon plot,

1/BC-2-NMT activity as a function of

PNMT

substrate concentration -- the Ki for the PNMT substrate (i.e,
inhibitor) was determined from this plot.
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Materials and Methods:
BC-2-NMT Inhibition
by L-Norepinephrine

Final concentrations of substrates and inhibitor (norepinephrinc)

in

the

assays were:
9-MeNH
SAM
3H-SAM
L-norepinephrinc

100 µM
105 µM
2.31 µCi
0, 10, 40, 100, and 250 µM

The total volume of the assay was 370 µl and the final pH was 8.5.

Assays were

prepared in 1.5 ml polypropylene microcentrifuge tubes as follows:

9-MeNH (370 µM stock in buffer "A")
SAM (1.943 mM stock in Milli-Q water)
3H-SAM (2.31 µCi in Milli-Q water)
L-norepinephrine (stock in buffer "A")
Bovine brain cytosol (1.156 mg protein)

L-norepinephrine stock solutions utilized were:

100 µl
20 µl
50 µl
100 µl
100 µl

37 µM, 148 µM, 370 µM, 925 µM.

Blank assays were prepared containing no 9-MeNH, without and with
norepinephrine (250 µM final).

Background N-methylation was subtracted

from values obtained in complete assays.

L-norepinephrine bitartratc was

obtained from Sigma Chemical Company (St. Louis, MO);
regarding this reagent is listed in Appendix E.

information
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Results:
Inhibition
N orepinephrine

BC-2-NMT

by

Norepincphrine inhibited 2N-methylation of 9-MeNH in a
concentration-dependent manner.
presence of

BC-2-NMT activity was inhibited 50% in the

48 µM norcpinephrine (Figure 44).

The biphasic nature of the

curve suggests the presence of two enzymes that are diffcrcnlially inhibited
by

norepinephrine.
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Figure 44.
Concentration-dependent inhibition of BC-2-NMT act1v1ly by
norepinephrine. Assay at pH 8.5 for 1 hour at 37 °C. Substrates: 100 µM 9MeNH, 0-250 µM norepinephrine, 105 µM (2.31 µCi) SAM.
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The Dixon plot (Figure 45) confirms a concentration-dependent
inhibition of BC-2-NMT activity by norepinephrine.

From this experiment

alone, the type of inhibition could not be determined.

Using the equations for

competitive, noncompetitive, and uncompetitive inhibition, the calculated Ki
for norepinephrine is probably in the range 21-36 µM.

l/v
0.4

= 0.021

+ 0.001 [norepinephri ne]
(r

= 0.945)
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Figure 45. Dixon plot for norepinephrine inhibition of BC-2-NMT act1v1ty.
Assay at pH 8.5 for I hour at 37 °C. Substrates: 100 µM 9-MeNH, 0-250 µM
norepinephrine, 105 µM (2.31 µCi) SAM.
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Materials and Methods:
BC-2-NMT Inhibition
by DL-Octopamine

The final concentrations of substrates and inhibitor in the assays were:
9-MeNH
lOOµM
SAM
105 µM
3H-SAM
3.33 µCi
DL-octopamine 0, 3, 12, 30, and 75 µM

The total volume of the assay was 370 µl and the final pH was 8.5.

Assays were

prepared in 1.5 ml polypropylene microcentrifuge tubes as follows:
9-MeNH (370 µM stock in buffer "A")
SAM (1.943 mM stock in Milli-Q water)
3H-SAM (3.33 µCi in Milli-Q water)
DL-octopamine (stock in buffer "A")
Bovine brain cytosol ( 1.156 mg protein)

DL-octopamine stock solutions utilized were:

100 µl
20 µl
50 µl
100 µl
100 µI

11.1 µM, 44.4 µM, 111 µM, 277 .5 µM.

Blank assays were prepared containing no 9-MeNH, without and with
DL-octopamine (75 µM final).

Background N-methylation was subtracted from

values obtained in complete assays.

DL-octopamine hydrochloride was

obtained from Sigma Chemical Company (St. Louis, MO); information regarding
this reagent is listed in Appendix E.
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Results:
BC-2-NMT Inhibition
by DL-Octopamine
Octopamine inhibited 2N-methylation of 9-MeNH in a concentrationdependent manner.

BC-2-NMT activity was inhibited 50% in the presence of

31 µM octopamine (Figure 46).

The biphasic curve indicates the presence of

two enzymes.
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Concentration-dependent inhibition of BC-2-NMT act1vlly by
octopamine. Assay at pH 8.5 for 1 hour at 37 °C. Substrates: 100 µM 9-MeNH, 075 µM octopamine, 105 µM (3.33 µCi) SAM.
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The Dixon plot also reveals a concentration-dependent inhibition of
BC-2-NMT activity in the presence of octopamine (Figure 47).

From this

experiment alone, the type of inhibition could not be determined.

Using the

equations for competitive, noncompetitive, and uncompetitive inhibition, the
calculated Ki for octopamine is probably in the range 9.2-21.4 µ M.

Linear Ret;ression

0.3

Analysis

---1/v = 0.0695 + 0.0017 [octopamine]
(r = 0.98)

_,_, 0.25

o~

.s
<8
:~
.....

C1.l

E-<

Q..

:E

z
I

N

I

OI)

0.2
0.15

E

.::::
u ::::
t:Q

-

0

0.1

E
Q..
:::::
0.05

0
-40

Figure 47.

-20

0
20
40
[Octopamine, µM]

60

80

Dixon plot for octopamine inhibition of BC-2-NMT activity.
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Materials and Methods:
BC-2-NMT Inhibition by
DL-Phe n y I e th ano I amine

The final concentrations of substrates and inhibitor rn the assays were:
9-McNH
SAM
3H-SAM
D L-phe ny I e th an o 1amine

lOOµM
105 µM
2.78 µCi
0, 40, 160, 400, and I mM

The total volume of the assay was 370 µl and the final pH was 8.5.

Assays were

prepared in 1.5 ml polypropylene microcentrifuge tubes as follows:
9-MeNH (370 µM stock in buffer "A")
SAM (1.943 mM stock in Milli-Q water)
3H-SAM (2.78 µCi in Milli-Q water)
DL-phenylethanolamine (stock in buffer "A")
Bovine brain cytosol (1.156 mg protein)

DL-phenylethanolamine stock solutions utilized were:
1.48 mM, 7.7 mM.

100 µI
20 µI
50 µI
100 µI
100 µI

148 µM, 592 µM,

Blank assays were prepared containing no 9-McNH, without

and with DL-phenylethanolamine (1

mM final).

Background N-methylation

was subtracted from values obtained in complete assays.

DL-

phenylethanolamine was obtained from Sigma Chemical Company (St. Louis,
MO); information regarding this reagent is listed in Appendix E.
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Results:
BC-2-NMT Inhibition by
Ph en yle th anol amine

Phenylethanolamine inhibited the 2N-methylation of 9-MeNH in a
concentration-dependent manner.
presence of 1000 µM

BC-2-NMT activity was inhibited 57% in the

phenylethanolamine

than 1000 µM were not evaluated.

(Figure 48);

concentrations

higher

Linear curve-fitting of these data after

plotting of BC-2-NMT activity as a function of the log of the
phenylethanolamine concentration predicts an ICso value of 1750 µM .
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Figure 48.
Concentration-dependent inhibition of BC-2-NMT by
phenylethanolamine. Assay at pH 8.5 for 1 hour at 37 °C. Substrates: 100 µM 9MeNH, 0-1 mM phenylethanolamine, 105 µM (2.78 µCi) SAM.
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The Dixon plot confirms a concentration-dependent

inhibition of

BC-2-NMT activity in the presence of phenylethanolamine (Figure 49).

From

this experiment alone, the type of inhibition could not be determined.

Using

the equations for competitive, noncompetitive,

and

uncompetitive inhibition,

the calculated Ki for octopamine is probably in the range 156-365

Linear Regression
-- y

µM.

Analysis
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Figure 49.
Dixon plot for phenylethanolamine inhibition of BC-2-NMT activity.
Assay at pH 8.5 for 1 hour at 37 °C. Substrates: 100 µM 9-MeNH, 0-1 mM
pheoylethanolamine, 105 µM (2.78 µCi) SAM.
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Conclusion

All three PNMT substrates inhibited BC-2-NMT activity in a
concentration-dependent manner.

The rank order Ki's of the three PNMT

substrates for BC-2-NMT inhibition were:
octopamine

< norepinephrine

(9-21 µM)

<

(21-36 µM)

phenylethanolamine
(156-365 µM)

This rank order is consistent with the KM 's of these same substrates for
monkey brainstem PNMT (Lew et al. 1977):
octopamine

$

norepinephrine

(21 µM)

(22 µM)

<

phenylethanolamine
(200 µM)

The hypothesis that BC-2-NMT and PNMT are the same enzyme is
supported by these data.

The PNMT substrates with the lowest KM

(norepinephrine and octopamine) exhibit the lowest Ki for inhibition of BC-2NMT.

These data show inhibition of BC-2-NMT by PNMT substrates with a rank

order that is comparable to the KM 's of these substrates for brain PNMT.
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Experiment 6:
BC-2-NMT Activity in Human Medulla Ohlongata
and Human Adrenal Medulla
Materials and Methods
Frozen postmortem human medulla oblongata or adrenal medulla was
obtained from the Loyola University/Hines VA Tissue Bank,
Medical Center, Maywood, IL 60253.

Loyola University

Frozen tissue was thawed slightly and

approximately 100 mg of tissue was removed using a clean tissue punch.

Tissue

was weighed and placed in a 2 ml glass homogenizer on ice, and was
homogenized in 5 volumes (5 µ1 per mg) of homogenation buffer.
Homogenation buffer (pH 7.2) consisted of 150 mM potassium chloride, 20 mM
sodium phosphate (Na2HP04), 1 mM ethylenediaminetetraacetic acid disodium,
and 1 mM dithiothreitol.

Homogenation was accomplished with five up and

down strokes of a motor-driven (300 rpm) teflon pestle.

Homogenate was

transferred to a 1.5 ml microcentrifuge tube, where centrifugation at 10,000g
for thirty minutes afforded crude particulate and supernatant fractions.
Particulate fraction was diluted with about 200 - 400 µI of homogenation buffer
prior to use in

~C-NMT

assays;

supernatant was not diluted prior to assay.

BC-

NMT activity was not determined in the particulate fraction from medulla
oblong at a.
The

~C-NMT

assay, work-up, and RP-HPLC analysis was done according to

the methods described in Chapter 5.

Prior to plotting these data, background

N-methylation (in the absence of BC) was subtracted from the corresponding
data obtained in the presence of BC.
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Results
BC-2-NMT or BC-9-NMT activily was not discernahlc from background

when the supernatant fraction from human medulla oblungata was used as the
enzyme

source.

BC-2-NMT was activity was highest in the supernatant fraction derived
from human adrenal medulla.
activity was detected.

Very little particulate fraction BC-2-NMT

Particulate and supernatant BC-9-NMT activity was

approximately 4-fold lower than supernatant BC-2-NMT activity (Figure 50).
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Figure 50.
BC-NMT activities in particulate and supernatant fractions from
human adrenal medulla.
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A large tritiated peak was present in blank particulate fraction assays;
this peak was not observed when BC-substrates were included in the
incubations.

The retention time of the unknown peak was approximately 2

minutes later than the retention time for 2,9-Me 2 N H +.

The peak corresponded

to the incorporation 61.6 ± 17 .6 pmol of tritiated methyl group/h/mg protein.

Conclusions
PNMT catalytic activity is present in the medulla oblongata and the
adrenal medulla (Axelrod 1971; Kitabchi et al. 1969; Kopp et al. 1979).

The

absence of BC-2-NMT activity in the human medulla oblongata is therefore
inconsistent with the idea that BC-2-NMT is PNMT.
However, the presence of supernatant BC-2-NMT activity in the adrenal
medulla -- a tissue that exhibits high PNMT activity
that BC-2-NMT and PNMT are the same enzyme.

supports the hypothesis
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Experiment 7:
Measurement of BC-2-NMT Activity
in Bovine Brain Cytosol After
Immunoprecipitation of PNMT

Materials and Methods
If BC-2-NMT is synonymous with PNMT, one would predict a loss in BC-2-

NMT after immunoprecipitation of PNMT from bovine brain cytosol.

The

protocol for this study was a modification of the method described by Anderson
and Blobel (1983).
PNMT antibody was purchased from lncstar Corporation (Catalog
#22572, Stillwater, MN).

This polyclonal antisera was obtained from rabbits

immunized with bovine adrenal PNMT. According to Incstar, this anti-PNMT
cross-reacts with brain PNMT from various species. ImmunoPure®
Immobilized Protein A/G Gel was obtained from Pierce (Catalog #20421,
Rockford, IL).

This gel has protein A (isolated from Staphylococcus

aureus)

and protein G (from Streptococcus species) covalently attached to agarose gel.
Proteins A and G bind the Fe portion of the constant region on
immunoglobulins derived from numerous species.

Bovine brain cytosol was

concentrated using a Centricon 30 concentrator.

The theoretical interaction

of PNMT from bovine brain cytosol, anti-PNMT, and protein A/G is diagramed
in Figure 51.
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The contents of each of two vials containing lyophilized anti-PNMT
were reconstituted using 100 µl Milli-Q water, and the resulting solutions
combined.

Concentrated bovine brain cytosol (60 µl) was added to each of

seven 1.5 ml polypropylene microcentrifuge tubes.

Tubes designated as

"control-cytosol" also received 80 µl of IO mM Na2HPO 4 buffer (pH 7.3); total
volume was therefore 140 µI.

Anti-PNMT was added to the remaining four

tubes -- 10, 30, 50, or 80 µl of antisera were added -- final volume of these four
tubes was also brought to 140 µl with buffer.

The tubes were gently vortexed

and then set at room temperature for one hour, prior to refrigeration for 19
hours.

The samples were centrifuged at 12,000g for 15 minutes, and portion of

the resulting supernatants (130 µl) was transferred to clean 1.5 ml
microcentrifuge

tubes.

Immobilized Protein A/G was equilibrated in 100 mM Na2HP04 (pH 7.3)
and then diluted with buffer to yield a 1:1 suspension of gel:buffer.

This

suspension (800 µl) was added to each of five clean 1.5 ml microcentrifuge
tubes. Tubes were centrifuged to pack the gel (400 µl), and resulting
supernatant was discarded.

Equilibration buffer (50 µI) was added to each of

these tubes, as well as to two empty tubes.

"Control-cytosol" from the previous

step -- i.e., cytosol not exposed to anti-PNMT -- was added to each of the 2 tubes
containing only equilibration buffer; these controls were never exposed to
anti-PNMT or Protein A/G.

The final control was designated "A/G-Control": it

was prepared by adding "control-cytosol" to Protein A/G gel.

To the

remaining four tubes that contained Protein A/G gel, the supernatants
resulting from anti-PNMT incubation were added.

All tubes were agitated

gently on a lab rocker for 3 hours at room temperature.

The mixture was
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centrifuged at 12,000g for 15 minutes to pack the gel.

In theory the packed gel

should contain the PNMT - PNMT antibody - Protein A/G agarose complex. A
portion of the resulting supernatant (150 µI) was transferred Lo clean
microcentrifuge tubes, and 100 µI of each of these soluLions were analyzed for
BC-2-NMT activity.

BC-2-NMT assays and work-up were done as described in

Chapter 5.

Results
BC-2-NMT activity was apparently unaffected by immunoprecipitation
of PNMT, because supernatant from bovine-brain cytosol that was exposed to
anti-PNMT and immobilized protein A/G exhibited the same BC-2-NMT activity
as supernatant from the protein A/G control incubation.

Conclusion
Assuming that PNMT was precipitated from the cytosol,

this experiment

does not support the hypothesis that BC-2-NMT and PNMT arc Lhc same enzyme.
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Summary of Results

The results of experiments (a) through (e), to be discussed further in
detail, are consistent with the hypothesis that BC-2-NMT and PNMT are the
same enzyme:

(a)

purified bovine adrenal PNMT 2N-methylates 9-MeNH

( b)

LY 134046 inhibits BC-2-NMT in concentration-dependent manner

( c)

PNMT substrates inhibit BC-2-NMT in a concentration-dependent
fashion

( d)

supernatant fraction derived from human adrenal medulla catalyzes
the 2N-methylation of 9-MeNH

( e)

demonstration of PNMT activity in bovine-brain cytosol as determined
by the conversion of norepinephrine to epinephrine in the presence of
SAM

However, the results of experiments (f) and (g), taken at face value, do
not support the hypothesis that BC-2-NMT and PNMT are equivalent enzymes:

( f)

the apparent absence of BC-2-NMT activity in the supernatant
fraction isolated from human medulla oblongata

( g)

the lack of effect on BC-2-NMT activity of immunoprecipitation of
PNMT from bovine-brain cytosol
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Discussion

PNMT 2N-Methylates 9-MeNH
The most compelling evidence to support the equality of BC-2-NMT and
PNMT is that purified bovine adrenal PNMT catalyzes the 2N-melhylation of 9MeNH, but not 2-MeNH+.

Similarly, 9-MeNH is 2N-methylaled 4-fol<l more

effectively than 2-MeNH+ is 9N-methylated in the presence of the crude
supernatant fraction derived from human adrenal medulla -- a tissue with
high PNMT activity.

In addition, these data suggest that BC-2N-methylation

and BC-9N-methylation may be catalyzed by two different enzymes.

The

specific activity of bovine adrenal PNMT toward 9-MeNH was 1.8% (17 .8
pmol/h/unit PNMT) of PNMT's labeled activity toward a more standard
substrate, normetanephrine (1 nmole/h/unit PNMT).

A comparable ratio is

obtained for bovine brain cytosol when the Vmax for PNMT ( 1.8 nmol
epinephrine/h/mg protein) is compared to the Vmax for BC-2-NMT (48
pmol/h/mg protein) under identical assay conditions -- 9-MeNH methylation
is 2.7% of that for norepinephrine.

These observations imply that 9-MeNH is a

poor substrate for PNMT, but that PNMT can nonetheless 2N-methylate a f3C.

BC-2-NMT Activity in the
Adrenal Medulla
Supernatant BC-2-NMT activity in human adrenal medulla was 43.7
pmol/h/mg protein.

Data from Chapter 5 of this dissertation show that

supernatant BC-2-NMT activity in human brain varied regionally from 13.3 31.3 pmole/h/mg protein.

Taken together these experiments indicate that BC-

2-NMT activity in the human adrenal medulla is 140 - 328% of BC-2-NMT
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activity in human brain. These results are consistent wilh those reported for
human PNMT, where adrenal medulla activity was 450% of cerebrum activity
(Kitabchi and Williams 1969).

The presence of the large unknown peak in the

blank assay (without BC substrate) from the particulate fraction of adrenal
medulla was surprising. It is postulated that this peak represents the
methylated product of an endogenous BC or catecholamine -- an endogenous
substrate whose methylation is inhibited in the presence of 9-MeNH or
2-MeNH+.

Inhibition of BC-2-NMT by PNMT
Substrates and a PNMT Inhibitor
The concentration-dependent inhibition of BC-2-NMT by the specific
PNMT inhibitor, LY134046, supports the hypothesis that the BC-2-NMT and
PNMT are the same enzyme.

The Ki for inhibition of rat brain PNMT by

LY134046 is 24 nM (Fuller et al. 1981), lower than the 400 nM Ki value for
L Y134046 inhibition of BC-2-NMT reported here. The Ki for an inhibitor is
dependent upon assay conditions, and those conditions differed between this
study and that of Fuller et al. (1981).

Specifically, Fuller utilized

partially-purified PNMT derived from rat brainstem supernatant, and an assay
pH of 7 .0.

The present study used crude supernatant fraction from whole

bovine brain, and an assay pH of 8.5.

It is reasonable to speculate that

differences in species and assay pH between experiments could account for the
differences rn Ki values for L Yl34046 determined in the two studies
Three distinct PNMT substrates -- norepinephrine, octopamine, and
phenylethanolamine -- inhibited BC-2-NMT activity in a concentrationdependent manner, indicating a competition between 9-MeNH and Lhose PNMT
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substrates for the same enzyme.

The biphasic nature of the inhibition plots

suggests the presence of two different enzymes, or isozymes of the same
enzyme, that are differently inhibited in the presence of the PNMT substrates.
Dixon plots of reciprocal BC-2-NMT activity as a function of PNMT substrate
(BC-2-NMT inhibitor) concentration were each linear.

The mechanism of

inhibition by these substrates cannot be confirmed with out further
experiments done at various 9-MeNH concentrations.
Recall that when SAM donates its methyl group to a substrate during a
N-methyltransferase-catalyzed reaction,

the

products

are

the

N-methylated

substrate and SAH.

SAH inhibits most SAM-dependent methyltransferases in a

competitive manner.

It is therefore reasonable to consider that BC-2-NMT

inhibition in the presence of PNMT substrates could be due to the SAH that is
formed as PNMT methylates its substrates.

When norepinephrine alone was

utilized in the PNMT assay, the calculated Vmax for epinephrine formation was
1.8 nmoles/h/mg protein -- an equivalent amount of SAH would be the coproduct of this reaction.

This amount of SAH (1.8 nmoles/h/mg protein)

corresponds to a concentration of 4.9 µM SAH in the BC-2-NMT assay.

BC-2-NMT

activity would only be inhibited to 72% of control activity at this SAH
concentration (refer to Chapter 3 for SAH inhibition curve), quite different
than the 10% of control BC-2-NMT activity observed in the norepinephrine
inhibition experiment.

Moreover, SAH probably does not accumulate during a

methyltransferase reaction, since it may be removed by the action of cytosolic
SAH hydrolase and adenosine deaminase to form inosine (Chiang et al. 1996).
Therefore it is improbable that SAH accounts for the observed inhibition of
BC-2-NMT in the presence of norepinephrine.
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BC-2-NMT Activity in the
Medulla Oblongata
The lack of BC-2-NMT activity in the medulla oblongata is disturbing
since this brain region ("C 1 area", dorsal to the mid portion of the inferior
olive) has a high level of PNMT activity (Fuller 1982; Kopp et al. 1979; Lew et al.
1977; Mefford 1988), and one would expect a high level of BC-2-NMT activity in
this brain region if PNMT and BC-2-NMT are the same enzyme.

The

supernatant used in my experiment was not dialyzed, and it is possible that
dialyzable endogenous compounds (e.g., epinephrine or other catecholamines)
may have been present that inhibited BC-2-NMT activity.
high

concentrations

of endogenous

catecholamines,

and norepinephrine (Pohorecky et al. 1973 ).

PNMT is inhibited at

including

epinephrine

Unfortunately a positive control

for PNMT activity -- conversion of norepinephrine to epinephrine -- was not
included in this study.

This experiment should be repeated using 2-3 different

medulla oblongatas in which the supernatant fraction is dialyzed to remove
endogenous inhibitors. In addition, positive controls should be included in
each case to assure that PNMT activity with norepinephrine as the substrate is
detectable under the assay conditions.

Immunoprecipitation of PNMT
lmmunoprecipitation of PNMT, followed by the assessment of BC-2-NMT
activity in the resulting supernatant, is a practical approach to addressing the
equivalency of PNMT and BC-2-NMT.

It is possible that the results reported

here are false-negative results due to technical problems such as insufficient
precipitation of PNMT.

Therefore, the experiment should be repeated with a

positive control that would assure that adequate anti-PNMT is utilized.
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Overall
In summary,

Conclusions

taken together these data provide strong evidence that

BC-2-NMT activity is due to PNMT.

Purification of BC-2-NMT and comparison of

its properties and primary sequence to that of PNMT would provide definitive
proof of their equivalency.

Assuming that BC-2-NMT is equivalent to PNMT,

there is substantial circumstantial evidence that PNMT-catalyzed formation of
cytotoxic 2-MeBCs+ may play a key role in the pathogenesis of PD.
evidence is discussed in subsequent text.

This

A new hypothesis regarding the

etiology of Parkinson's disease -- a hypothesis that incorporates a role for
PNMT -- is presented at the end of that discussion.

Evidence That is Consistent With a Role For PNMT
in the Pathof;enesis of Parkinson's Disease
PNMT Co-Localization With PD Pathology
PNMT catalytic activity and immunoreacti vity are present in regions of
human brain that are affected by PD.

Primary pathological findings in PD

include nerve cell loss and the presence of Lewy bodies in the substantia
nigra, locus ceruleus, and peripeduncular nucleus (Forno 1995).

These same

human brain nuclei exhibit PNMT activity ranging from trace activity in the

"

interpeduncular nucleus to an activity of 2.6 pmole/h/mg protein in the locus
coeruleus (Kopp et al. 1979).

In addition, several other loci that frequently

demonstrate pathology in PD also express PNMT, such as the hypothalamus,
dorsal motor nucleus of the vagus, raphe nuclei, and the olfactory tubercle.

It

is conceivable that PNMT-catalyzed formation of neurotoxic 2-MeBCs+ in these
nuclei contributes to the specific neuronal loss in PD.

Further investigation
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may reveal a high degree of correlation between PNMT (BC-2-NMT) activily
and brain pathology in PD.
Consistent with this speculation, Gai et.al (1993) reported a selective loss
of PNMT-positive neurons in PD.

Specifically, in PD medulla oblongata the

number of neurons in the Cl cell group was reduced to 47% of control, and m
the C3 area numbers were 12% of control values.

It is plausible that this

decrease in cell number could be a result of PNMT-catalyzed formation of
neurotoxic

2-MeBCs+ within the Cl and C3 neurons early in the disease process.

Cell death induced by 2-MeBCs+ would manifest as a loss in PNMT-posilive cells.
In addition, PNMT activity is reduced in the hypothalamus and pallidum of PD

brains (Nagatsu et al. 1977, 1984 ),
could generate 2-MeBCs+.

areas that express PNMT, and consequently

Epinephrine in the CSF from PD patients is either

unchanged (Tohgi et al. 1990) or decreased (Eldrup et al. 1995), the later being
consistent with decreased brain PNMT activity resulting from loss of
PNMT-posi ti ve

neurons.

Adrenal Medulla Pathology in PD
The adrenal medulla exhibits high PNMT activity compared lo other
tissues.

Evidence presented in this chapter demonstrates the presence of

substantial BC-2-NMT activity and trace BC-9-NMT activity in human adrenal
medulla.

The sequential action of BC-2-NMT (PNMT) followed by BC-9-NMT

activity would form 2-MeBCs+ and then 2,9-Me2BCs+ in the adrenal medulla
toxins that may kill those cells in which they are formed.

Interestingly, many

PD patients demonstrate pathology, including Lewy bodies, in the adrenal
medulla (den Hartog Jager 1970; Stoddard 1994).

In a recent review article

addressing the condition of the adrenal medulla in PD (Stoddard 1994 ),
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Stoddard concluded Lhat adrenal tissue, plasma, and urinary catecholamines
are decreased in PD cases relative to control subjects.

These results would be

consistent with those expected subsequent to PNMT-catalyzed formation of
toxic MeBCs+ in the adrenal medulla.

As the PNMT-posiLive cells die due to the

toxicity of MeBCs+, the capacity of the medulla to synLhesize epinephrine
would also be expected to decrease.

Perhaps this inability to synthesize

epinephrine contributes to the hypotension observed in idiopathic PD.

It is

noteworthy that PC 12 cells -- an immortalized cell-line derived from adrenal
tissue -- are susceptible to the toxicity induced by MeBCs+ (Cobuzzi ct al. 1994).

Peripheral BC-2-NMT (PNMT) Activity
Demonstration of BC-2-NMT and BC-9-NMT activity in the adrenal
medulla is interesting because it implies that MeBCs+ could be formed
peripherally following exposure to BCs (substrates for BC-2-NMT).
Furthermore, Matsubara recently reported that 2-MeNH+ and 2,9-Me2NH + are
able to penetrate the blood-brain barrier (Matsubara et al. 1996).

Taken

together these observations suggest that 2-MeBCs+ formed in adrenal medulla
have access to the brain.

Within the brain 2-MeBCs+ could be selectively

transported into dopaminergic neurons via the dopamine transporLer, and
therein exert their toxic effects (Drucker et al. 1990).

PD, Stress, and PNMT
Physiological stress results in increased brain and adrenal PNMT
activity (Turner et al. 1979; Turner et al. 1978).

Assuming that BC-2-NMT is

PNMT, then in theory during a stressful situation 2-MeBC+ formaLion would be
concomitantly increased (if substrates were present).

Eatough ct al. (1990)
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reported that PD patients experienced significantly greater extreme stress
during life, especially in childhood, compared to control individuals.

Perhaps

also relevant is the report which indicates a higher incidence of PD in
survivors of prisoner of war camps (Gibberd et al. 1980).

It is possible that the

association between extreme physiological stress and PD is due to cxcessi ve
formation of MeBCs+ resulting from increased PNMT activity.
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The PNMT Hypothesis of
Parkinson's Disease
This expanded hypothesis includes an early, and possibly precipitating,
role for PNMT in the pathogenesis of Parkinson's disease (Figure 52).

This

hypothesis states that physiological stress, which is suggested as a
predisposing factor to PD,

increases PNMT (BC-2-NMT) activity both in the

adrenal medulla and brain (Turner et al. 1978, 1979).

Norharman, a substrate

for BC-2-NMT, is elevated in the plasma of PD patients (Kuhn et al. 1995).

PNMT

(BC-2-NMT) may catalyze the formation of cytotoxic 2-MeBCs+ (e.g., 2-MeNH+)
peripherally and centrally in PNMT-containing cells.

The MeBCs+ could

remain in the cells in which they were formed, or may exit and enter
dopaminergic neurons via the dopamine transporter (Drucker et al. 1990).
These 2-MeBCs+ and/or their N,N-dimethylated metabolites (2,9-Me2BCs+)
inhibit mitochondrial respiration (Albores et al. 1990; Fields et al. 1992),
thereby depleting ATP and causing neuronal death. Mitochondrial inhibition
may also increase oxidative stress within affected neurons (Takeshige and
Minakami 1979; Zeevalk and Bernard 1996; Zoccarato et al. 1988) -neurofilaments may become oxidatively damaged, and consequently prone to
aggregation and Lewy body formation (Hill 1996; Montine et al. 1995; Troncoso
et al. 1995).
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Figure 52. The PNMT hypothesis for Parkinson's disease: a proposal that the
risk for development of PD increases as the number of factors (a-e) present
increases. Each of this factors has an association with PD (see test for details).
Factors are: (a) increased stress, (b) increased load of BC substrates, (c)
decreased xenobiotic metabolism, (d) increased BC-9-NMT activity, (e)
decreased mitochondrial function due mtDNA defect.

CHAPTER 7
SUMMARY AND SPECULATIONS

Summary
It is hypothesized

that

B-carboline-N-methyltransfcrascs

(BC-NMTs)

and/or the neurotoxic products of their catalytic activities, N-mcthylated
B-carbolinium cations

(MeBCs+ ), may play a role in the pathogenesis of

idiopathic Parkinson's disease (Collins 1994; Collins and Neafsey 1985).
primary

focus

of this

activity

(BC-2-NMT),

dissertation

was

The

J3-carboline-2N-methyltransferase

but J3-carboline-9N-methyltransferase

(BC-9-NMT)

activity was also studied, although much less rigorously.
The most important finding was that in the frontal cortex of
Parkinson's disease (PD) brains, supernatant BC-9-NMT activity is increased
relative to activity in control tissue.

This implies that higher levels of 2,9-

Me2J3Cs+ may be formed in PD brain compared to normal brain.

It is possible

that brain BC-9-NMT activity is globally elevated in PD -- particularly early in
the disease process -- but that with disease progression, elevated BC-9-NMT
activity becomes undetectable due to MeBC+-induced death of the cells that
originally contained

the

enzyme.
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An equally important and exciting finding is the detection of relatively
high BC-2-NMT activity in human adrenal medulla, suggesting that neurotoxic
2-MeBCs+ may be formed in this tissue.

There are at least four possible fates

for adrenal-derived 2-MeBCs+: (1) liver metabolism to nontoxic compounds, (2)
toxic effects on adrenal cells, (3) entry into the central nervous system, and
(4) conversion to more toxic 2,9-Me2BCs+ by the action of adrenal and brain
BC-9-NMT.

Notably, this dissertation is the first report describing BC-9-NMT

activity in human brain, as well as the measurement of l3C-2-NMT and l3C-9NMT activities in human adrenal medulla.
The presence of BC-2-NMT activity in the adrenal medulla is consistent
with a new hypothesis proposed in this dissertation (Figure 52). A fundamental
aspect of this hypothesis is that BC-2-NMT activity is due to the epinephrinesynthesizing

enzyme,

phenylethanolamine-N-methyltransferase

an enzyme very similar to PNMT.

(PNMT)

or

This hypothesis is supported by three key

observations: (1) purified bovine adrenal PNMT catalyzes the 2N-methylation
of 9-methylnorharman, (2) L Y134046, a selective inhibitor of PNMT, also
inhibits BC-2-NMT, and (3) substrates of PNMT inhibit BC-2-NMT activity in a
concentration-dependent

manner.

Another observation that may have relevance to PD is that l3C-2-NMT
activity is increased 2-fold in the presence of iron (Fe2+ or Fe3+ ).

Iron

concentration is high in the substantia nigra compared to other brain
regions, and its level appears to be higher in PD brain compared to control
tissue.

Perhaps elevated nigral iron in PD brain increases BC-2-NMT activity,

which results in increased local formation of neurotoxic 2-Mel3Cs+ there.
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Only a panial purification of BC-2-NMT was achieved in this study.
However, the observations and suggestions presented here, regarding BC-2NMT purification, should be useful if this project is continued by another
investigator -- however the development of less labor-intensive assay should
be a priority.

The inhibition experiments presented in Chapter 6 indicate that

BC-2-NMT activity may be due to two enzyme activities; this would also
complicate purification of BC-2-NMT activity.

Speculations
As summarized in Figures 52 and 53, it is hypothesized that PNMT may
play a key role in the pathogenesis of PD.

Stress-induced elevation of PNMT

(presumably BC-2-NMT) could result in excessive formation of 2-MeBCs+ both
in the adrenal medulla and brain.
methylated by BC-9-NMT -- the
more toxic 2,9-Me2BCs+.

Resultant 2-MeBCs+ could then be 9Nactivity that is elevated in PD brain -- to the

Local formation of MeBCs+ may culminate in cell death

due to neurotoxin-induced mitochondrial inhibition.

In addition, 2-MeBCs+

may cross the plasma membrane and subsequently enter other cells either
passively or actively via the dopamine transporter.

Active transport into

dopaminergic cells may explain why nigrostriatal neurons are more severely
affected in PD.

It is interesting to consider that BC-2-NMT (PNMT) may also

catalyze the formation of other proposed N-methylated dopaminergic
neurotoxins,

such as

(Naoi et al. I 989b).

N-methylated derivatives

of tetrahydroisoquinolines

Perhaps an early event associated with the pathogenesis of

PD is N-methylation of several distinct classes of azaheterocycles (including
BCs) to form mildly to moderately neurotoxic derivatives.

Chronic exposure to

these compounds over several years could eventually kill sufficient
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dopaminergic neurons to manifest the clinical symptoms of Parkinson's
disease.
It is fascinating to consider the role that microbe-catalyzed formation of
2-MeBCs+ may play in the pathogenesis of PD.

Both Kitasatosporia setae and

Nocardia asteroides are Actinomycetes, which are vegetable parasites that
reside in soil. Kitasatosporia setae cultures transform norharman to 2-MeNH+
(Peczynska-Czoch et al. 1987), and mice inoculated with Nocardia
develop a parkinsonian-syndrome (Kohbata and Beaman 1991 ).

asteroides

It is plausible

that Nocardia asteroides may also be able to produce neurotoxic 2-MeBCs+ from
simple BCs.

Thus human ingestion or inhalation of these soil pathogens could

provide "additional enzymatic machinery" able to produce
MeBCs +.

neurotoxic 2-

Perhaps the association between rural living and PD is closely related

to exposure to these soil (groundwater?) pathogens.

Regarding this

speculation, two questions arise: (1) does Nocardia asteroides possess BC-2-NMT
activity, and/or (2)

in PD, is there evidence of Kitasatosporia

setae infection?

Overall Model of Parkinson's Disease
An overall model for the etiology of idiopathic Parkinson's disease is
presented in Figure 53 -- with BC-NMT-catalyzed formation of MeBCs+ playing
a key role.

Steps that are marked with an asterisk (*) were either discovered

or studied during the development of this dissertation.

Steps marked with a

question-mark (?) have been postulated by the author or proposed by other
investigators.
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Figure 53. N-methylated-8-carboline hypothesis of Parkinson's disease.
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APPENDIX A:
PROTEIN ASSAYS
Solution preparation was modified from Scopes (1994d ).
Lowry

Reaction

Solution A: Copper Sulfate Solution
Dissolve 500 mg copper sulfate heptahydrate (CuS0 4 •5H 2 0) and 1 g sodium
citrate tribasic in 100 ml of Milli-Q water. Scopes states that is more stable than
the commonly used copper tartrate solution and may be stored indefinitely.
Solution B: Sodium Carbonate Solution
Dissolve 10 g of sodium carbonate (Na 2 C03) and 2 g sodium hydroxide (NaOH) m
500 ml Milli-Q water
Solution C: Make fresh the day of protein assay, by m1xmg 50 ml (50 parts) of
solution B and 1 ml (1 part) of solution A. This solution will be very basic (~ pH
10). Use 2 ml of this solution per protein assay.
Solution D: Dilute Folin-Ciocalteau reagent with an equal volume of Milli-Q
water. Prepare a total volume that is sufficient to carry out all assay -- use 200
µl per protein assay.
Standard

and

Sample Preparation

Standard Preparation:
Bovine serum albumin (BSA, Fraction V) was dissolved in 1 mM sodium dodecyl
sulfate (SDS) to a final concentration of 1 µg/µl (BSA stock)). Tubes for
generation of the protein standard curve were prepared according to Table 23.
Standards were prepared in triplicate.
The reference (blank) sample was the
same as the standard that did not contain BSA.
Table 23.--Preparation of BSA Standards
~

1

2
3
4

5
6

BSA/tube
0
20
50
100
150
200

Cu~)

BSA Stock Cul)
0
20
50
100
150
200

1 mM SDS Cul)
200
180
150
100
50
0

Sample Preparation:
Concentrated samples (homogenates, extracts, or column fractions) were
diluted in 1 mM SDS; the dilution usually varied from 1:5 to 1:50. Dilute samples
were not diluted prior to analysis for protein.
Diluted or undiluted samples
were assayed in triplicate if sufficient sample was available. A predetermined
volume of sample was added to a tube, and the volume was brought to 200 µl
using 1 mM SDS.
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Assay:
To each standard and sample tube added 2.0 ml of "Solution C". Tubes were
vortexed and set at room temperature for 5-10 minutes. Then 200 µ 1 of
"Solution D" was added to each tube. It is important that tubes were mixed
quickly after addition of "Solution D", therefore tubes were vortexed in sets of
10-15 following the addition of "Solution D". Tubes remained at room
temperature for 20-30 minutes. Solutions developed a blue color, the
absorbance of which was determined at 700 nm using a Gilford Response
spectrophotometer.
Polystyrene disposable semi-micro cuvettes were used ( 1.5
ml, 1 cm light path). Standards were analyzed using the standard curve
program on the spectrophotometer; this program automatically generates the
curve and the corresponding linear equation with correlation coefficient.
The samples are run following standard analysis according to the prompts on
the spectrophotometer monitor.
The program uses the standard curve
information to calculate the protein (µg) per sample cuvettc. Protein in the
original sample is then calculated taking into account sample dilution prior to
assay.
Coomassie Blue Dye Binding
Mix 600 mg of Coomassie Brilliant Blue G-250 with 1000 ml of a 2% perchloric
acid solution. This solution is stable indefinitely. Filter to remove undissolved
material. Use 2-3 ml of this solution per protein assay. this solution will color
blue glassware and plasticware. This color can be removed with either
methanol or a detergent solution.
Standard. Sample Preparation. and Assay
These steps were identical to the Lowry method with two exceptions. Following
standard or sample preparation, 3 ml of Coomassie blue dye solution as added to
each tube.
Tubes were vortexed and maintained at room temperature for
between 2 and 30 minutes. Standard and sample absorbance was determined at
595 nm.
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APPENDIXB:
HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY
Preparation of HPLC Mobile Phase

RP-HPLC Mobile Phase Composition
83% (v/v) 0.25 M NaH 2 P0 4 plus 50 mM TEA in water (pH 3)
17% (v/v) Acetonitrile
To make 2 L of mobile phase: In a 2 L beaker equipped with magnetic stir bar,
add 49.8 g sodium phosphate monobasic (NaH 2P04, fwt 120), 1500 ml Milli-Q
water, and 7.0 ml of triethylamine (TEA). Stir until all solids are dissolved (1530 minutes). Adjust pH to 3.0±0.1 using concentrated phosphoric acid.
Transfer this solution to 2 L graduated cylinder an dilute to a final volume of
1660 ml using Milli-Q water. Transfer back to the 2 L beaker and mix. Add 340
ml of HPLC grade acetonitrile while mixing. Vacuum filter through a 0.2 µm
nylon membrane filter (47 mm diameter).
Stir under house vacuum in order
to degas the mobile phase. The final mobile phase pH is approximately pH 3.4.
SCX-HPLC Mobile Phase
60% (v/v) 0.3 M NH4Cl plus 0.2 M NH40Ac in water (pH 4)
40% (v/v) Acetonitrile
In a 2 L beaker equipped with magnetic stir bar, add 19.4 g ammonium chloride
(NH4Cl, fwt 53.9), 18.5 g ammonium acetate (NH40Ac, fwt 77.08), and 1000 ml of
Milli-Q water. Stir for 15-30 minutes to dissolve solids. Adjust the pH to 4.0±0. 1
using glacial acetic acid (90-120 ml required). Transfer this solution to a 2 L
graduated cylinder and dilute to 1200 ml with Milli-Q water. Transfer back to
the 2 L beaker, mix, and add 800 ml HPLC-grade acetonitrile. Mix, filter, and
degas as described above. The final pH of the mixture is approximately pH 5.
Fluorescence

Detector

Model: Perkin-Elmer LC240
Wavelengths: Excitation 310 nm, Emission 450 nm (optimal for 2,9-Me2NH +)
AF: usually set at 1024 (decreasing this value will increase sensitivity)
Response: usually set at 5
Note: after turning instrument on, press "58 control" to prevent lamp from
automatically turning off after 30 minutes
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Inte&rator (used

with

fluorescence

detection)

Model: Shimadzu C-R 1B Chromatopac Reporting Integrator
Usual settings are:
Width = 20 (width is set to peak width at 0.5*peak height for narrowest peak in
trace)
Slope = 800-1000 (decreasing slope will increase detection of small changes
from baseline -- if slope is too low, noise in baseline will be reported as peaks)
Speed (of chart) = 2
Att (attenuation) = 5-6 for normal BC-NMT assays (decreasing attenuation value
will increase sensitivity)
Min Area (minimum area) = variable (represents the minimum area for peaks
that are to be included in the integrating report -- if this value is too low, the
report will include many small peaks that really represent only noise
Stop Time = 15-20 minutes (the time that data collection is terminated -depends upon compounds that are present)
Radioactive

Detector

Model:
Radiomatic Flo-One\Beta
(supported by Packard Instruments)
Program Disk is needed to boot system and change operating parameters, while
the Run (data) disc is needed to store runs.
Determination of background is done with mobile phase and scintillation
cocktail flowing through flow cell. The settings below were used for the
background determination prior to the beginning of sample analysis:
Condition = H-3
Update Time = 10
Mode = Scaler
Results = Net cpm
Cell type = liquid
Cell size = 2.5
Auto pump = yes
Pump flow rate = 2.8
HPLC Flow rate = 0.8
Scaler time = 1
Spitter Ratio = 100
Fraction collector channel = 0
Discriminator settings =
Channel 1 Channel 2 Channel 3
1-40
5-100
Background subtract = 0
the background check was run for 10 minutes. Total cpm reported is divided by
10 to give the average cpm in minute (usually 40 cpm). this value is used in
the "background subtract" field during sample analysis.
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Typical instrumenl setlings for sample analysis were:
Condition = H-3
Update Time = 10
Mode = Integrate
Results = Net cpm
Cell type = liquid
Cell size = 2.5
Auto pump = yes
Pump flow rate = 2.8
HPLC Flow rate = 0.8
Scaler time = 1
Spitter Ratio = 100
Fraction collector channel = 0
Discriminator settings =
Channel 1 Channel 2
1-40
5-100
Background subtract = 40
Minimum peak area: 80 (i.e., 2x background subtract)

Channel 3
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APPENDIXC
SYNTHESIS OF 9-METHYLNORHARMAN HCL
The synthesis was a modification of that described by Rubotlom and Chabala
(1974).
Reaction
The reaction was carried-out in an oven-dried 25 ml round-bottom singlcnecked flask equipped with a magnetic stir bar.
Norharman free base (NH,
678.5 mg, 3.95 mmole) was dissolved in 14 ml of hexamethylphosphoramide
(HMPA) that had been stored over molecular sieves at least overnight. Sodium
amide (NaNH2, 1.04 g, 3.4 equivalents with respect to NH) was washed into the
reaction flask with the aid of about 2 ml HMPA. The flask headspace was
purged with nitrogen and immediately stoppered to minimize exposure of the
reaction to moisture. The contents of the flask were stirred for five hours at
room temperature. The mixture was light yellow, with a blue-tint at the airmixture interface.
After the five hour stir, the reaction was chilled to 5-10 °C. Methyl
iodide (CH 3 1, 4.35 mmole, 271 µl, 1.1 equivalents with respect to NH) was
quickly added. The mixture became blue and then green. The mixture was
sampled after 15 minutes so that the extent of the reaction could be determined
by SCX-HPLC (see Chapter 1 and Appendix B). After 15 minutes the reaction
was green and 50% of the NH remained. After 30 minutes the reaction was
brownish-green and 30% of the NH was still unreacted. An additional 61 µI
CH 3! (0.98 mmole) was added and the reaction was stirred for IO minutes at 5-10
°C. Little to no NH was detected by SCX-HPLC.
Reaction Work-Up
Milli-Q water (16 mL) was added to the reaction mixture; the reaction pH was
13.5. Reaction pH was adjusted to pH 7 using concentrated HCI. mixture was
mixed vigorously and then transferred to a separatory funnel.
Diethyl ether
(Et2 0, 25 ml) was added to the contents of the separatory funnel. The funnel
was inverted several times in order to extract the aqueous layer with the Et20.
The two layers were allowed to separate and the Et20 (upper) layer added to a
250-ml flask containing anhydrous magnesium sulfate (MgSO.i); the MgS04
served to remove water from the Et20 extract. The lower aqueous layer was
extracted four more times using 25 ml of Et2 0 each time. All ether extracts
were combined with the original extract over MgS04. The Et20/MgS04 mixture
was filtered to remove MgS0 4. The Et20 filtrate was evaporated to an oil using a
Rotovap evaporator. Methanolic- HCl (2.7 ml) was added to the oil, followed by
the addition of about 5-10 ml of Et20. The mixture was placed at -20 °C to
expedite crystallization of 9-methylnorharman hydrochloride.
The pale
yellow crystals were filtered through Whatman 40 filter paper, and the
crystals were washed with cold Et20. The crystals were dried overnight in a
vacuum oven at 40-50 °C.
Yield: 495 mg (2.27 mmoles based on a molecular weight of 218)
Percent yield = (2.27 mmole/3.95 mmole)*IOO = 57%
Purity:
>95% by SCX-HPLC; structure confirmed by NMR (Dr. David Crumrine,
Department of Chemistry, Loyola University Chicago)
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Table 24.--ANOVA RESULTS
Enzyme Activity = f(F + R + G + F*R + F*G + R*G + F*R*G)
F = Fraction = Particulate or SupernaLanl
R = Brain Region = Substantia nigra or Putamcn or Frontal Cortex
G=Group = Control or Parkinson's disease
BC-2N-Meth):'.I tran sf~rase
df
MS

Activit):'.
F-ratio

Source

S.S.

Main Effects
Fraction (F)
Region (R)
Group (G)

5488.349
4077.090
1421.680
3.665

4
1
2
1

1372.087
4077.090
710.840
3.665

4.037
11.997
2.092
0.011

0.005
0.001
0.131
0.918

2-way
F*R
F*G
R*G

869.735
648.584
4.799
208.268

5
2
1
2

173.947
324.292
4.799
104.134

0.512
0.954
0.014
0.306

0.766
0.390
0.906
0.737

3-way interactions
F*R*G

73.634
73.634

2
2

36.817
36.817

0.108
0.108

0.897
0.897

Explained
Residual
Total

6515.019
23110.105
29625.124

11
68
79

592.274
339.854
375.002

1.743

0.082

Source

BC-9N-Methyl tran sf~ras~
df
SS
MS

Main effects
Fraction (F)
Region (R)
Group (G)

3477.492
2522.520
719.763
253.178

4
1
2
1

869.373
2522.520
359.882
253.178

4.947
14.354
2.048
1.441

0.001
0.0003
0.136
0.234

2-way
F*R
F*G
R*G

2357.925
217.100
408.632
1764.280

5
2
1
2

471.585
108.550
408.632
882.140

2.683
0.618
2.325
5.020

0.028
0.542
0.132
0.0091

3-way interactions
F*R*G

770.573
770.573

2
2

385.287
385.287

2.192
2.192

0.119
0.119

Explained
Residual
Total

11
6728.328
12653.152 72
19381.480 83

611.666
175.738
233.512

3.481

0.001

interactions

interactions

Activity
F-ratio

p-value

p-value
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MATERIALS USED IN CHAPTER 6
Purified Bovine-Adrenal PNMT
Catalog # I lot #
Enzyme Commission #
Source
Activity

P-8924 I 15H3891
EC 2.1.1.28
bovine adrenal medulla
"one unit will convert 1.0 nanomolcs of
normetanephrine to melancphrinc per hr
at pH 8.5 at 37 °C"
"lyophilized powder containing approx. 70%
protein (Biuret); balance is primarily
phosphate buffer salts, pH 7 .5: 1.1 mg solid, 24
units/mg solid, 32 units/mg prot."

Contents

LY134046 CPNMT Inhibitor)
Catalog # I lot no.
Molecular weight
Chemical name

Norepinephrine

CPNMT

L-105 I GG-389A
252.57
8, 9-dichloro-2,3 ,4,5-tetrahydro- l H-2benzazepine, hydrochloride salt
substrate)

Catalog # I lot no.
Molecular weight
Chemical name

A-9512 I 36H0770
319.3
(-)-arterenol, bitartrate salt, or
2-amino-1-( 3 ,4-dihydroxyphen yl)
ethanol, bitartrate salt

Octopamine (PNMT substrate)
Catalog # I lot no.
Molecular weight
Chemical name

DL-phenylethanolamine
Catalog # I lot no.
Molecular weight
Chemical name

0-0250 I 128F0347
189.6
1-(p-hydroxyphenyl)-2-ami nocth anol,
hydrochloride salt
CPNMT

substrate)
H-1754 I 36H2514
137.2
D L- ~ -hydroxypheneth y 1amine

GLOSSARY
Allosteric effector: a compound that binds Lo the enzyme at a site other than
the active site, and affects the reaction catalyzed by the enzyme -enzyme activity may be increased or decreased
Allosteric site: a site or sites on an enzyme, distinct form the active site, where
compounds bind, and consequently affect the catalytic activity of the
enzyme
Catalytic constant:
kcai. experimentally-defined the rate constant for
formation of product [P] from the enzyme-substrate complex [ES]
equivalent to turnover number
Catalytic site: equivalent to active site -- the site on an enzyme where
substrate [S] binds and the actual formation of product [P] occurs
Competitive inhibitor: a compound that binds to free enzyme [E] at the active
site in competition with the substrate [S] -- the inhibition may be
overcome by increasing [S] -- inhibitor presence increases the KM of
the substrate, while V max is unaffected
Enzyme-substrate complex:
[ES],
with the substrate [S]

the concentration of enzyme [E] in a complex

Free enzyme:
[E],
the concentration of free enzyme, i.e., the concentration of
enzyme not in a complex with substrate [S]
Inhibitor:
[I], the inhibitor concentration, an inhibitor decreases the
activity of an enzyme

k1:

rate constant for the formation of the enzyme-substrate complex from
free enzyme [E] and substrate [S]

k_J:

rate constant for the dissociation of the enzyme-substrate complex [ES] to
free enzyme [E] and substrate [S]

k_2:

rate constant for the association of free enzyme [E] and product [P] to
form the enzyme-substrate complex [ES] -- this constant assumed to be
negligible in simple Michaelis-Menten kinetics

Ki:

the inhibitor constant, the dissociation constant for the inhibitor-enzyme
complex

Michaelis constant:
KM, a function of kinetic constants experimentally equal
to the substrate concentration at which the reaction velocity (v) is
proceeding at one-half maximal velocity (0.5*V max)
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Maximum velocity:
V max, a kinetic constant which represents the maximum
velocity for product [PJ formation under stated reaction conditions -- at
V max the enzyme is said to be saturated with substrate [SJ
Noncompetitive inhibitor:
binds to the enzyme and inhibitor presence
decreases V max, but does not affect substrate KM
Product:
[P],
the product concentration, i.e., the compound formed by action
of an enzyme on a substrate, in an enzyme-catalyzed reaction
Substrate:

[SJ'

the substrate concentration in an enzyme-catalyzed reaction

Specific activity: the amount of product [PJ formed by an enzyme per unit
time per mass of protein (e.g., pmol/h/mg protein) -- more precisely
the units of enzyme per mg protein
Turnover number:
equivalent to kcat -- the number of substrate molecules
transformed per minute by a single enzyme molecule when the
enzyme concentration is the rate limiting factor, formerly called the
molecular or molar activity
Uncompetitive inhibitor:
both KM and Vmax
Unit:

binds to enzyme and inhibitor presence decreases

U, the amount of an enzyme that will catalyze the transformation of one
µmole of substrate [SJ to product [PJ per minute at a specified
temperature (usually 25 °C), at a defined substrate concentration

Velocity: v, the rate at which substrate [SJ is converted to product [PJ in an
enzyme-catalyzed reaction, units are in concentration per unit time
(e.g., pmoles/hour)
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